Protocol I5B-MC -JGDR(a)   
  
 
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With 
Advanced or Metastatic Soft Tissue Sarcoma  
  
 
[STUDY_ID_REMOVED]     
  
 
Approval Date: 26-Jun-2018  
 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 1
LY3012207Protocol I5B-MC-JGDR (a)
A Phase 1b Study  of Olaratumab, Doxorubicin and Ifosfamide 
in the Treatment of Patients with A dvanced or Metastatic Soft 
Tissue Sarcoma
Confidential Information
The information contained in this protocol is confidential and is intended for the use of clinical investigators.  It 
is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to 
persons not involve d in the clinical investigation of olaratumab (LY3012207) , unless such persons are bound 
by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. 
Note to Regulatory Authorities :  This document may contain protected personal data and/or commercially 
confidential information exempt from public disclosure.  Eli Lilly and Company requests consultation 
regarding release/redaction prior to any public release.  In the United States, this document is subject to 
Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated 
without the written approval of Eli Lilly and Company or its subsidiaries.
Olaratumab (LY3012207)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed an d Approved b y Lilly:14March 2017 .
Amendm ent (a) Electronically Signed and Approved by Lillyon approval date provided 
below.
Approval Date: 26-Jun-2018 GMT
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 2
LY3012207Table of Contents
Section Page
1. Synopsis ............................................................................................................................. 9
2. Schedule of Act ivities....................................................................................................... 13
3. Introduction ...................................................................................................................... 22
3.1. Background .................................................................................................................. 22
3.1.1. Soft Tissue Sarco ma............................................................................................. 22
3.1.2. Olaratum ab.......................................................................................................... 22
3.2. Study Rationale ............................................................................................................ 23
3.2.1. Rationale for Amendment (a) ............................................................................... 24
3.3. Benefit -Risk Assessment .............................................................................................. 24
4. Object ives and Endpo ints.................................................................................................. 25
5. Study  Design ..................................................................................................................... 27
5.1. Overall Design ............................................................................................................. 27
5.1.1. Dose -Finding Phase:  Olaratumab 15 -mg/kg Dose Level ...................................... 30
5.1.2. Dose -Finding Phase:  Olaratumab 20 mg/kg Loading Dose 
Cycle Level .......................................................................................................... 30
5.1.3. Dose -Finding Phase:  Ifosfamide Dose Reduction Options ................................... 30
5.1.4. Dose Confirmat ion Phase ..................................................................................... 30
5.2. Number of Patients ....................................................................................................... 30
5.3. Study  Com pletion Defi nition........................................................................................ 30
5.4. Scientific Rationale for Study  Design ........................................................................... 31
5.5. Justification for Dose ................................................................................................... 31
5.5.1. Olaratum ab.......................................................................................................... 31
5.5.2. Doxorubi cin, Ifosfamide and Mesna ..................................................................... 31
6. Study  Popul ation............................................................................................................... 32
6.1. Inclusio n Cri teria.......................................................................................................... 32
6.2. Exclusio n Cri teria........................................................................................................ 34
6.3. Screen Failures ............................................................................................................. 36
7. Treatments ........................................................................................................................ 37
7.1. Treatment Administered (Dosing Schedule) .................................................................37
7.1.1. Olaratum ab Prem edicat ions and Required Monitoring .......................................... 40
7.1.2. Doxorubi cin Premedicat ions and Dexrazoxane 
Administrati on..................................................................................................... 40
7.1.3. Ifosfamide Premedicat ions and Mesna Administratio n......................................... 40
7.2. Method of Treatment Assignm ent................................................................................ 41
7.2.1. Selection and Timing o f Doses ............................................................................. 41
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 3
LY30122077.2.2. Dose -Finding Phase ............................................................................................. 41
7.2.2.1. Dose -Limit ing Toxicit y Determination ........................................................... 41
7.3. Blinding ....................................................................................................................... 45
7.4. Dosage Del ays, Discont inuat ions and Modificat ions.................................................... 45
7.4.1. Delays.................................................................................................................. 45
7.4.2. Discontinuati ons .................................................................................................. 46
7.4.3. Dose Modificat ions.............................................................................................. 46
7.4.3.1. Olaratum ab Dose Modificat ions..................................................................... 46
7.4.3.1.1. Hem atologic Toxi city............................................................................... 47
7.4.3.1.2. Nonhematologic Toxicit y.......................................................................... 48
7.4.3.2. Doxorubi cin Dose Modifications .................................................................... 50
7.4.3.2.1. Hem atologic Toxi city............................................................................... 50
7.4.3.2.2. Nonhematologic Toxicit y.......................................................................... 51
7.4.3.2.3. Moni toring for Doxorubi cin-Associated 
Cardi otoxi city........................................................................................... 51
7.4.3.3. Ifosfamide Toxicit ies and Dose Modifications ................................................ 52
7.4.3.3.1. Ifosfamide -Associ ated Central  Nervous System  
Toxicit y.................................................................................................... 53
7.4.3.3.2. Ifosfamide -Associ ated Urotoxi c Effects .................................................... 53
7.4.3.3.3. Ifosfamide -Associ ated Proximal Tubular Damage .................................... 54
7.5. Packaging and Labeling ............................................................................................... 54
7.5.1. Olaratum ab.......................................................................................................... 54
7.5.2. Doxorubi cin, Ifosfamide and Mesna ..................................................................... 54
7.5.3. Granulocyte -Colony St imulat ing Factors .............................................................. 54
7.5.4. Dexrazoxane ........................................................................................................ 55
7.6. Preparati on/Handling/Storage/Accountabilit y............................................................... 55
7.6.1. Olaratum ab.......................................................................................................... 55
7.6.2. Doxorubi cin......................................................................................................... 55
7.6.3. Ifosfamide ............................................................................................................ 55
7.6.4. Mesna .................................................................................................................. 56
7.7. Treatment Compliance .................................................................................................56
7.8. Concomitant Therapy
 and Supportive Care .................................................................. 56
7.8.1. Olaratum ab Infusio n-Related React ions............................................................... 56
7.8.2. Granulocyte -Colony-Stimulat ing Factors and Erythro id 
Growth Factors .................................................................................................... 57
7.8.3. Transfusio n of Blood Products ............................................................................. 58
7.8.4. Antiemetic Therapy .............................................................................................. 58
7.8.5. Inducers and Inhibitors of CYP3A4, CYP2D6 and P -gp....................................... 58
7.8.6. Other Concomitant Therapies ............................................................................... 58
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 4
LY30122077.9. Treatment after the End of the Study ............................................................................ 59
7.9.1. Continued Access .................................................................................................59
8. Discontinuati on Cri teria .................................................................................................... 61
8.1. Discontinuati on from Study  Treatm ent......................................................................... 61
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 61
8.2. Discontinuati on from the Study .................................................................................... 61
8.3. Lost to Follow -Up........................................................................................................ 62
9. Study Assessments and Procedures ................................................................................... 63
9.1. Efficacy Assessments ................................................................................................... 63
9.1.1. Secondary  Efficacy  Assessments .......................................................................... 63
9.1.2. Appropriateness of Assessments .......................................................................... 63
9.2. Adverse Events ............................................................................................................ 63
9.2.1. Serious Adverse Events ........................................................................................ 64
9.2.2. Suspected Unexpected Serious Adverse React ions............................................... 65
9.2.3. Adverse Events of Special Interest ....................................................................... 66
9.2.4. Com plaint Handling ............................................................................................. 66
9.3. Treatment of Overdose .................................................................................................66
9.4. Safety........................................................................................................................... 66
9.4.1. Other Safet y Measures ......................................................................................... 66
9.4.2. Safety Moni toring ................................................................................................ 66
9.5. Pharmacokinet ics......................................................................................................... 67
9.6. Genetics....................................................................................................................... 68
9.6.1. Who le Blood Samples for Pharmacogenet ic Research .......................................... 68
9.7. Biomarkers ................................................................................................................... 68
9.7.1. Samples for Nonpharmacogenet ic Bio marker Research ........................................ 69
9.7.2. Tissue Samples for Bio marker Research ............................................................... 69
9.8. Immunogenicit y Assessments ....................................................................................... 70
10. Statistical Considerations .................................................................................................. 72
10.1. Sample Si ze Determinat ion.......................................................................................... 72
10.2. Popul ations for Analyses .............................................................................................. 72
10.3. Statistical Analyses ...................................................................................................... 73
10.3.1. Efficacy Analyses ................................................................................................ 73
10.3.2. Safety Analyses .................................................................................................... 73
10.3.3. Other Analyses ..................................................................................................... 74
10.3.3.1. Patient Disposi tion.......................................................................................... 74
10.3.3.2. Patient Characteri stics.................................................................................... 74
10.3.3.3. Concomitant Therapy ..................................................................................... 74
10.3.3.4. Post-study Treatment Discont inuat ion Therapy ............................................... 74
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 5
LY301220710.3.3.5. Treatment Compliance .................................................................................... 74
10.3.4. Pharmacokinet ic Analyses .................................................................................... 74
10.3.5. Biomarker Analyses ............................................................................................. 75
10.3.6. Immunogenicit y Analyses .................................................................................... 75
10.3.7. Subgroup Analyses .............................................................................................. 75
10.3.8. Interim Analyses .................................................................................................. 75
11. References ........................................................................................................................ 76
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 6
LY3012207List of Tables
Table Page
Table JGDR.1. Pretreatment Schedule of Act ivities........................................................ 14
Table JGDR.2. On-Study  Treatm ent Schedule of Act ivities............................................ 16
Table JGDR.3. Post-Treatment Follow -Up Schedule of Act ivities.................................. 19
Table JGDR.4. Continued Access Schedule of Act ivities................................................ 21
Table JGDR.5. Object ives and Endpo ints....................................................................... 26
Table JGDR.6. Treatments Administered (Dosing Schedule) .......................................... 38
Table JGDR.7. Dose -Limit ing Toxicit y Thresholds for Study  JGDR .............................. 43
Table JGDR.8 . General Guidelines for Olaratumab Dose Modification due to 
Hem atologic Toxi cities........................................................................... 47
Table JGDR.9. Olaratum ab Day  8 Dosing Algori thm Based on ANC and Platelet 
Count ..................................................................................................... 48
Table JGDR.10. General Guidelines for Olaratumab Dose Modification due to 
Nonhematologic Toxicit ies..................................................................... 49
Table JGDR.11. General Gui delines for Doxorubicin Dose Modification Due to 
Neutropenia ............................................................................................ 51
Table JGDR.12. General Guidelines for Dose Modificat ion of Ifosfam ide due to 
Toxicit y.................................................................................................. 52
Table JGDR.13. Dose Modificat ion of Ifosfamide due to Hepatic Impairment .................. 53
Table JGDR.14. Dose Modificat ion of Ifosfamide due to Renal Impairment ..................... 54
Table JGDR.15. Olaratum ab Infusio n-Related React ion Treatm ent Gui delines ................. 57
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 7
LY3012207List of Figures
Figure Page
Figure JGDR.1. Illustrati on of  study  design. ..................................................................... 29
Figure JGDR.2. Continued access diagram. ...................................................................... 60
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 8
LY3012207List of Appendi ces
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 79
Appendix 2. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 83
Appendix 3. Clinical Laboratory  Tests ........................................................................ 86
Appendix 4. Pharmacokinet ic, Bio marker, Pharmaco genet ics and 
Immunogenicit y Sampling Schedules ..................................................... 87
Appendix 5. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 91
Appendix 6. Creatinine Clearance Formula .................................................................92
Appendix 7. Fridericia’s QT Correcti on Form ula........................................................ 93
Appendix 8. Protocol  Amendment I5B -MC- JGDR(a) Summary A Phase 1b 
Study  of Olaratum ab, Doxorubi cin and Ifosfamide in the 
Treatment of Patients with Advanced or Metastatic Soft Tissue 
Sarcom a.................................................................................................94
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 9
LY30122071.Synopsis
Protocol Title:
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients with Advanced or 
Metastatic Soft Tissue Sarcoma
Rationale:
Study I5B -MC -JGDG (Study  JGDG) was a Phase 1b/randomized Phase 2 study evaluating the efficacy of 
doxorubicin with or without olaratumab in the treatment of advanced soft tissue sarcoma (STS) .  The study met its 
primary  endpoint for progression -free survival (PFS) ( hazard ratio [ HR]= 0.67; p = 0.06 as compared to a 
prespecified alpha level of 0.2) with an improvement in median PFS and overall survival (OS) of 2.5 months and 
11.8 mo nths, respectively, for olaratumab plus doxorubicin over doxorubicin alone , with a manageable safety 
profile .  The OS HR of 0.46 was highly statistically significant (p =0.0003; Tap et al. 201 6).  Based on these results, 
olaratumab has received conditional approv alin the United States and European Union in combination with 
doxorubicin for the treatment of adult patients with STS.
While doxorubicin alone o r in combination with other chemotherapeutic agents has been the mainstay of treatment 
for decades (Linch et al. 2014), in more recent ye ars the combination of doxorubicin ,ifosfamide and mesna has 
demonstrated increased tumor response and PFS compared to doxorubicin alone . However, this regimen is 
associated with a higher rate of Grade 3 and 4 toxicities and no improvement in OS (Judson e t al. 2014) , limiting the 
use of this regimen to distinct clinical setting s, such as when shrinkage of the tumor is important and the risk of 
greater toxicit y is felt to represent an acceptable benefit -risk. This regimen has also been evaluated in the 
neoadjuvant and adjuvant settings for patients with STS (Gortzak et al. 2001; Grobmyer et al. 2004; Pisters et al. 
2016).
The positive efficacy results seen with olaratumab in combination with doxorubicin in Study JGDG provide stro ng 
rationale for determining whether olaratumab can alsobe safe ly added to the doxorubicin, ifosfamide and mesna
regimen. It is plausible that the addition of olaratumab to doxorubicin, ifosfamide and mesna may further increase
efficacy endpoints such as tumo r response rate , PFS and OS , without a clinically significant increase in toxicity.
Study I5B -
MC-JGDR (Study JGDR) will characterize the safety and tolerability of olaratumab in combination with 
doxorubicin, ifosfamide and mesna in patients with advanced STS , and if acceptable, determine the dosing regimen 
of olaratumab in combination with doxorubicin and ifosfamide appropriate for future studies of this combination.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 10
LY3012207Objectives and Endpoints:
Objectives Endpoints
Primary
To characterize the safety profile of olaratumab 
when given in combination with doxorubicin, 
ifosfamide and mesna and to determine the 
dosing regimen appropriate for a future Phase 2 
studyDLTs, TEAEs, SAEs and clinical laboratory 
abnormalities per NCI -CTCAE Versio n4.0 
Secondary
To evaluate the PKof olaratumab when 
combined with doxorubicin, ifosfamide and 
mesna
To evaluate the immunogenicity of olaratumab 
when combined with doxorubicin, ifosfamide
and mesna
To document any antitumor activity of 
olaratumab when combined with doxorubicin, 
ifosfamide and mesnaPK:  Cmaxand AUC from time 0 to the last 
time point with a measurable concentration, and 
AUC from time 0 to infinity of olaratumab.  
Other noncompartmental parameters, such as 
half-life, clearance and volume of distribution 
may be reported.  Plasma doxorubicin and 
ifosfamide concentrations will be summarized 
by descriptive statistics
Immunogenicity:   Anti-olaratumab antibody 
levels at baseline, during the study, at the 
30-day  follow -up visit and in the event of 
olaratumab IRRs
Antitumor activity:   Radiographic 
assessments according to RECIST Version 1.1 
criteria ever y 6 weeks (-7 days) until 
radiographic documentation of PD.  Efficacy 
endpoints will include objective response rate, 
PFS, duratio n of response, disease con trol rate 
and OS
Exploratory
To explore biomarkers related to, but not 
limited to tumor microenviroment, immune 
cells/immune functioning, mechanism of action 
of study drugs, PDGF, cancer -related pathways 
and disease state, and their association with 
demographics, disease state and clinical 
outcomesBiomarker assay results with other trial data
Abbreviations: AUC = area under the concentration curve; C max= maximum observed concentration; DLT = dose -
limiting toxicity; IRR = infusion -related reaction; NCI-CTCAE = National Cancer Institute -Common 
Terminology Criteria for Adverse Events; OS = overall survival; PD = progressive disease; PDGF = platelet -
derived growth factor; PFS = progression -free survival; PK = pharmacokinetics; RECIST = Response Evaluation 
Criteria in Solid Tumors; SAE = serious adverse event; STS = soft tissue sarcoma; TEAE = treatment -emergent 
adverse event.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 11
LY3012207Overall Design:
Study JGDR is a Phase 1b, multicenter, nonrandomized, open -label study of olaratumab combined with 
doxorubicin, ifosfamide and mesna in the treatment of patients with advanced or metastatic S TS.
Dose -Finding Phase:
Olaratumab 15 mg/kg and Loading Dose Cycle Cohorts –Approximately 15 patients will be initially  enrolled 
andtreated with a 15-mg/kg dose of olaratumab (on Days 1 and 8 of a 21 -
day cycle) in combination with 
doxorubicin, ifosfamide and mesna and assessed for safety after 1 cy cle of therapy .  If safety of the 15-mg/kg dose 
of olaratumab is established, 15 additional patients will be enrolled and receive a 20-mg/kg loading dose cycle of 
olaratumab on Days 1 and 8 of a 21 -day cycle in Cy cle 1 only , followed by 15 mg/kg on Day s 1 and 8 ofsubsequent 
cycles in combination with doxorubicin, ifosfamide and mesna .
Should unacceptable toxicity be observed at the olaratumab 15 -mg/kg dose, t he study will include an option to 
explore the same regimen using a reduced if osfamide dose .  Provided safety is established at this lower dose of 
ifosfamide , a loading dose cycle of olaratumab as previously described will also be explored using the reduced 
ifosfamide dose.
Dose Confirmation Phase :
Ifa safe and tolerable dos ing regimen of olaratumab is identified , approximately 15 additional patients will be 
enrolled in a Dose Confirmation Phase to confirm the safety of this treatment regimen for use in any future studies 
of this combination.
Patients in both study phases wil lcontinue treatment for a maximum of 6 cycles, or until there is documented 
disease progression, unacceptable toxicity, death, or other discontinuation criteria are met .  Patients who discontinue 
doxorubicin, ifosfamide and mesna treatment without evidenc e of disease progression willreceive olaratumab as 
monotherapy until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria 
are met .  Patients who undergo surgical tumor resection following study treatment are not eligible to receive 
olaratumab as monotherapy.
Number of Patients :  approximately 45 -60total enrolled
Dose -Finding Phase:
Entered: approximately 33 -48
Enrolled:  approximately 30-45
Dose Confirmation Phase:
Entered:  approximately 17
Enrolled:  approximately 15
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 12
LY3012207Treatment Arms and Duration:
Phase and 
Dose Cohort Drug Name and DoseDay of 21 -day (±3 days) 
Cycle Total DoseDose-Finding Phase
Olara 15 mg/kgOlara 15 mg/kg a D1and D 8
Dox 25 mg/m 2per day D1, D2, D3 75 mg/m 2
Ifos 2.5 g/m 2per day b D1, D2, D3, D4 a 10 g/m 2a
Mesna dose ≥60% of ifos dose b D1, D2, D3, D4Loading Dose
CycleOlara 20mg/kg Cycle 1
Olara 15 mg/kg Cycles 2 to 6aD1and D 8
D1 and D8
Dox 25 mg/m 2per day D1, D2, D3 75 mg/m 2
Ifos 2.5 g/m 2per day b D1, D2, D3, D4 10 g/m 2
Mesna dose ≥60% of ifos dose b D1, D2, D3, D4Dose Confirmation
Phase
Olara 
recommended 
doseOlara dose determined from Dose -
Finding Phase aD1and D 8
Dox 25 mg/m 2per day D1, D2, D3 75 mg/m 2
Ifos 2.5 g/m 2per day b D1, D2, D3, D4 10 g/m 2
Mesna dose ≥60% of ifos dose b D1, D2, D3, D4
Abbreviations:  D = day; DLT = dose-limiting toxicity ;dox = doxorubicin; g = grams; ifos = ifosfamide; IV = 
intravenous; kg = kilogram; m2= square meters; mg = milligrams; olara = olaratumab.
aAll patients will receive study therapy (olaratumab + doxorubicin/ifosfamide/mesna) for a maximum of 6 cycles, 
or until a discontinuation criterion is m et.  Patients who discontinue doxorubicin, ifosfamide and mesna treatment
without evidence of disease progression willreceive olaratumab as monotherapy until there is evidence of 
disease progression, death, intolerable toxicity, or other withdrawal criter ia are met .
bIf DLT rules are exceeded in the olaratumab 15 -mg/kg cohort, a reduced dose of ifosfamide (7.5 g/m2total dose) 
will be explored.  This will be accomplished by omitting the Day 4 dose (that is, ifosfamide will be administered 
at a dose of 2.5 g/m2on D1, D2 and D3).  The Day 4 dose of mesna will be correspondingly omitted.   A Loading 
Dose Cy cleof olaratumab (20 mg/kg on Days 1 and 8 of C1, then 15 mg/kg on Days 1 and 8 of subsequent 
cycles) may also be explored in combination with thereduced dose of ifosfamide.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 13
LY30122072.Schedule of A ctivities
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 14
LY3012207Table JGDR .1. Pretreatment Schedule of Activities
Day Relative to C1D1 28 14 7 Instructions
Procedure
Informed consent X ICF must be signed before any 
protocol -specific procedures are performed. 
Assessments performed prior to the date of 
consent may be used as study -required 
assessments ,provided they are appropriately 
documented .
Inclusion/exclusion criteria X
Physical exam ination X Including height, weight and vital signs 
(temperature, blood pressure, pulse rate, 
respiration rate )
ECOG per formance status X
Medical history X Including assessment of preexisting conditions
and histo rical illnesses .
Priorand current medication X
Prior therapies for treatment of 
underlying diseaseX
AE collection X After consent, c ollect AEs continuously 
throughout pretreatment period.
CTCAE Version 4.0
Radiologic imaging and measurement 
of palpable or visible lesionsX RECIST 1.1
Scans performed prior to the date of consent 
may be used ,provided they are within 28 days 
of enrollment .  Imaging requirements include 
CT scan or MRI of the chest, abdomen and 
pelvis and other areas, as clinically indicated. 
It is recommended that CT imaging of the 
abdomen/pelvis be performed with IV contrast, 
whenever possible. If this is not 
feasible/advisable secondary to hypersensitivity 
or other conditions, then gadolinium -enhanced 
MRI is preferred. For patients with known 
serious allergic reactions to CT contras t 
material, a CT of the chest without contrast and 
contrast -enhanced MRI of the abdomen/pelvis 
are encouraged.
ECG X
Echocardiogram and/or MUGA scan X
Hematology X See Appendix 3 .  To be performed locally for 
patient management and centrally for analysis 
purposes.
Coagulation X See Appendix 3 .  To be performed locally.
Clinical chemistry X See Appendix 3 . To be performed locally for 
patient management and centrally for analysis 
purposes.
Urinaly sis X See Appendix 3 . To be performed locally .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 15
LY3012207Serum p regnancy  test X Applies only to women of childbearing 
potential .  SeeAppendix 3 .  To be performed 
locally.
Tumo r tissue X See Section 9.7.2 .
Sample collection See Appendix 4 .
Pharmacodynamics
Pharmacokinetics
Immunogenicity
Pharmacogenetics
Other biomarkers
Abbreviations:  AE = adverse event; C1D1 =Cycle 1 Day 1; CT = computed tomography ; CTCAE =Common 
Terminology Criteria for Adverse Events (NCI 2009); ECG =electrocardiogram; ECOG =Eastern Cooperative 
Oncology Group (Oken et al. 1982); ICF =informed consent form; IV = intravenous ; MRI = magnetic resonance 
imaging ; MUGA = mu ltiple -gated acquisition; RECIST 1.1 = Response Criteria in Solid Tumors Version 1.1 
(Eisenhauer et al. 2009).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 16
LY3012207TableJGDR .2. On-StudyTreatment Schedule of A ctivities
Day within Cycle
ProcedureCycles 1-6
(olaratumab + doxorubicin 
+ifosfamide ;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy a
(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Physical 
exam inationX X X Perform prior to infusion of study drug(s).
Includes weight and BSA.
Vital signs X X X X X X X Vital signs include temperature, blood pressure, pulse rate, respiration rate.  
Concomitant 
medicationX X Concomitant medications will be recorded continuously throughout the treatment period.
AE collection X X Collect continuously throughout the treatment period; CTCAE Version 4.0.
ECOG performance 
statusX X
Radiologic imaging 
and measurement of 
palpable or visible
lesionsX X Perform according to RECIST 1.1, by the same method used at baseline, q 6weeks ( -7days) 
from the start of treatment until radiographic disease progression, death, or study completion, 
whichever occurs first.
Perform as scheduled, even if study treatment is delayed or omitted.
ECG X X Perform local 12-lead ECG on Day 1 of Cycle 1 through Cycle 6 .
Perform local 12 -lead ECG on Day 1 of Cycle 7 and approximately 6 months (±14 days) and 
12months (±14 days) after discontinuation of doxorubicin and ifosfamide treatment
Echocardiogram 
and/o r MUGA scanX
C4 and C6X Perform at the end of C4 and C6; perform additional evaluations in the setting of cardiac 
symptoms and/or at the discretion of the investigator.
For patients receiving olaratumab as monotherapy following discontinuation of combination 
therapy , perform approximate ly 6 months (±14 days) and 12 months (±14 days) after 
discontinuation of doxorubicin and ifosfamide treatment.
Hematology X X X X X 3days prior to administration of study treatment on D1 and ≤1 day prior to administration of 
study treatment on D8 , unless more frequent assessment is clinically indicated . Day  15 labs may  
be drawn within ±1 day of Day 15.  See Appendix 3 .  To be performed locally for patient 
mana gement and centrally for analysis purposes.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 17
LY3012207Day within Cycle
ProcedureCycles 1-6
(olaratumab + doxorubicin 
+ifosfamide ;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy a
(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Coagulation X X 3 days prior to administration of study treatment on D1, unless more frequent assessment is 
clinically indicated.  For patients receiving olaratumab as monotherapy following combination 
therapy  discontinuatio n, perform o n D1 of ever y other cycle.  See Appendix 3 .  To be performed 
locally.
Clinical chemistry X X X X 3 days prior to administration of study treatment on D1 and ≤1 day prior to administration of 
study treatment on D8, unless more frequent assessment is clinically indicated. Day 15 labs may 
be drawn within ±1 day of Day 15.  See Appendix 3 .  To be performed locally for patient 
management and centrally for analysis purposes.
Urinaly sis X X X X Monitor patients for evidence of micro -and/o r macroscopic hematuria and treat according to 
institutional standards.
Pregnancy  test X X Applies only to women of childbearing potential
Where required by local law or regulation, perform once every 21 days ( -7 days) prior to 
administration of study treatment. 
To be performed locally
Administer 
olaratumabX X X X Administer IV over 60 (±5) min.  Administer until a maximum of 6 cycles is complete, or until 
PD, unacceptable toxicity, death, or other withdrawal criteria are met.  Patients who discontinue 
doxorubicin, ifosfamide and mesna treatment without evidence of disease progression willreceive 
olaratumab as monotherapy until there is evidence of di sease progression, death, intolerable 
toxicity, or other withdrawal criteria are met.  Patients who undergo surgical tumor resection 
following study treatment are not eligible to receive olaratumab as monotherapy.   See section 
7.1.1 for olaratumab premedication requirements.  See section 7.8.1 for olaratumab IRR 
monitoring period requirements.
Administer 
doxorubicin X X X Administer IV over less than 60 (±5) min or as a continuous IV infusion (according to 
institutional guidelines) after completion of olaratumab infusion and any required observation 
period.  Administer until a maximum of 6 cycles iscomplete, or until PD, u nacceptable toxicity, 
death, or other withdrawal criteria are met. See Section 7.1.2 for details of dexrazoxane 
administration.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 18
LY3012207Day within Cycle
ProcedureCycles 1-6
(olaratumab + doxorubicin 
+ifosfamide ;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy a
(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Administer 
ifosfamideX X X X
*Administer IV over 3 hours (±15 min).  Administer until a maximum of 6 cycles iscomplete, or 
until PD, unacceptable toxicity, death, or other withdrawal criteria are met. 
*Patients treated in cohorts with ifosfamide dose reduction will have the Day 4 dose omitted (that 
is, ifosfamide will be administered at a dose of 2.5 g/m2on D1, D2 and D3).
Administer mesna X X X X See Section 7.1.3 for details of mesna administration.
G-CSF X The use of G -CSFs is required.  Administer according to ASCO and NCCN guidelines.  In 
general, G -CSF products like filgrastim or pegfilgrastim should be administered approximately 24 
hours after the completion of cytotoxic chemotherapy (for example, on Day 5 for patients in full -
dose ifosfamide cohorts or Day 4 for patients in reduced -dose ifosfamide cohorts).
Sample collection For all sample collection, s ee Appendi x 4.
Pharmacodynamics 
Pharmacokinetics
Immunogenicity
Pharmacogenetics
Other biomarkers
Abbreviations:  AE = adverse event; ASCO = American Society of Clinical Oncology; BSA =body surface area; C= cycle; CTCAE =Common Terminology 
Criteria for Adverse Events (NCI 2009); D= day ; ECG =electrocardiogram; ECOG = Eastern Cooperative Oncology Group (Oken et al. 1982); G-CSF = 
granulocyte -colon y stimulating factor; IRR =infusion -related reaction; IV = intravenously; LVEF = left ventricular ejection fraction; min = minutes; MUGA 
= multiple -gated acquisition; NCCN = National Comprehensive Cancer Network; PD = progressive disease; q = every; RBC = red blood cell; RECIST 
1.1=Response Criteria in Solid Tumors Version 1.1 (Eisenhauer et al. 2009).
aOlaratumab monotherapy schedule applies to patients whohave completed 6 cycles of olaratumab plus doxorubicin and ifosfamide and are continuing 
treatment with olaratumab monotherapy or have discontinued doxorubicin plus ifosfamide and are continuing with olaratumab mon otherapy.  Note: if a 
patient discontinues doxorubicin plus ifosfamide treatment prior to completing 6 cycles and is continuing treatment with olaratumab monotherapy, perform 
procedures according to the olaratumab monotherapy schedule beginning the next cycle after the patient discontinues doxorubi cin/ifosfamide .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 19
LY3012207Table JGDR .3. Post -Treatment Follow -Up Schedule of A ctivities
ProcedureShort -Term 
Follow -Up aLong -Term 
Follow -Up Instructions
Visit 801 802–8XX
Physical exam ination X Including weight and vital signs ( temperature, blood pressure, pulse rate, 
respiration rate )
Concomitant medication X
AE collection X CTCAE Version 4.0 . 
ECOG per formance status X
Radiologic imaging and measurement of 
palpable or visible lesionsX X* *For patients whose disease has not progressed :
Perfor m q 6 weeks ×2, then q 3 mo until:
the patient has objective disease progression according to 
RECIST 1.1 or
thestudy’s primary /final analy sis
Perform using the same method used at baseline and throughout the study .
For patients who have had objective disease progression :
Radiologic tests and measurement of palpable or visible lesions are no 
longer required ; these patient sshould be followed up for OS and 
collection of post -study treatment anticancer therapy information 
collection as indicated below .
Collection of survival information X Perfor m q 2 mo (±7 days) for the firs t 2 years after discontinuation from 
study treatment and q 6 mo (±14 day s) thereafter until death or study 
completion .  If an in -person visit is not possible, confirm survival by 
contacting the patient directly via phone.
Collection of post -study treatment anticancer 
therapy  informationX X Perform q 2 mo (±7 days) for the first 2years after discontinuation from 
study treatment and q 6 mo (±14 days) thereafter until death or study 
completion.
ECG X X All patients should have a 12- lead ECG performed at short -term 
follow -up.
Patients should also have a 12- lead ECG performed approximately 6 
months ( ±7 days) and 12 months ( ±7 days) after the end of treatment 
with doxorubicin and ifosfamide .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 20
LY3012207ProcedureShort -Term 
Follow -Up aLong -Term 
Follow -Up Instructions
Visit 801 802–8XX
Echocardiogram and/or MUGA scan X P erform at 6 months ( ±7 days) and 12 months ( ±7 days) after the end of 
treatment with doxorubicin and ifosfamide .  Echocardiograms/MUGA 
scans may  be discontinued if the patient begins another anticancer therapy.   
Perform additional evaluations in the setting of cardiac symptoms and/or 
at the discretion of th e investigator.
Hematology X See Appendix 3 .  To be performed locally for patient management and 
centrally  for analy sis purposes.
Coagulation X See Appendix 3 .  To be perfo rmed locally.
Clinical chemistry X See Appendix 3 .  To be performed locally for patient management and 
centrally  for analy sis purposes.
Urinaly sis X See Appendix 3 .  To be perfo rmed locally.
Sample collection
For all sample collection, see Appendix 4 .Pharmacodynamics
Pharmacokinetics
Immunogenicity
Pharma cogenetics
Other biomarkers
Abbreviations:  AE=adverse event; CTCAE =Common Terminology Criteria for Adverse Events (NCI 2009) ; ECOG = Eastern Cooperative Oncology Group 
(Oken et al. 1982); mo = month; MUGA = multiple -gated acquisition; OS = overall survival ; q =every; RECIST 1.1 =Response Criteria in Solid Tumors 
Version 1.1 (Eisenhauer et al. 2009).
aShort -term fo llow-up begins the day after the patient and the investigator agree that the patient will no longer continue study treatment and l asts 
approximately 30 days (±7 days).   No follow -up procedures will be performed for a patient w ho withdraws informed consent unless he or she has explicitly 
provided permission and consent.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 21
LY3012207TableJGDR .4. Continued A ccess Schedule of A ctivities
VisitStudy Treatment Follow -Up a
Instructions501-5XX 901
Procedure b
AE collection X X CTCAE Version 4.0
See Section 9.2.
Pharmacokinetics and immunogenicity X If a patient experiences an IRR, collect blood samples for 
pharmacokinetics and immunogenicity analy sis at the following time 
points:  (1) as soon as possible after the onset of the IRR, (2) at the 
resolution of the IRR and (3) 30 days after the IRR.
Administer olaratumab X 21-day  cycles
Administer until PD, unacceptable toxicity, death, or other withdrawal 
criteria are met. 
Abbreviations:  AE =adverse event; CTCAE = Common Terminology Criteria for Adverse Events; IRR =infusion -related reaction.
aContinued access follow -up begins 1 day after the patient and the investigator agree that the patient will no longer continue treatment in the continued access 
period and lasts approximately 30 days. No follow -up procedures will be performed for a patient who withdraws informed consent unless he or she has 
explicitly  provided permission and consent.
bEfficacy assessments will be done at the investigator’s discretion based on the standard of care.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 22
LY30122073.Introduction
3.1. Background
3.1.1. Soft Tissue Sarcoma
Soft tissue sarco ma (STS) is a heterogeneous group of malignant tumors that arise fro m tissue of 
mesenchymal origin. Soft tissue sarco ma arises primarily fro m the embry onic m esoderm , with 
some neuroectodermal contribut ion and different iation to non -epithelia l extraskeletal t issue, 
including striated skeletal and smooth muscle, adipose and fibrous tissue (Sharma et al. 2013; 
D’Angelo et al. 2014; Linch et al. 2014).  There are approximately 50 different ty pes of  STS that 
can be found in almost any anatomic loc ation (Ameri can Cancer Soci ety 2014; Linch et al. 
2014).  STS is rare, comprising approximately 1% of adult cancers.  The annual incidence o f 
STS in the United Kingdo m and United States (US) is 3300 and 10,000, respectively (Jemal et 
al. 2009 ; Soft tissue sarco ma statist ics page [WWW] 2010 ).  A m ultidisciplinary  setti ng wit h 
teams specializing in the treatment of STS is the best treatment approach for these tumors.  
Management of localized disease is usually  with curative intent, using surgical resect ion with or 
without radi otherapy  and chemotherapy. In spite of init ial aggressive management, there is 
frequent recurrence of local inoperable or metastatic disease, and at this po int systemic therapy  
plays a prominent role in the mult idisciplinary  management o f STS (Linch et al. 2014).
The m ainstay  therapy for treating advanced -stage STS has been chemotherapy , which in the 
first-line setting has provided overall response rates of approximately 25% (Linch et al. 2014).  
Even with the use of chemotherapy , advanced -stage STS is usually  fatal and there remains a 
need for novel and effect ive therapies.  Doxorubicin either al one or in combinat ion has served as 
the init ial treatm ent for metastati c sarcom a for m any years. Various other drug combinat ions 
have also been explored (Linch et al. 2014).  In more recent y ears,the addi tion of  ifosfamide to 
doxorubi cinhas demonstrated increased tumor response and progressi on-free survival (PFS)
compared to doxorubicin alone, wi th a similar overall  survival ( OS)and a higher incidence o f 
Grade 3 and 4 toxicit ies(Judson et al. 2014) .  This regimen is used in the clinical setting where 
shrinking of the tumor is important and where the patient can tolerate the risk of greater toxicit ies 
compared to doxorubicin alone; this regimen has also been evaluated in the neo adjuvant and 
adjuvant settings for pati ents wi th STS (Gortzak et al. 2001; Grobmyer et al. 2004; Pisters et al. 
2016) . 
3.1.2. Olaratumab
Olaratum ab is a recombinant human immunoglobulin G subclass 1 -type m onocl onal ant ibody  
that binds to platelet -derived growth factor receptor alpha(PDGFR α).This antibody possesses 
high-affini ty binding for PDGFR αand blocks platelet -derived growth factor (PDGF )-AA, -BB 
and -CC fro m binding to the receptor. In addit ion to blocking ligand -induced cell mitogenesis 
and receptor autophosphorylat ion, olaratum ab inhibits ligand -induced phosphorylat ion of the 
downstream signaling mo lecules Akt and m itogen -activated protein kinase (Loizos et al. 2005; 
Study  Report IMC -3G3-01).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 23
LY3012207In norm al mesenchymal bi ology, PDGF/PDGFR signaling has a significant role in mesenchymal 
stem cell different iation, growth of mesenchymal cells, angioge nesis and wound healing (Andrae 
et al. 2008; Ng et al. 2008; Li et al. 2014). PDGF/PDGFR α signaling has been implicated in the 
pathogenesis of mult iple cancers, including osteosarcoma, chondrosarcoma, prostate cancer, 
breast cancer, ovarian cancer and oth ers. In malignant disease, the PDGF/PDGFR αaxis 
prom otes tum or growth and proliferat ion through both autocrine and paracrine mechanisms. 
PDGFR αis expressed on stromal cells, as well as the cancer cells themselves, within certain 
tumors. Furthermore, st udies have shown that PDGF/PDGFR αsignaling affects tumor 
vasculature through paracrine mediation o f vascular endothelial growth factor production (Shah 
et al. 2010).
3.2. Study Rationale
Study  I5B-MC-JGDG (Study  JGDG) was a Phase 1b/rando mized Phase 2 study  evaluat ing the 
efficacy  of doxorubi cinwith or wi thout olaratum ab in the treatment of advanced STS.  The study  
met i ts primary  endpoint for PFS ( hazard ratio [ HR] = 0.67; p = 0.06 as compared to a 
prespecified alpha level o f 0.2) wi th an improvement in median PFS and OS of 2.5 months and 
11.8 m onths, respect ively, for olaratumab plus doxorubi cinover doxorubi cinalone, with a 
manageable safet y profile .  The OS HR of 0.46 was highly  stati stically significant (p =0.0003; 
Tap et al . 201 6).  Based on these results, olaratumab has received condit ionalapprov alin the US 
and European Unio nin combinat ion with doxorubicin for the treatm ent of adult patients with 
STS. 
While doxorubi cinalone or in combinat ion with other chem otherapeutic agents has been the 
mainstay  of treatm ent for decades (Linch et al. 2014), in more recent y ears the combinat ion of 
doxorubi cin, ifosfamide and mesna has demo nstrated increased tumor resp onse and PFS 
compared to doxorubicin alone. However, this regimen is associated with a higher rate of Grade 
3 and 4 toxicit ies and no improvement in OS (Judson et al. 2014) , limit ing the use of this 
regimen to distinct clinical setting s, such as whenshrinkage of the tum or is important and the 
risk of greater toxicit y is felt to represent an acceptable benefit -risk.  This regimen has been 
evaluated in the neoadjuvant and adjuvant settings for patients with STS (Gortzak et al. 2001; 
Grobmyer et al. 2004; Pi sters et al. 2016) .
The posi tive efficacy  resul ts seen wi th olaratum ab in combinat ion with doxorubi cinin Study  
JGDG provi de strong rati onale for determining whether olaratumab can also be safely  added to 
thedoxorubicin, ifosfamide and mesna regimen. It is plausible that the addit ion of o laratumab to 
doxorubi cin, ifo sfamide and mesna may further increase efficacy endpo ints such as tumor 
response rate , PFS and OS, without a clinically significant increase in toxicity.Study  
I5B-MC-JGDR (Study  JGDR) will characteri ze the safet y and tol erabili ty of olaratum ab in 
combinat ion with doxorubi cin, ifosfamide and mesna in pat ients with advanced STS , and if 
acceptable, determine the dosing regimen o f olaratum ab in combinat ion with doxorubi cin and 
ifosfamide appropri ate for future studies of this combinat ion.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 24
LY30122073.2.1. Rationale for Amendment (a)
The ori ginal  Study  JGDR protocol ,versio n dated 14 March 2017, was amendedto remove visits 
and/or procedures not intended for patients receiving olaratumab mo notherapy only after 
completing6 cycles of olaratumab plus doxorubi cinand ifosfamide (or discont inued doxorubi cin 
and ifo sfamide before).  In parti cular, visits and procedures specifically used to administer and 
monitor for toxicit y from the doxorubi cin and ifo sfamide co mbinat ionhave been remo ved for 
patients receiving olaratum ab m onotherapy .
The timing of ECHO/MUGA scans after discont inuation of doxorubicin plus ifo sfamide 
treatm ent was cl arified and ECG evaluat ions were ad ded at the same frequency to ensure 
complete evaluat ion of any  potenti al cardi otoxic effects following treatment with doxorubicin 
plus ifo sfamide.
The wording pertaining to required contraceptive use fo llowing study  treatm ent has been 
clarified to align with label requi rement f or doxorubicin .
In addit ion, some minor editorial changes have been made throughout the protocol to improve 
clarity and pract icalit y of the protocol  and secure alignment with the intended study  design.
3.3. Benefit -Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of olaratum abare to be found in the 
Invest igator’s Brochure (IB).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 25
LY30122074.Objectives and Endpoints
TableJGDR .5shows the objectives and endpo ints ofthe stu dy.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 26
LY3012207TableJGDR .5. Objectives and Endpoints
Objectives Endpoints
Primary
To characterize the safety profile of olaratumab 
when given in combination with doxorubicin, 
ifosfamide and mesna and to determine the 
dosing regimen appropriate for a future Phase 2 
studyDLTs, TEAEs, SAEs and clinical laboratory 
abnormalities per NCI -CTCAE Version 4.0 
Secondary
To evaluate the PKof olaratumab when 
combined with doxorubicin, ifosfamide and 
mesna
To evaluate the immunogenicity of olaratumab 
when combined with doxorubicin, ifosfamide 
and mesna
To document any antitumor activity of 
olaratumab when combined with doxorubicin, 
ifosfamide and mesnaPK:  Cmaxand AUC from time 0 to the last 
time point with a measurable concentration, and 
AUC from time 0 to infinity of olaratumab.  
Other noncompartmental parameters, such as 
half-life, clearance and volume of distribution 
may be reported.  Plasma doxorubicin and 
ifosfamide concentrations will be summarized 
by descriptive statistics
Immunogenicity:   Anti-olaratumab antibody 
levels at baseline, during the study, at the 
30-day  follow -up vi sit and in the event of 
olaratumab IRRs
Antitumor activity:   Radiographic 
assessments according to RECIST Version 1.1 
criteria ever y 6 weeks (-
7 days) until 
radiographic documentation of PD.  Efficacy 
endpoints will include objective response rate, 
PFS, du ration of response, disease con trol rate 
and OS
Exploratory
To explore biomarkers related to, but not 
limited to tumor microenviro nment, immune 
cells/immune functioning, mechanism of action 
of study drugs, PDGF, cancer -related pathways 
and disease state, and their association with 
demographics, disease state and clinical 
outcomesBiomarker assay results with other trial data
Abbreviations: AUC = area under the concentration curve; C max= maximum observed concentration; DLT = 
dose-limiting toxicity ; IRR = infusion -related reaction; NCI- CTCAE = National Cancer Institute Common 
Terminology Criteria for Adverse Events; OS = overall survival; PD = progressive disease; PFS = progression -
free survival; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious 
adverse event; TEAE = treatment -emergent adverse event.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 27
LY30122075.Study  Design
5.1. OverallDesign
Study  JGDR is a multicenter , nonrando mized, open -label, Phase 1 bstudy  ofintravenous (IV) 
olaratumab in combinat ion with doxorubi cin, ifosfamide and mesna in patients with advanced or 
metastati c STS.
Dose- Finding Phase
Bone m arrow suppressi on occurs rel atively frequent ly wit h the doxorubicin, ifo sfamide and 
mesna regimen and can lead to complicat ions suc h as fever and neutropenia, infect ion, or 
bleeding, which are generally considered DLT -level toxici ties and thus can confound 
determinat ion of DLT in the setting of co mbinat ion with olaratum ab.  The EORTC Phase 3 study  
(Judson et al. 2014) demonstrated a 4 6% rate of febrile neutropenia in pat ients with STS who 
were treated with doxorubicin, ifosfamide and mesna.  Because of this relatively high rate of  
DLT -level toxicit y with the backbone doxorubicin, ifosfamide and mesna regimen and the 
generally acceptab le toxi city profile of the 15 -mg/kg dose of olaratumab (Days 1 and 8 every  
21days) in co mbinat ion with other chemotherapeutic agents including doxorubicin, 
approximately  15 pati ents will be enrolled at the first dose level o f olaratum ab (and evaluated 
after 6, 9 and 15 patients have received 1 cy cle of therapy) to allow sufficient patient numbers to 
judge init ial tol erabilit y of o laratumab in co mbinatio n with doxorubi cin, ifosfamide and mesna.   
See Table JGDR. 7for a detailed explanation o f the dose-limiting toxicit y
(DLT )thresho lds that 
will be used to govern enro llment in the Dose -Finding Phase and Secti on 10.1 for the statist ical 
justificat ion of the study  design .
Olaratumab 15- mg/kg Dose Level:   The first phase of the study (Dose -Finding Phase)will 
evaluate the safet y and tol erabili ty ofadding olaratum ab to the regimen of doxorubicin 
(75mg/m2plus given as IV infusions of 25 mg/m2on Day s 1 to 3) ,ifosfamide ( 10 g/m2given as 
IVinfusio ns of 2.5 g/m2on Day s 1 to 4 ) and mesna according to a 21 -day cycle .  Fifteen patients 
will be init ially enro lled and treated with a 15 -mg/kg dose of olaratumab (on Day s 1 and 8 of a 
21-day cycle) in combinat ion with doxorubi cin, ifo sfamide and mesna and assessed for safet y 
after 1 cy cle of therapy . The full cohort of 15 patients will be enro lled if 5 or fewer patients with
DLTs are observed in the first 6 and 9 patients , respectively .
Olaratumab 20- mg/kg Loading Dose Cycle Dose Level:   Following an evaluat ion of safet y in 
the full cohort of 15 patients (and provided 8 or fewer of these pat ients have experienced DLTs) , 
the study  will progress to evaluate a loading dose cycle of olaratum ab (20 m g/kg IV on Day s 1 
and 8 of Cycle 1 only , then 15 m g/kg on Day s 1 and 8 of subsequent cy cles) in combinat ion with
doxorubi cin, ifo sfamide and mesna in a new cohort of 15 patients. Section 5.5.1 details the 
rationale for the l oading dose. The full cohort of 15 pati ents will be enrolled if 5 or fewer
patients withDLTs are observed in the first 6 and 9 pati ents, respecti vely.  
Olaratumab 15-mg/kg Dose Level:  Ifosfamide Dose Reduction Option
If during enro llment into the olaratumab 15 -mg/kg dose level, DLT sare observed in 6 of the first 
6 pati ents, in ≥6 of the first 9 patients ,or in ≥9 of the full cohort of 15 pati ents,the study  will 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 28
LY3012207proceed to explore a reduced ifosfamide dose (7.5 g/m2total dose) in combinat ion with 
olaratum ab 15 m g/kg and the same do xorubicin dose in a new cohort of 15 patients.  If DLT sare 
observed in 6 of the first 6 patients, in ≥6 of the first 9patients , or in ≥9 of the full cohort of 15 
patients at this reduced ifosfamide dose, the study  will halt and no f urther patients will b e 
enrolled.  If 8 or fewer patients withDLTs are observed in thisfull cohort of 15 patients , the 
study  will progress to expl ore the ol aratumab Loading Dose C ycleas previ ously  described in 
combinat ion with the reduced ifosfamide dose (and same doxorubici n dose) as previ ously  
described.
Olaratumab 20-mg/kg Loading Dose Cycle Dose Level :  Ifosfamide Dose Reduction Option
If during enro llment into the olaratumab 20-mg/kg Loading Dose Cycle dose level, DLT sare 
observed in 6 of the first 6 patients, in ≥6 of  the first 9 patients, or in ≥9 of the full cohort of 
15patients, no further patients will be enro lledat this dose l evel and ol aratum ab 15 m g/kg will 
be declared the recommended dose for combinat ion with reduce d-dose ifosfamide/mesna and 
doxorubi cin.  If 8or fewer patients withDLTs are observed in this full cohort, the olaratumab 
20-mg/kg loading dose cycle together with a reduced ifosfamide/mesna dose will be declared the 
recommended dose sfor combina tion wi th doxorubicin.
Dose Confirmation Phase :  If a safe and tolerable regimen of o laratumab in co mbinat ion with 
doxorubi cin, ifo sfamide and mesna is established in the Dose -Finding Phase, the second phase of 
the study  (Dose Confirmat ion Phase )will open to further eval uate the regimen at the 
recommended dosesof olaratum aband ifosfamide/mesna in combinat ion with doxorubi cinin an 
additional 15 pati ents, wi th the goal  of treating a total of 30 patients with the recommended 
regimen .  Patients will continu e combinat ion treatment for up to a maximum o f 6 cycles, unless
there is documented disease progression, unacceptable toxicit y, death, or other discontinuation 
criteria are met (Section 8).  Patients who discont inue doxorubi cin, ifosfamide and mesna
treatm ent wi thout evi dence of disease progression willreceive ol aratum abasmonotherapy  until  
there is evidence of disease progression, death, intolerable toxicit y, or other wi thdrawal  criteria 
are met (Section 8).  Patien ts who undergo surgical tumor resection following study  treatm ent 
are not eligible to receive olaratumab as monotherapy .
Figure JGDR .1illustrates the study  design.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 29
LY3012207Abbreviations:   D = day; DLT = patients experiencing a dose-limiting toxicity; Dox = doxorubicin; g = grams; Ifos = ifosfamide; kg 
= kilogram; m2= square meters; mg = milligrams; Olara = olaratumab; N = number; TBD = to be determined.
aPatients who discontinue combination study therapy without evidence of disease progression will receive olaratumab as 
monotherapy until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are m et.
Figure JGDR .1. Illustration of study design.

I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 30
LY30122075.1.1. Dose -Finding Phase :  Olaratumab 15 -mg/kg Dose Level
The purpose of this single -arm cohort is to determine whether a 15- mg/kg dose of olaratumab
(on Days 1 and 8) may be safely added to the doxorubicin, ifo sfamide and mesna regimen in
patients wi th advanced or m etastati c STS. No intrapatient dose escalat ion is permitted in this 
cohort .Patients who do not complete Cy cle 1 treatm ent for reasons other than a DLT wi ll be 
replaced.   Safety  data for th is patient cohort will be reviewed prior to dose escalation . The total
number of patients with DLTs andthe type of DLTs will be considered prior to m aking a 
decisio nto escalate the olaratumab dose .
5.1.2. Dose -Finding Phase : Olaratumab 20 mg/kg Loading DoseCycle
Level
The purpose of this single arm cohort is to determine whether a20 m g/kg loading dose cycle of 
olaratum ab (given on Days 1 and 8 of Cycle 1 only , followed by 15 m g/kg on Days 1 and 8 of 
subsequent cy cles) may be safely added to the doxorubi cin, ifo sfamide and mesna regimen in 
patients wi th advanced or m etastati c STS.   Patients who do not complete Cy cle 1 treatm ent for 
reasons other than a DLT will be replaced. Safety data for thiswill be reviewed prior to dose 
determinat ion for the Dose ConfirmationPhase.   The total number of patients with DLTs andthe 
type of DLTs will be considered prior to making a dose determinat ion.
5.1.3. Dose -Finding Phase:  Ifosfamide Dose Reduction Option s
If DLT rul es (see Section 7.2.2.1 ) are exceeded at the o laratumab 15 -mg/kg dose, the study 
includes the option to explore a reduced ifosfamide dose (7.5 g/m2given as daily IV infusio ns of 
2.5 g/m2on Day s 1 to 3) in combinat ion with olaratum ab 15 mg/kg (and doxorubicin) .  
See 
Secti on 5.5.2 for the rationale for this re duced dose. If the 15- mg/kg dose of olaratumab is 
determined to be safe and tolerable in combinat ion with the reduced ifosfamide dose (see Section 
7.2.2 for DLT cri teria to advance to next phase), a second cohort exploring a 20 -mg/kg loading 
dose cycle of olaratum abin combinat ion with ifosfamide at the reduced dose will be enrolled.   
These cohorts will be evaluated in the same manner as described in Sections5.1.1 and 5.1.2 .
5.1.4. Dose Confirmation Phase
Provi ded a safe and tol erable dose of ol aratum ab in co mbination wit h doxorubi cin, ifo sfamide 
and mesna (ifosfamide/mesna at full dose or reduced dose) is ident ified, this dose will be 
explored in a Dose Confirmat ion Phase of the study .
5.2. Number of Patients
Study  JGDR aims to enroll approximately  45 to 60 patients in total , with the goal  of treating a 
total of approximately 30 pati ents wi th the recommended regimen .
5.3. Study Completion Definition
The s tudy will be considered complete 30 days after all pat ients in the Dose Confirmation Phase 
complete or di scont inue o laratumab and doxorubicin, ifo sfamide and mesna combinat ion 
therapy .  See Section 7.9for details on treatment after the completion o f the study .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 31
LY30122075.4. Scientific Rationale for Study Design
See Secti on 3.2.
5.5. Justification for Dose
5.5.1. Olaratumab
In combinat ion with doxorubicin, ifo sfamide and mesna , this study will start at an olaratum ab 
dose of 15 m g/kg on Day s 1 and 8 of a 21- day cycle .  This dosing regimen has been 
demonstrated to have an acceptable safet y profile in co mbin ation wi th doxorubi cin
(Study JGDG) and was associated with improvement in PFS and OS . If this dose of ol aratumab 
is found to be safe and tolerable with the doxorubicin and ifosfamide combination , then an 
olaratum ab Loading Dose C ycleof20mg/kg on Days 1 and 8 of a 21 -day cycle in Cycle 1 only , 
followed by 15 m g/kg on Days 1 and 8 of subsequent cy cleswill be expl ored.
In Study  JGDG, PK m odel simulat ions indicate dthat olaratum ab loading doses of 20 mg/kg 
administered on Day  1 and Day  8 of Cycle 1 would allow steady -state ol aratum ab serum  levels 
to be achieved with the first administration and would minimize the number of pat ients whose 
serum  trough level at the end of the first cy cle of  treatm ent(Cmin1)falls below 61 µg/mL during 
the first 2 cy cles.  Addi tionally, a dose of 20 m g/kg olaratumab administered on Day  1 and Day  8 
during the first cy cle, foll owed by 15 m g/kg administered on Day  1 and Day  8 of all subsequent 
cycles is p redicted to yield maximum serum concentrations within the overall range observed in 
Study  JGDG.  Therefore, olaratumab -relatedsafety risks related to high serum concentrations or 
exposure using this loading dose approach are expected to be similar to thos e in Study  JGDG.   
This dosing strategy  is expected to minimize the number of patients exposed to subtherapeutic 
olaratum ab serum  levels wit hout an increased risk of toxicit y, thereby  optimizing the benefit -risk 
ratio.This loading dose cy cle strategy  is analogous to that used in Study  JGDK and under study  
in the ongo ing Phase 3 Study  JGDJ. 
5.5.2.D oxorubicin, Ifosfamide and Mesna
The doxorubi cin, ifo sfamide and mesna regimen is an effect ive option for patients with sarcoma 
and has been studied using a diverse range of doses and across subtypes ( Worden et al. 2005; 
Maurel et al . 2009; Judson et al. 2014 ).  The doses of doxorubi cin, ifo sfamide and mesna chosen 
for Study  JGDR ar e based on the EORTC study reported by Judson et al, the largest randomized 
study  to date using the doxorubi cin, ifosfamide and mesna regimen in patients wi th STS. In that 
study , patients receive ddoxorubi cin 25 mg/m2per day  on Days 1 to 3 and ifosfamide 2.5g/m2
per day onDays 1to 4 (plus mesna ), followed by pegfilgrast im. Treatm ent was repeated every  
3weeks unt il disease progression or unacceptable toxic effects, up to a maximum of 6cycles.  
In the event the 15 -mg/kg dose of olaratumab in combinat ion with doxorubi cin, ifosfamide and 
mesna is not tolerated, the study includes an option to explore a reduced dose of ifosfamide 
(7.5g/m2given as daily IV infusio ns of 2.5 g/m2on Days 1 to 3 , a dose of ifo sfamide use d in 
clinical practice [Grobmyer et al. 2004] )during the Dose -Finding phase.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 32
LY30122076.Study  Population
All patients meeting the eligibilit y requirements will be considered for enrollment regardless of 
race, religio n, or gender. The invest igator or the sponsor will not grant except ions to eligibilit y 
criteria.  Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also 
known as protocol waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Patients areeligible to be included in the study  only  if theymeet all o f the following criteria:
[1] Havea histologicaldiagnosis of advanced STS (by local patho logy review), 
for which treatm ent wi th doxorubi cin, ifo sfamide and mesna is deemed 
appropriate by  the in vestigator .  Patients with a diagnosis of Grade 1 
liposarcoma ( atypical  lipomatous neoplasms) are eligible if there is 
histol ogical or radi ographic evidence of evo lution to more aggressive di sease.
[2] Havemeasurable or nonmeasurable but evaluable disease as defined by the 
Response Evaluat ion Cri teria in Solid T umors (RECIST 1.1) (Eisenhauer 
etal. 2009).   Tumors wi thin a previously  irradiated field will be designated as 
“nontarget” lesio ns unless progression is documented or a biopsy is obtained 
to confir m persistence at l east 90 days fo llowing com pletion of radiotherapy .
[3] Are18 years of age at the time of consent .
[4] Havegiven wri tten inform ed consent prior to any  study -specific procedures .
[5] Haveadequate hem atologic, organ and c oagulati on function within 2 weeks 
(14 days) prior to enrollment:
Absolute neutrophil count (ANC) ≥1.5 × 10 9/L.  G ranulocy te-colony-
stimulat ing factor ( G-CSF) cannot be administered within 2 weeks (14 days) 
prior to enrollment.
Platelet coun t ≥100 × 10 9/L
Hem oglobin ≥9.0 g/dL.  No transfusio ns are allowed within 2 weeks 
(14days) prior to enrollment.
Serum  creatinine ≤1.5 times upper limit of normal (ULN).  If creatinine is 
above the ULN, the patient’s creatinine clearance must be ≥65mL/min 
(refer to Appendix 6 for the Cockcroft -Gault formula for creatinine 
clearance).
Total  bilirubin withinULN (except for pati ents wi th Gilbert’s syndro me, 
who must have a total bilirubin <3 mg/dL)
Alanine aminotransferase (ALT )/aspartate aminotransferase 
(AST) ≤3.0 ×ULN; if the liver has tumor invo lvement , AST and ALT 
≤5.0 ×ULN are acceptable
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 33
LY3012207An adequate coagulat ion function as defined by internat ional normalized 
ratio (INR) ≤1.5 ×ULN or prothromb in time ≤1.5 ×ULN, and partial 
thromboplastin time ≤1.5 ×ULN (unless receiving anticoagula nt therapy ).  
Patients receiving warfarin are recommended to switch to low mo lecular 
weight heparin and shoul d have achieved stable coagulat ion status pri or to 
the first dose of study  treatm ent.
[6] Havea perform ance status of 0 to 1 on the Eastern Cooperative Onco logy 
Group scale .
[7] Havereceived no prior lines of systemic therapy (adjuvant or neo-adjuvant
treatm ent willnot be count edas a prior line) and aresuitable to receive 
doxorubi cin, ifo sfamide and mesna .  All  previ ous anti cancer treatm ents m ust 
have co mpleted ≥3 weeks (21 days) prior to the first dose of study  treatm ent.
[8] Have left ventricular ejection fraction (LVEF) ≥50% assessed within 28 days 
prior to enrollment.
[9] Haveresolution of AEs, wi th the except ion of alopecia, and of all clinically  
significant toxi c effects of pri or locoregi onal therapy , surgery orradiotherapy  
to ≤Grade 1, by Nat ional Cancer Institute -Commo n Termino logy Criteria f or 
Adverse Events (NCI -CTCAE) Version 4.0.
[10] Have sufficient available materi al from archived form alin-fixed 
paraffin -embedded tum or tissue for bi omarker -related studi es.  If such t issue 
is not available, a newly obtained core or excisio nal biopsy  of a tum or lesion 
must be performed.  Patients for whom it is inadvisable to undergo a new 
biopsy in the opinio n of the invest igator (for example, due to technically 
challenging tumor location) may be enro lled, after prior discussio n with the 
Lilly clinical research physician (CRP). Refer to Section 9.7.2 regarding 
tissue collection requirements.
[11] Arereliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures.
[12] If male, must be sterile or agree to use an effective method of contraception or 
a highly effective method of contraception during th e study  and f or at l east: 
3 months f ollowing the l ast dose of ol aratum ab
6 months f ollowing the l ast dose of doxorubicin or ifosfami de
Refer to Appendix 1 for definit ions of effective method of contraception and 
highly effective method of contraception .
[13] If female and of child -bearing potential ,must:
a.have a negat ive serum  pregnancy test wi thin 7 days prior to the first dose 
of study  treatm ent, an d
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 34
LY3012207b.agree to use a highly effective method of contraception during the study 
and fo rat least 3 m onths fo llowing the l ast dose of olaratum ab and 6 
months following the l ast dose of doxorubicin or ifosfamide .
Refer to Appendix 1 for the definit ionsof highly effective method of
contraception andeffective method of contraception .
Females not of child -bearing potenti al due to surgical  sterilizat ion (at least 
6 weeks following surgical bilateral oophorectomy with or without 
hysterectomy or tubal ligat ion) confirmed by medical history  or m enopause
are permitted on the study .
Apost-menopausal womanis a woman meet ing either of the fo llowing 
criteria:
spontaneous amenorrhea for at least 12 months, not induced by a 
medical condi tion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea that induced the amenorrhea (for example, oral 
contraceptives, horm ones, gonadotropi n-releasing horm one, 
antiestrogens, selective estrogen receptor modulators, or 
chemotherapy)
spontaneous amenorrhea for 6 to 12 months and a fo llicle-stimulat ing
horm one l evel >40 m IU/mL
[14] Havea life expectancy  of at least 3 months, in the opinio n of the invest igator.
6.2. Exclusion Criteria
Patients will  be excluded from  the study  if they  meet anyof the fo llowing cri teria:
[15] Are current ly enrolled in a clinical trial involving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study.
[16] H ave part icipated within the p
ast30 day s in a clinical trial involving an 
investigat ional product.  If the previous investigational product has a long 
half-life, 3 months or 5 half -lives (whichever is longer) should have passed .
[17] H ave previously co mpleted or withdrawn fro m any study  invest igating 
olaratum ab.
[18]Have received pri or treatm ent wi th olaratum ab, doxorubicin ,or ifosfamide , or 
have participated in other trials invest igating olaratumab .
[19] Have received prior radiotherapy  of the m ediastinal/pericardial area or whole 
pelvis radiat ion.
[20]
Have know n urinary  outfl ow obstructi on, or i nflammat ion of the urinary  
bladder (cystit is).
[21] Arediagnosed wi th gastrointestinal stromal tumor or Kaposi sarco ma.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 35
LY3012207[22] Have active central nervous system (CNS) or leptomeningeal metastasis
(brain metastasis) at the time o f enrollment .  Patients with a history  of CNS
metastasis (previously  treated wi th curative intent [for example, stereotactic 
radiation orsurgery ]) that hasnot progressed on follow -up imaging, have been 
asymptomat ic for atleast 60 days ,and are not receiving systemic 
corticosteroi ds and/ oranticonvulsants are eligible.  Patients with signs or 
symptoms of neuro logical com promise shoul d have appropriate radiographic 
imaging performed before enrollment to rul e out brain metastasis.
[23] Havea history  of another primary  malignancy , with the excepti on of :
a.curatively  treat ed non -melano matous skin cancer
b.curatively  treated cervi cal carcino ma in situ
c.non
-metastatic prostate cancer, or 
d.other primary  nonhematol ogic malignancies treated with curat ive 
intent, no known active disease, and no treatment administered 
during the last 3 y ears pri or to enrollment, that the investigator 
and Lilly  Medical representative agree will not affect 
interpretati on of  study  resul ts or woul d be unsui table for 
particip
ation in the study .
[24] Have an act ive fungal, bacterial and/or known viral infect ion including human 
immunodeficiency  virus or viral (A, B, or C) hepatit is (screening is not 
requi red). 
[25] Have Grade 3 or 4 peri pheral  neuropathy  perNCI-CTCAE Version 4.0.
[26] Have a seri ous cardiac condi tion, such as :
unstable angina pectoris
angioplasty ,cardiac stent ing or myocardial infarct ion within 6months of 
enrollment
valvulopathy that is severe, moderate, or deemed clinically  significant
arrhy thmias that are symptomatic or require treatment
[27]Have a rest ing heart rate of >100 bpm.
[28]Have aQTcFinterval of >450 m sec for males and >470 m sec for females on 
screening electrocardiogram (ECG) utilizing Fridericia’s correcti on (refer to 
formula in Appendix 7 ).  
[29] Have uncontrolled intercurrent illness including, but not limited to, an 
ongoing/act ive infection requiring parenteral ant ibiotics .
[
30]Have a psychiatri c illness/soci al situation that would limit compliance with 
study  requi rements.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 36
LY3012207[31] Haveelect ively planned or will require major surgery  during the course of the 
study .
[32] Arefemale swho arepregnant or breastfeeding.
6.3. Screen Failures
The dura tion of  the screening period is 14 day s for the m ajority of procedures (see Section 2); 
certain noted procedures may be performed wit hin 28 day s of enrollment .  Individuals who do 
not m eet the cri teria for parti cipat ion in this study  within the extended 28-day screening peri od
(screen failure) may be re -screened after discussi on with the Lilly  CRP . Individuals may be 
re-screened a maximum of 1time.   The interval between re -screenings should be at least 28days.
If
re-screening is performed, the individual must sign a new inf ormed consent form  (ICF) and 
will be assigned a new ident ificat ion number.
Repeat ing laboratory  tests during the 28- day screening period does not const itute re-screening.   
Screening laboratory  tests may not be repeated more than once in order to meet eligi bility during 
the 28-day screening period.If a repeat screening laboratory value meets eligibilit y, it is 
recommended that the test is rechecked to confirm stabilit y.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 37
LY30122077.Treatment s
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the drugs and planned duration of each individual’s 
treatm ent to the patient and study  site personnel
verifying that instructions are fo llowed properly
maintaining accurate r ecords of study drug dispensing and collect ion
at the end of the study  returning all unused medication to Lilly , or i ts desi gnee, 
unless Lilly  and si tes have agreed all  unused m edicati onshave to be destroy ed by  
the site, as allowed by  local law.
7.1. Treatment Administered (Dosing Schedule)
Table JGDR. 6shows the treatment regimens.   On days where mult iple study  drugs are to be 
administered, the drugs should be administered in the order shown in Table JGDR. 6.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 38
LY3012207Table JGDR. 6. Treatment sAdministered ( Dosing Schedule )
Phase and 
Dose Cohort
Drug Name and DoseDay of 21 -day 
(±3days) cycleTotal 
dose Route and duration of 
administration NotesDose-Finding Phase
Olara 15 mg/kgOlaratumab 15 mg/kg a D1and D 8 IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements andSection 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4b 10bg/m 2IV over 3 hours (±15min) Administer after doxon D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4b According to institutional practiceOlara Loading Dose CycleOlaratumab 20mg/kg Cycle 1
Olaratumab 15 mg/kg Cycles 2 to 6 aD1and D 8
D1 and D8IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements andSection 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1 and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4b 10bg/m 2IV over 3 hours (±15 min) Administer after doxon D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4b According to institutional practiceDose Confirmation Phase
Recommended Olara DoseOlaratumab dose determined from 
Dose -Finding Phase aD1and D 8 IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements andSection 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1 and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4b 10bg/m 2IV over 3 hours (±15 min) Administer after doxon D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4b According to institutional practice
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 39
LY3012207Abbreviations:  C = cycle; CRP = clinical research physician; D = day; DLT = dose -limiting toxicity; dox = doxorubicin; g = grams; ifos = ifosfamide; IRR= 
infusion -related reaction; IV = intravenous; kg = kilogram; m2= square meters; mg = milligrams; min = minutes ; olara = olaratumab .
aAll patients will receive study therapy (olaratumab + doxorubicin/ifosfamide/mesna) for a maximum of 6 cycles, or until a discontinuation crite rion is met. 
Patients who discontinue do xorubicin, ifosfamide and mesna treatment without evidence of disease progression will receive olaratumab as monotherapy until 
there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met .
bIf DLT rules (see Section 7.2.2.1 ) are exceeded in the olaratumab 15 -mg/kg cohort, a reduced dose of ifosfamide (7.5 g/m2 total dose) will be explo red.  This 
reduced dose will be communicated by the Lilly CRP and will be accomplished by omitting the Day 4 dose (that is, ifosfamide w ill be administered at a dose 
of 2.5 g/m 2on D1, D2 and D3).  The Day 4 dose of mesna will be correspondingly omitted.  A Loading Dose Cycle of olaratumab (20 mg/kg on Days 1 and 8 
of C1, then 15 mg/kg on Days 1 and 8 of subsequent cycles) may also be explored in combination with thereduced dose of ifosfamide.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 40
LY30122077.1.1. Olaratumab Premedications and Required Monitoring
The infusio n rate of olaratumab should not exceed 25 mg/min.  Infusio n durations longer than 
60 min are permitted in specific circumstances (that is, for patients with higher body weight for 
whom the upper limit of infusio n rate is limited or in the setting of prior olaratumab Grade 1 or 2 
infusio n-related reacti on [IRR]); the infusio n duratio n must always be accurately recorded.
Prem edicate pati ents prior to administration of olaratumab as bel ow: 
On Days 1 and 8 of Cy cle 1 :  Mand atory administration of a histamine H1 antagonist 
(for example, diphenhydramine) and dexamethasone prior to the start of the olaratum ab 
infusio n.
For subsequent cy cles, premedication with a histamine H1 antagonist (for example, 
diphenhydramine) is reco mmended prior to each dose of olaratumab.
Addit ional premedication (s)may be provided at the invest igator’s discretion.  Premedicat ion 
must be provided in the setting of a prior Grade 1 or 2 olaratumab IRR, as detailed in 
Secti on7.8.1 .  All premedicat ionsadministered must be adequately documented in the electronic 
case report form (eCRF).
Patients are requi red to be m onitored f or 1 hour after the olaratum ab infusio n in Cycles 1 and 2 
for signs or symptoms of IRRs; see Sect ion7.8.1 for full descript ion of required o laratumab 
monitoring period in Cycles 1 and 2.  Patients should complete the required monitoring period 
prior to the start of the doxorubicin administrati on.
7.1.2. Doxorubicin Premedications and Dexrazoxane Administration
Given the emetogenic potential of doxorubi cin, premedicat ion with antiemetics per inst itutional 
guidelines is recommended.  Addit ional premedication (s)may be provided at theinvest igator ’s 
discreti on.
If antiemetic prem edicati on is requi red pri or to the doxorubic ininfusion, this must be done after 
the com pletion of  the ol aratumab infusio n (not before the olaratumab infusion ).  This 
prem edicat ion may be administered immediately following the end of observat ion peri od (if 
applicable) or after the complet ion of the olaratumab infusio n.
Patients may receive dexrazoxane for the prevention of cardiotoxicit yat the di scret ion of the 
investiga toraccording to institutional protocol . 
7.1.3. Ifosfamide Premedications and Mesna Administration
Mesna must be administered to all pat ients for the prevent ion of ifosfamide -induced hemorrhagic 
cystitis.  Mesna should be administered at a minimum dose equal to 60% of the ifosfamide dose 
according to inst itutional guidelines.  Note that as the dose of mesna administered is dependent 
on the dose of ifosfamide administered, any dose modifications to ifosfamide will require a 
corresponding dose modificat ion to m esna in order to maintain the correct dosage (mesna dose = 
minimum 60% of ifosfamide dose).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 41
LY3012207Ifosfamide should be given with extensive hydration consist ing of oral or IVfluid ( ≥2L/m2per 
dayIV) to prevent bladder toxicit y or according to inst itutional guidelines.
Ifosfamide is associated with moderate em etic potent ial and ant iemetics are recommended to 
prevent nausea or vomit ing.
If ifosfamide prem edicat ion is required ,itshoul d be administered together wi th any doxorubicin 
prem edicat ions prior to doxorubicin administration.
7.2. Method of Treatmen t Assignment
Patients who m eet all cri teria for enrollment will be assigned to receive olaratum abin 
combinat ion with doxorubi cin, ifosfamide and mesna in this study . After the patient si gns the 
ICF, the si te will register the patient in the i nteractive web response system (IWRS), which is 
web-based and accessible 24 hours a day . The IWRS registration consists of assigning the 
patient a uni que study  identificat ion number. Once the patient is registered through the IWRS, 
he/she is considered to be enrolled in the study .
7.2.1. Selection and Timing of Doses
A cycle is defined as an interval of 21 days .  In Cycle 2 and beyo nd, upto 3 day s delay  of a cycle
(that is, Day  1)or Day 8 will be permitted due to holidays, weekends, bad weather, or other 
unforeseen circumstances and will not count as a protocol deviat ion.  In except ional cases, longer 
delays may be allo wed in later cy cles f ollowing consultat ion with Lilly medical represent ative.
The actual  dose of olaratumab to be administered will be determined by measuring the patient ’s 
weight in kil ograms on Days 1 and 8 of each cycle.  See also Section 7.5for further details on 
olaratum ab.  The actual doses of doxorubi cin, ifo sfamide and m esna to be administered will be 
determined by calculat ing the patient ’s body  surface area at the beg inning of each cycle.   If the 
patient’s weight does not fluctuate by  ±10% f rom the weight used to calculate prior dose s, the 
olaratum aband doxorubi cin, ifo sfamide and mesna doseswill not need to be recalculated, unless 
deem ed clinically  meaningful.  A 5% variance in the calculated total dose s will be allowed for 
ease of dose administration.
Patients will  cont inue treatment for a maximum of 6 cy cles, or un til there i s docum ented di sease 
progression, unacceptable toxicit y, death, or other discontinuat ion criteria are m et (Secti on 8).  
Patients who discont inue doxorubi cin, ifo sfamide and mesna treatm ent wi thout evi dence of 
disease progressi on will receive ol aratumab asmonotherapy until there is evidence o f disease 
progression, death, intolerable toxicit y, or other withdrawal criteria are met (Section 8).Patients 
who undergo surgical tumor resection fo llowing study  treatm ent are not eligible to receive 
olaratum ab as m onotherapy .
7.2.2. Dose -Finding Phase
7.2.2.1. Dose -Limiting Toxicity Determination
Because of the relatively  high rate of DLT -level toxicity with the backbone doxorubi cin, 
ifosfamide and mesna regimen (Judson et al. 2014) and the generally acceptable toxicit y profile 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 42
LY3012207of the 15-mg/kg dose of olaratum ab (Days 1 and 8 every 21days) in combinat ionwithother 
chemotherapeut ic agents including doxorubi cin, approximately  15 pati ents will be enrolled at the 
first dose l evel of ol aratum ab (provided safet y data confirms the required number of pat ients 
without DLTs have been met for each DLT threshold as described in Table JGDR. 7)to allow 
sufficient patient numbers to judge init ial tolerability  of olaratum ab in co mbinat ion with 
doxorubi cin, ifo sfamide and mesna .
In the Dose -Finding Phase, DLT asse ssment will be performed.  A DLT is defined as events such 
as the fo llowing, graded according to the NCI -CTCAE Version 4.0, when it occurs within 
Cycle 1 and is considered to be related to study  treatm ent by  the invest igator in conjunct ion with 
the sponsor :
1.Grade 3 or 4 f ebrile neutropenia ,or sepsis .
2. G rade 4 neutropenia last ing 7 days or longer .
3.Grade 4 thrombocy topeni a, or Grade 3 thrombocy topeni a com plicated by  hemorrhage .
4.Nonhematologic Grade ≥3 toxi city, except for toxici ties (such as nausea, vomiting, 
transi ent el ectroly te abnorm alities, di arrhea )thatcan be controlled with optimal 
medical management within 48 hours or clinically non -significant laboratory  
abnorm alities.
A dose-limiting equivalent toxicit yis an AE that meets the DLT criteria as defined above and 
occurs in any  cycle other than Cycle 1 .  In addit ion to the DLT assessment period in Cycle 1, 
available safety data bey ond Cycle 1 mayalso be taken into consideration prior to a decisio n to 
advance to the next dose l evel or the deter minat ion of the Confirmat ionPhase dose.
Note: Infusio n-related reacti ons will  not be considered as DLTs, as they occur independent of 
dose level.
Table JGDR. 7shows the DLT thresho lds that will be used to determine study  progressi on.  
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 43
LY3012207Table JGDR. 7. Dose -Limiting Toxicity Thresholds for Study JGDR
Dose Level Regimen If… Thenb…
Olara 15 mg/kg
(Starting Dose 
Level)Olara 15 mg/kg D1, D8
Ifos10 g/m 2D1 to D4 a
Dox 75 mg/m 2D1 to D36 DLT sin first 6 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients).
≤5 DLTs in first 6patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6DLTs in first 9 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients) .
≥9 DLTs in full 15 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients) .
≤8 DLTs in full 15 patients Proceed to Olara 20- mg/kg Loading Dose Cycle Dose Level.
Olara 15 mg/kg 
with Ifos 
ReductionOlara 15 mg/kg D1, D8
Ifos7.5 g/m 2D1 to D3 a
Dox 75 mg/m 2D1 to D36 DLT sin first 6 patients Halt study .  No further patients enrolled.
≤5 DLTs in first 6patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6DLTs in first 9 patients Halt study .  No further patients enrolled.
≥9 DLTs in full 15 patients Halt study .  No further patients enrolled.
≤8 DLTs in full 15 patients Proceed to Olara 20- mg/kg Loading Dose Cycle Dose Level with Ifos 
Reduction .
Olara 20 -mg/kg 
Loading Dose 
CycleOlara 20 mg/kg D1, D8 
of C1; then 15 mg/kg D1, 
D8 of C2 to C6 
Ifos10 g/m 2D1 to D4 a
Dox 75 mg/m 2D1 to D36 DLT sin first 6 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≤5 DLTs in first 6patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6DLTs in first 9 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≥9 DLTs in full 15 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≤8 DLTs in full 15 patients Proceed to Recommended Dosing Regimen cohort with Olara 20 -mg/kg 
Loading Dose Cycle as recomm ended dose.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 44
LY3012207Dose Level Regimen If… Thenb…
Olara 20 -mg/kg 
Loading Dose 
Cycle with Ifos 
ReductionOlara 20 mg/kg D1, D8 
of C1; then 15 mg/kg D1, 
D8 of C2 to C6 
Ifos7.5 g/m 2D1 to D3 a
Dox 75 mg/m 2D1 to D36 DLT sin first 6 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg with Ifos reduction as recommended 
dose.
≤5 DLTs in first 6patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6DLTs in first 9 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg and Ifos 7.5 g/m 2as recommended 
doses.
≥9 DLTs in full 15 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg and Ifos 7.5 g/m 2as recommended 
doses.
≤8 DLTs in full 15 patients Proceed to Recommended Dosing Regimen cohort with Olara 20 mg/kg 
Loading Dose Cycle and Ifos 7.5 g/m 2as recommended doses.
Recommended 
Dosing RegimenOlara dose TBD
Ifosdose TBD
Dox 75 mg/m 2D1 to D3Enroll 15 patients and treat with Recommended Dosing Regimen.
Abbreviations:  D = day; DLT = patients experiencing a dose-limiting toxicity; dox = doxorubicin; g = grams; Ifos = ifosfamide; kg = kilogram; m2= square 
meters; mg = milligrams; Olara = olaratumab; TBD = to be determined.
aWith concomitant mesna administration.
bIfa sufficient number of patients successfully complete the DLT period at a given dose level (ensur ingthe DLT threshold will not be exceeded ), further 
enrollment may proceed as described in Table JGDR. 7
,upon agreement of the Sponsor and Investigators .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 45
LY30122077.3. Blinding
This is an open -label study .
7.4. Dosage Delays, Discontinuations and Modifications
To begin dosing at Cycle 2 and each Day  1thereafter (for cy cles in which olaratumab is 
administered with doxorubicin and ifo sfamide) , the fo llowing cri teria must be f ulfilled (see 
Table JGDR. 9for hematological parameters for dosing o laratumab on Day 8) :
ANC ≥1.5 × 10 3cells/µL ( ≥1500 cells/µL; ≥1.5 × 10 9/L)
Platelets ≥100 × 10 3cells/µL ( ≥100,000 cells/µL; ≥100 × 10 9cells/L)
Hem oglobin ≥8.0 g/dL .  Note: For study inclusio n, hemoglobin ≥9.0 g/dL
Total  bilirubin below ULN .  In pati ents wi th Gilbert’s syndrome, total bilirubin should be 
3 mg/dL
Serum  creatinine ≤1.5 times ULN .  If creatinine is above ULN, the patient’s creat inine 
clearance is ≥60mL/min (refer to Appendix 6 for the Cockcroft -Gault formula for 
creatinine clearance)
AST and ALT ≤3
×ULN, or ≤5 ×ULN if the transaminase elevat ion is due to liver 
metastases
Nonhematologic toxicit y must be Grade ≤2 or must have returned to baseline , unless the 
toxicity is deemed not clinically significant by  the investi gator or i s a laboratory  
abnorm alitythat is manageable by institutional standards (for exam ple, l ow serum  
potassi um, magnesium, or phosphate) .
In addit ion, patients shoul d be m onitored f or evi dence of  micro-and/or macroscopic hematuria 
and treated according to inst itutional standards.
7.4.1. Delays
In general, dose delays of 1study  drug (ol aratum ab,doxorubi cin,or ifosfamide /mesna) due to 
toxicitiesoutlined in Secti on7.4.3 willnot necessitate delays of the other study  drug s.  However, 
close considerat ion must be made by the invest igator to administer all study treatments per the 
schedule outlined in Sect ion7.1.
Treatment may be delayed for up to 14days to allo w a patient sufficient time for recovery  from 
study  drug -related toxici ty.  If Day 8 treatment is delayed >7 days, treatm ent may  be resumed 
with planned Day  1 treatm ent of  the next cy cle.
Dosing delay bey ond 14 day s may be permissible if AEs are not considered to be primarily  
related to ol aratum ab and the invest igator deems continuat ion of study  treatm ent to have clinical 
benefit for the patient. This decisio n has to be documented and be jo intly made by  the 
investigator and the Lilly team.
In the event of unfor eseen circumstances or schedul ing issues that require adjust ments to the 
schedule, appropriate adjustmen ts or del ays to the schedule may be made fo llowing discussio n 
between the invest igator and the sponsor and written approval by the Lilly medical 
representative .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 46
LY30122077.4.2. Discontinuations
The need to permanently discont inue doxorubicin and/or ifosfamide due to drug- related toxi city 
shoul d be done according to local standard of care and labels.  Criteria for ol aratumab 
discontinuat ion are discussed in the olaratumab dose modificat ion sect ion (7.4.3.1 )and in the 
olaratum ab infusio n-related reaction section (7.8.1 ).
Patients whose di sease has not progressed at the time of doxorubicin, ifosfamide and mesna 
discontinuat ion will  receive ol aratumab as monotherapy until there i s evidence of disease 
progress ion, death, intolerable toxicit y, or other withdrawal criteria are met (Section 8).These 
patients will  cont inue study  assessments as outlined in TableJGDR .2.Patients who undergo 
surgi cal tum or resecti on following study  treatm ent are not eligible to receive o laratumab as 
monotherapy .
Patients who exhibit disease progression at the time of doxor ubicin, ifosfamide and mesna 
discontinuat ion will receive post -treatm ent follow-up assessments as outlined in Table JGDR .
3.
7.4.3. Dose Modifications
General guidelines for dose modificat ionsare provided below.  Sections 7.4.3.2 and 7.4.3.
3
outline guidelines for dose modificat ions of doxorubicin and ifosfamide , respectively; variat ions 
from these guideline smay be allowed according to local standard of care and labels .
7.4.3.1. Olaratumab Dose Modifications
A reduction in the dose of olaratumab will be permitted if the doses of doxorubi cin and 
ifosfamide have been previously reduced for toxi city, and the same or similar toxicity has 
recurred despite reduction of doxorubi cin, ifosfamide and mesna , and the toxi city is deemed 
potenti ally related to the addi tion of  olaratum ab in combinat ion with doxorubi cin, ifosfamide and 
mesna .  In this scenario, an olaratumab dose reductio n shoul d occur in conjunct ion with a 
reducti onin the doxorubi cin and ifosfamide doses according to the guidance outlined in 
Secti ons7.4.3.1.1 and 7.4.3.1.2 .
A second reduct ion in the olaratumab dose will not be permitted during treatment w ith 
combinat ion therapy  of olaratum ab pl us doxorubi cin and ifosfamide .  
Patients who have not progressed on study  willreceive olaratumab asmonotherapy following 
discontinuat ion of the co mbination therapy until there is evidence of disease progression, death, 
intolerable toxi city, or other wi thdrawal cri teria are m et.  Patients receiving olaratumab as 
monotherapy  will have assessments performed as per TableJGDR .2
Patients who have a dose reduction of olaratumab during the combinat ion therapy  porti on and 
then proceeding to receiv eolaratum ab m onotherapy  after discont inuat ion of doxorubicin and 
ifosfamide combinat ion may have thei r dose of olaratum ab re-escalated to the ori ginal  dose level
at the investigator ’s discret ion.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 47
LY30122077.4.3.1.1. Hematologic Toxicity
Table JGDR. 8shows ol aratumab dose modificat ionsthat shoul d be made for hematologic 
toxicities judged as potentially related to olaratumab in combinat ion with doxorubicin, 
ifosfamide and mesna , and that have recurred or failed to improve/reso lve despite 1 reducti on in 
doxorubi cinand ifo sfamide doses.   These guidelines should be used for olaratumab dosing, when 
given in co mbinat ion with doxorubi cin and ifosfamide.
Table JGDR. 8. General Guidelines for Olaratumab Dose Modification due to 
Hematologic Toxicit ies
Toxicity Dose Modification
Neutropenia
  ANC Grades 1-3 No dose modification required
  ANC <500 cells/ µL (Grade ≥4) No treatment administered; treatment cycle delayed
  Atre-treatment:
  If ≥Grade 3 neutropenic fever/infection
has occurred and 1reductio n in 
doxorubicin, ifosfamide and mesna doses 
has already occurredWithhold dose until ANC is ≥1500 cells/µL; 
15-mg/kg Dose Level :  Reduce dose to 12 mg/kg
20-mg/kg Loading Dose Cycle Level :  Reduce dose to 
15mg/kg
  If Grade 4 neutropenia lasting ≥1week
has occurred and 1reductio n in 
doxorubicin, ifosfamide and mesna doses 
has already occurredWithhold dose until ANC is ≥1500 cells/µL; 
15-mg/kg Dose Level :  Reduce dose to 12 mg/kg
20-mg/kg Loading Dose Cycle Level :  Reduce dose to 
15mg/kg
  Grade 4 ANC without fever/infection 
lasting ≤1weekAdminister next olaratumab at full dose ,atinvestigator ’sdiscretio n
After 1 reduction of olaratumab and 2 
reductions of doxorubicin, ifosfamide 
and mesna , recurrence of either:
  1) ≥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting ≥1 weekDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfa mide/mesna) .  Patients w ho have not progressed 
will receive o laratumab as monotherapy until there is evidence of 
disease progression, death, intolerable toxicity, or other withdrawal 
criteria are met .
Abbreviation:  ANC = absolute neutrophil count.
Omitt ing the Day 8 dose of olaratumab based on ANC and platelet counts judged as potentially 
related to ol aratum abin combinat ion with doxorubicin, ifo sfamide ,and mesna is permissible as 
shown in Table JGDR. 9.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 48
LY3012207Table JGDR. 9. Olaratumab Day 8 Dosing Algorithm B ased on ANCand Platelet 
Count
Treatment DayANC
(cells/ µL)Platelet Count
(cells/ µL) Olaratumab
Day 8≥500 and ≥75,000 Administer
<500 and Any Omita
Any and <75,000 Omit 
Abbreviations : ANC = absolute neutrophil count; µL= microliter.
aDay 8 administration of olaratumab may be delayed for a maximum of 7 days.  If the ANC level has not
increased to 500 cells /µL within 7 days, then the Day 8 olaratumab dose in thatcycle should be skipped and 
dosing resumed on Day 1 of the following cycle (if criteria for dosing are met).  If all dosing criteria are met, a 
delay  or omission of the Day 8 olaratumab dose should not result in a delay of the Day 1 olaratumab dose of the 
following cycle. 
7.4.3.1.2. Nonhematologic Toxicity
Specific guidelines for dose adjustments in pat ients who experience olaratumab -related IRRs 
may be found in Sect ion 7.8.1 .
Table JGDR. 10shows ol aratumab dose modificat ions that should be made for nonhematologic 
toxicities judged as potentially related to olaratumab in combinat ion with doxorubicin, 
ifosfamide and mesna and tha t have recurred despite 1reduction in doxorubi cin, ifosfamide and 
mesna dose.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 49
LY3012207Table JGDR. 10. General Guidelines for Olaratumab Dose Modification due to 
Nonhematologic Toxicities
Grade Required Dose Modification
Grade 1 No dose modification is required.
Grade 2 At the investigator’s discretion, the pat ient may  continue to receive olaratumab at the full 
dose, provided the event does not pose a serious health risk or is easily treated.
Grade 3 and 1 
reductio n in 
doxorubicin, 
ifosfamide and 
mesna doses has 
already  occurredIf not adequately controlled with appropriate supportive care, withh olddose until ≤Grade 1 or 
has returned to pretreatment baseline .
Treatment may resume a s follows:
15-mg/kg DoseLevel:  Reduce dose to 12 mg/kg
20-mg/kg Loading D oseCycle Level:  Reduce dose to 15 mg/kg
If toxicity recurs after therapy resumes, discontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna).  Patients w ho have not progressed will receive o laratumab as 
monothera pyuntil there is evidence of disease progression, death, intolerable toxicity, or 
other withdrawal criteria are met .
Grade 4 and 1
reductio n in 
doxorubicin, 
ifosfamide and 
mesna doses has 
already  occurredWithhold dose until toxicity is ≤Grade 1 or has returned to pretreatment baseline.
Permanent discontinuation of olaratumab should be considered for any patient experiencing 
Grade 4 nonhematologic toxicity assessed as related to olaratumab . 
However, if resumption of dosing is deemed appropriate by the investigator, treatment may 
resume o nly after consultation with the Lilly CRP as follows:
15-mg/kg Dose Level:  Reduce dose to 12 mg/kg
20-mg/kg Loading D oseCycle Level:  Reduce dose to 15 mg/kg
If toxicity recurs after therapy resumes, discontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna).  Patients w ho have not progressed will receive o laratumab as 
monotherapy until there is evidence of disease progression, death, intolerab le toxicity, or 
other withdrawal criteria are met .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 50
LY30122077.4.3.2. Doxorubicin Dose Modifications
Dose m odificat ions of doxorubicin will fo llow the guideline s outlined bel ow and may be 
adjusted according to local standard of care and label .
7.4.3.2.1. Hematologic Toxicity
Doxorubi cinwill not be administered after the init ial dose if the patient’s ANC is < 1500 cells/µL 
or if the platelet coun t is <100,000 cells/µL.  When necessary , the next treatm ent cycle should be 
delayed unt il the ANC is ≥1500 cells/µL and the platelet count is ≥100, 000cells/µL and any 
nonhematologic toxicit ies have resolved.  For patients who experience ≥Grade 3 neutropenic 
fever or infect ion or Grade 4 neutropenia without fever last ing more than 1 week, doxorubicin
shoul d be reduced to 75% of the starting dose (that is, to approximately  60 mg/m2).  If a pati ent 
experiences a second incidence of neutropenic fever/infection or has another episode of Grade 4 
neutropeni a last ing >1 week, then a se cond dose reduction to 45 mg/m2shoul d occur .
Therapeut ic and prophylact ic use of pegfilgrast im or other G -CSFs is requi red per current 
American Societ y of Clinical  Oncol ogy (ASCO; Smi th et al . 2006) and Nati onal Com prehensive 
Cancer Network (NCCN) guideli nes (NCCN 2014).   In general, G -CSF products like filgrast im 
or pegfilgrast im shoul d be administered approximately  24 hours after the com pletion of 
cytotoxi c chem otherapy  (for example, on Day  5 for patients in full -dose ifosfamide cohorts or 
Day 4 for pati ents in reduced- dose ifosfamide cohorts).   For patients with Grade 4 ANC without 
fever/infect ion lasting less than 1 week, re -treatm ent will be allowed at the invest igator’s 
discreti on wi th the full dose of doxorubicin (75 m g/m2) with requireduse of G -CSFs per current 
ASCO guidelines (Smit h et al . 2006).  See Table JGDR. 11for doxorubicin dose m odificat ion for 
neutropeni a.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 51
LY3012207Table JGDR. 11. General Guidelines for Doxorubicin Dose Modification Due to 
Neutropenia
Toxicity Required Dose Modification
ANC < 1500 cells/ µL No doxorubicin administered; entire treatment 
cycle delayed.
At re -treatment:
If ≥Grade 3 neutropenic fever/infection has occurredApproximately 60 mg/m 2doxorubicin .
If Grade 4 neutropenia lasting longer than 1 week has occurred Approximately 60 mg/m 2doxorubicin .
If Grade 4 neutropenia without fever/infection lasting less than 
1 week has occurredRetreatment with doxorubicin at full dose at
investigator ’sdiscretio n with requi red use of G -
CSFs.
Second incidence of either:  
1) ≥Grade 3 neutropenic fever/infection
2) Grade 4 neutropenia lasting longer than 1 weekSecond dose reduction to 45 mg/m 2.
Third incidence of either:
1) ≥Grade 3 neutropenic fever/infection
2) Grade 4 neutropenia lasting longer than 1 weekDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna) and follow per 
Section 7.4.2 .
Abbreviations:  ANC = absolute neutrophil count; G -CSR = granulocyte -colon y-stimulating factor.
7.4.3.2.2. Nonhematologic Toxicity
Perm anent discont inuat ion of doxorubi cinshoul d be considered for any  patient experiencing 
Grade 4 nonhematologic toxicit y assessed as related to doxorubicin .  If the invest igator feels re -
dosing of doxorubicin is appropriate (except for Grade 4 cardiotoxicit ies,which require 
mandato ry discont inuat ion (see Section 7.4.3.2.3 ), treatment may only resume after consultat ion 
with the Lilly CRP , with the dose reduced to 60 mg/m² (or le ss if agreed by the invest igator and 
Lilly CRP ).  If Grade 4 nonhematological toxicity recurs after therapy  resum es, doxorubicin (in 
combinat ion with ifosfamide and mesna) will be perm anent ly discont inued and the pati ent will 
be followed as outlined in Sec tion7.4.2 .
For appropriate management of cardiac toxicit ies, refer to Section 7.4.3.2.3 .
7.4.3.2.3. Monitoring for Doxorubicin- Associated Cardiotoxicity
Cardi otoxi city is a recognized risk of doxorubi cinthat increases wi th higher cum ulative drug
exposure. Cardiac mo nitoring is conducted by  a combinat ion of monitoring of clinical
param eters, ECG, and echocardiogram (ECHO)/m ultiple-gated acquisit ion(MUGA )scan.
Changes in ECG , arrhy thmias, tachy cardia and/or chest pain should be managed based on the
specific findings.   
Patients will  undergo baseline LVEF determinat ion using ECHO or MUGA scan.  This 
evaluat ion may be repeated at any  time during the study  if clinically  indicated.  A decrease in 
LVEF of 10% and below the lower limit of normal, or an ab solute decrease of 20%, or if the 
absolute LVEF decreases to or below 40%, then doxorubi cinwill be di scontinued. Doxorubi cin
shoul d also be discont inued if the patient develops Grade 3 or 4 left ventricular systolic 
dysfunct ion (symptomat ic congest ive he art failure).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 52
LY3012207The di agnost ic met hod used at baseline for cardiovascular assessments (for example, ECHO or
MUGA scans) should be the same method used throughout the study , unless there i s clinical or
instrum ental  evidence that further invest igations are nee ded.
7.4.3.3. Ifosfamide Toxicities and Dose Modifications
Dose m odificat ions of ifosfamide will fo llow the guidelines outlined below and may  be adjusted 
according to local standard of care and label. Two reductions in ifosfamide dose for toxi citywill 
be permitted during the study .  If a thi rd dose reducti on is necessary ,the pati ent will be 
discontinued fro m the combinat ion therapy  (olaratum ab + doxorubi cin/ifo sfamide/mesna) and
followed as outlined in Sect ion 7.4.2 .
General guidelines for ifosfamide dose modification are shown in Table JGDR. 12.  Dose 
modificati ons of  ifosfamide due to hepatic impairment are shown in Table JGDR. 13.
Table JGDR. 12. General Guidelines for Dose Modification of Ifosfamide due to 
Toxicity
Worst Toxicity/Counts in Previou s Cycle Ifosfamide Dose Reduction a
Febrile neutropeniaFirst episode:  Maintain full dose
Subsequent episodes:  Decrease 20%
Platelets <75,000/mm 3If less than 1 week duration:  Maintain full dose
If greater than 1 week duration:  Decrease 20%
Thrombocytopenic bleeding Decrease 20%
Somnolence or other signs of encephalopathyDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna) and follow per 
Section 7.4.2 .Administer methylene blue 50 mg 
intravenous lyevery 4 hours until resolution.
Grade 3 or 4 neurotoxicity other than encephalopathyDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna) and follow per 
Section 7.4.2 .
Grade 3 related organ toxicity/nonhematologic Decrease 20%
Grade 4 related organ toxicity/nonhematologicDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna) and follow per 
Section 7.4.2 . 
Abbreviation:  mg = milligrams .
aDo not re-treat until criteria in Section 7.4are met.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 53
LY3012207Table JGDR. 13. Dose Modification of Ifosfamide due to Hepatic Impairment
Bilirubin
and/orAST/ALT Ifosfamide Dose Reductiona
1-2 ×ULN <2 ×ULN Full dose
2-4 ×ULN 2-5 ×ULN 75% of initial dose
>4 ×ULN >5 ULN Discontinue combination 
therapy  (olaratumab + 
doxorubicin/ifosfamide/mesna) 
and follow per Section 7.4.2 .
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.
aBased on clinical judgment –less conservative adjustments can be considered if hepatic changes are secondary to 
metastases rather than hepatic cirrhosis or hepatitis.
7.4.3.3.1. Ifosfamide -Associated Central Nervous System Toxicity
Central  nervous system toxicit y appears to be dose dependent, and is variable in onset, but 
usually reso lves when ifosfamide is discontinued. Incidence is higher with higher doses, 
concomitant use of aprepitant, electroly te imbalances, renal/hepat ic impairment ,or preexist ing 
CNS di sorders. It may manifest as transient mental status changes (somnolence, confusio n, 
hallucinat ion, disorientati on and l ethargy), cerebellar dysfunction, extrapy ramidal  symptom s, 
transi ent weakness, cranial nerve dysfunct ion,or sei zure act ivity.  Methylene blue, which may 
act as an electron acceptor or decrease chloro acetaldehyde format ion, has been suggested as 
treatm ent or prophylaxis forifosfamide -induced encephalopathy.   Due to the potential for 
additive effects, drugs acting on the CNS (such as ant iemetics, sedatives, narcotics, or 
antihistamines) must be used with particular caution or, if necessary, be discontinued in case of 
ifosfamide -induced encephalopathy.
7.4.3.3.2. Ifosfamide -Associated Urotoxic Effects
The incidence of urotox ic effects without an uroprotector can be up to 40% and is dose 
dependent ; coadministration ofmesna and adequate hydration aremandatory in this study .  
Patients m ay present wi th hematuri a, symptom atic cystit is, or bladder fibrosis.  Past or 
concomitant r adiation of the bladder or busulfan treatment may increase the risk of hemorrhagic 
cystitis.  Several methods of treatment for established hematuria have been described:  bladder 
irrigation with water or norm al saline, intravesical inst illation of astringe nts (alum, silver nitrate), 
systemic administration of ant ifibrino lytics (amino caproi c acid, tranexamic acid), cy stoscopy  to 
evacuate the bladder of clots, continuous bladder irrigat ion and intravesical prostaglandins.  For 
severe or refractory  hematuri a, intravesical formalin, pheno l, or prostaglandin has been used with 
or wi thoutsurgical intervent ion (electrocautery , cryosurgery , diversi on of urine flow, 
hypogastric artery  ligat ion, or cy stectomy).  Discont inuat ion or dose reduction of ifo sfamide 
shoul d follow local standard of care and label for patients with macroscopi c hematuri a.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 54
LY30122077.4.3.3.3. Ifosfamide -Associated Proximal Tubular Damage
Glomerular, proximal, or distal tubular impairment may  all occur, often in combinat ion and m ay 
progress even after ifosfamide has been discontinued.  Proximal tubular damage often presents as 
Fanconi syndro me with low serum bicarbonate, proteinuria, glucosuria, aminoaciduria and 
hypochloremic metabolic acidosis.  Risk factors for the development of nephrotoxicit y include 
preexist ing renal impairment ,concurrent use of nephrotoxic drugs, reduced renal reserve 
(unilateral nephrectomy) ,hydronephrosis and total cumulative dose.  Renal impairment may 
increase the risk of myelo suppress ion and possibly, cardiotoxicit y.  Mesna does not appear to be 
protective against the proximal tubular abnormalit ies induced by  ifosfamide.  Dose m odificati ons 
guidelines of ifosfamide due to renal impairment are shown in Table JGDR .14.
Table JGDR. 14. Dose Modification of Ifosfamide due to Renal Impairment
Creatinine Clearance (mL/ min)aIfosfamide Dose Reduction
>60 Full dose
40-60 Reduce to 75% of initial dose
20-40 Reduce to 50% of initial dose
<20 Discontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna) and follow per Section 7.4.2 .
Abbreviations:  min = minutes; mL = milliliters.
aCalculated using Cockcroft and Gault formula (see Appendix 6 ). 
7.5. Packaging and Labe ling
7.5.1. Olara tumab
Olaratum ab will be provided to study  sitesby Lilly. Clinical trial materials will be labeled 
according to the country’s regulatory  requi rements.
Olaratum ab will be supplied as a sterile preservat ive-free solut ion for IV infusio n in single -use 
vials containing 500 mg/50 mL of olaratumab (10 mg/mL).
Olaratum ab is form ulated in 10 mM histidine, 100 mM glycine, 50 mM sod ium chloride, 75 mM 
mannito l and 0.02% polysorbate -20, with a pHof5.5.  All excipients used in the formulat ion of 
olaratum ab drug product are of pharm acopoei agrade.
Clinical study  materials will be l abeled according to the country ’s regul atory  requi rements.
7.5.2.D oxorubicin, Ifosfamide and Mesna
Where co mmercially available, doxorubi cin,ifosfamide and m esna will be purchased by the 
sites.  In the event that there are regional restrict ions or supply limit ations, doxorubicin, 
ifosfamide and/or mesna may be provided to the sites by  Lilly .
Clinical study  materials will be l abeled according to the country ’s regul atory  requi rements.
7.5.3. Granulocyte -Colony Stimulating Factors
G-CSFs will be purchased by the sites.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 55
LY30122077.5.4. Dexrazoxane
Where co mmercially available, dexrazoxane will be purchased by the sites.  In the event that 
there are regional restrict ions or supply limitat ions, dexrazoxane may  be provi ded to the si tes by 
Lilly.
Clinical study  materials will be l abeled according to the country ’s regul atory  requi rements.
7.6. Preparation/Handling/Storage/Accountability
7.6.1. Olaratumab
Olaratum abdrug product m ust be stored under refrigerat ion at 2 °Cto 8°C (36 °F-46°F) wi th 
protecti on from direct light. Do not freeze and/or shake olaratum ab drug product. Stabilit y 
studi es have dem onstrated that the drug product can withstand transient excursion to room 
temperature wi thout adverse effect; however, storage at this tem perature is not recommended.
Please refer to the Pharmacy  Manual for information on preparing the olaratumab dosing 
solution for infusio n.
7.6.2. Doxorubicin
Invest igators should consult the approved doxorubicin hydro chloride package insert for complete 
preparati on, handling and storage requirements.   If a patient should have an IRR to doxorubicin , 
the investigator should fo llow the manufacturer’s recommendations and clinical guidelines in the 
management of the patient .
Doxorubi cinis administered as an IVinfusio n. Doxorubicin may be administered either as a 
bolus over 60 min utes or l ess, or as a24
-hour con tinuous infusio n, depending on inst itutional 
protocol .
If erythematous streaking along the vein proximal to the site of infusion or facial flushing occur, 
decrease the rate of doxorubicin administrati on.
Doxorubi cinmust be reconstituted prior to infusio n. The reconstituted solut ion is stable for 
7days at room  temperature and under normal room light and 15 day s under refri gerat ion (2°C to 
8°C). It should be protected from exposure to sunlight.
Parenteral  drug products should be inspected visually  for parti culate matter and disco loration 
prior to administration, whenever solut ion and container permit.
7.6.3. Ifosfamide
In
vestigators should consult the approved ifo sfamide package insert for complete preparation, 
handling and storage requirements.
Ifosfamide single -dose vials should be s toredat controlled room temperature from 20°C to 25°C 
(68°F to 77°F) and p rotect edfrom temperatures above 30°C (86°F).
Exercise caut ion wh ile handling ifosfamide. The handling and preparation of ifosfamide shoul d 
always be in accordance wit h current guidelines on safe handling o f cytotoxi c agents. Several
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 56
LY3012207guidelines on this subject have been published (OSHA 1999; NIOSH 2004 ;ASHP 2006;
Polovich et al . 2014 ).  Skin reactions associated with accidental exposure to ifosfamide m ay 
occur. To minimize the risk o f derm al exposure, always wear impervious gloves wh ile handling 
vials and so lutions containing ifosfamide.  If ifosfamide solution contacts the skin or mucosa, 
immediately  wash the skin thoroughly wit h soap and water or rinse the mucosa wi th copi ous 
amounts of water.
7.6.4. Mesna
Invest igators should consult the approved mesna package insert for complete preparation, 
handling and storage requirements.
Mesna inject ion solution shoul d be stored at 20°C to 25°C (68°F to 77°F), with excursio ns 
permitted to 15°C to 30°C (59°F to 86°F).
7.7. Treatment Compliance
The study  medication will be administered only at the invest igational sites by  the authorized 
study  site personnel.  As a result, treatment compliance is ensured.
7.8. Concomitant Therapy and Supportive Care
7.8.1. Olaratumab Infusion -Related Reactions
As wi th other m onocl onal antibodies, hypersensit ivity react ions m ay occur during or following 
olaratum ab administration.
A 1-hour observat ion peri od is requi red after the administration of olaratumab in the first and 
second cycles .  If there i s no evi dence of an IRR during the init ial 2 cycles of o laratumab, then 
no observat ion peri od is requi red for subsequent treatment cy cles.  In the event that a 
Grade 1or2 IRR occurs after Cy cle 2, the 1 -hour observat ion peri od will  be reinst ituted for a 
minimum o f 2 cycles.  The reinst ituted observat ion peri od m ay be suspended after 2 cycles if the 
patient shows no further signs or symptoms of an IRR.  During the observat ion peri od, patients 
treated with olaratumab should be closel y monitored for si gns and symptom s indicative of an 
IRR by the medical staff fro m the start of the infusio n unt il at least 1 hour after the end of the 
infusio n in an area where emergency medical resuscitation equipment and other agents 
(epinephrine, predni solone equivalents, etc.) are available.
Treatment guidelines for olaratumab IRRs as well as premedicat ions for subsequent infusio ns are 
described in Table JGDR. 15.
Olaratum ab infusio n react ions will be defined according to the NCI -CTCAE Version 4.0 
definit ion of IRRs .
Symptom s occurring during or following infusio n of investigational therapy may also be defined 
according to AE categories such as allergi c react ion, anaphylaxis, or cy tokine rel ease syndrom e 
(NCI -CTCAE Version 4.0 Section “Immune system disorders”).  In the setting of symptoms 
occurring during or fo llowing infusio n of invest igational therapy, invest igators are encouraged to 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 57
LY3012207use the AE term “infusio n-related reaction” and any  addi tional term s (including those not listed 
here) that best describe the event.
Table JGDR. 15. Olaratumab Infusion -Related Reaction Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication 
at Subsequent Infusions
Grade 1 or 2 Stop infusion and monitor symptoms.
Additional appropriate medical therapy should be given 
according to standard medical practice; may include, but 
is not limited to:
antihistamines (for example, 
diphenhydramine HCl)
steroids (for example, dexamethasone)
acetaminophen
oxygen
After recover y, the infusion rate should be decreased 
50% for the duration of the infusion.  Patients should be premedicated 
with antihistamines, steroids, 
acetaminophen, etc., as 
appropriate.
Grades 3 o r 4 Stop infusion.
Administer immediate treatment ; may include, but is not 
limited to:
epinephrine
bronchodilato rs and/o r glucocorticoids for 
symptomatic b ronchospasm
IV fluids and/or pressors for hypotension
Treatment with olaratumab should be i mmediately 
and permanently discontinued.No subsequent dosing
All attempts should be made to obtain an anti -olaratumab antibody and olaratumab PK blood samples as 
close to the onset of the event as possible, at the resolution of the event and 30 days (±3 days) following the 
event.  The procedure for sample collection and handling is described in a separate procedural manual.
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug admin istratio n.
Abbreviations:  HCl = hydrochloride; IV = intravenous; NCI CTCAE = National Cancer Institute -Common 
Terminology Criteria for Adverse Events.
7.8.2. Granulocyte -Colony -Stimulating Factors and Erythroid Growth 
Factors
Because the doxorubicin, ifosfamide and mesna regimen is known to be highly  suppressive of 
the bone marrow, G -CSFs such as pegfilgrastim must be used at each cycle and s hould be 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 58
LY3012207administered according to ASCO guidelines (Smit h et al . 2006) a nd NCCN guidelines (NCCN 
2014). In general, G -CSF products like filgrast im or pegfilgrast im shoul d be administered 
approximately  24 hours after the com pletion of cy totoxic chem otherapy  (for example, on Day  5 
for pati ents in full -dose ifosfamide cohorts or Day 4 for patients in reduced -dose ifosfamide 
cohorts). Erythro id-stimulat ing factors (such as eryt hropoi etin) may  be used at the di screti on of  
the invest igator and should also be administered according to ASCO and NCCN guidelines.
7.8.3. Transfusion of Blood P roducts
Transfusio ns of red blood cells, platelets, or other blood products are permitted at the 
investigator’s discret ion, but may not be used to meet hematologic criteria for inclusion in the 
study .
7.8.4. Antiemetic Therapy
Both prophylactic and symptom -directed ant iemetic therapy  are recommended and should be 
used in accordance wit h institutional guidelines and/or at the investigator’s discret ion.
7.8.5. Inducers and Inhibitors of CYP3A4, CYP2D6 and P -gp
Avoid concurrent use of doxorubicin HCl wit h inhibitors and inducers of cytochrom e 
(CYP )3A4, CYP2D6 and/or P -gp.  Doxorubicin is a major substrate of CYP450 ,CYP3A4 and 
CYP2D6, and P -glycoprotein (P -gp).  Clinically s ignificant interactions have been reported with 
inhibitors of CYP3A4, CYP2D6 and/or P -gp (for example , verapamil), resul ting in increased 
concentration and clinical effect of doxorubicin. Inducers o f CYP3A4 ( for example ,
phenobarbital, phenyto in, St. John ’s Wort) and P -gp inducers may decrease the concentration of 
doxorubi cin.
Ifosfamide is a substrate for both CYP3A4 and CYP2B6.  CYP3A4 inducers ( for example , 
carbamazepine, phenyto in, fosphenyto in, phenobarbital, rifampin, St. John’s Wort) m ay increase 
the metabo lism o f ifosfamide to i ts active alkylat ing metabo lites. CYP3A4 inducers may 
increase the format ion of the neurotoxic/nephrotoxic ifo sfamide metabolite, chloroacetaldehyde. 
Closely  monitor pati ents taking ifosfamide wit h CYP3A4 indu cers for toxicit iesand consider 
dose adjustment.  CYP3A4 inhibitors ( for example , ketoconazo le, fluconazo le, itraconazole, 
sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice) may decrease the metabo lism o f 
ifosfamide to its active alkylat ing metabo lites, perhaps decreasing the effect iveness of ifosfamide 
treatm ent.
7.8.6. Other Concomitant Therapies
No other chemotherapy , radi otherapy , immunotherapy , cancer -related horm one therapy , or
experimental drugs will be permitted while the patients are on this study . An except ion will be
made for: 
prostate cancer patients continuing GnRH agonist therapy or breast cancer patients 
continuing anti -estrogen therapy  (for example, an arom atase inhibitor) as long as those 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 59
LY3012207therapi es have been installed for at lea st 3 m onths and are known to have been well 
tolerated
bisphosphonate osteoclast inhibitors (for example, zoledronic acid or pamidronate) for 
treatm entof bone m etastases will be permitted while pat ients are on study  treatm ent. The
osteocl ast inhibitor denosumab is also allowed.  Denosumab is a monoclonal ant ibody  
and is associated with a risk of hypersensit ivity reacti ons. Therefore, denosumab should 
not be administered within 3 days of o laratumab administration.
palliat ive local treatm ent (fo r example, radiotherapy o f ≤14 calendar days) in Cycles 2 
and bey ond following discussio ns between the investigators and the sponsor ( for 
example , for pain control of a so litary [non -skull ] skel etal metastasi s) and wri tten 
approval  by the spons or, as l ong as the pati ent has not developed another reason for study  
discontinuat ion.
7.9. Treatment after the End of the Study
7.9.1. Continued Access
Patients who are still on olaratum ab monotherapy at the time of study  com pletion may  continue 
to receive olaratum abmonotherapy if they are experi encing clinical benefit.
A continued access period will apply to this study only if at least 1 patient is st ill on olaratum ab 
monotherapy when study  com pletion occurs.  Lilly will notify invest igators when the continued 
acces s peri od begins.
The patient ’s cont inued access toolaratum ab study drug will en d when a cri terion for 
discontinuat ion is met (Section 8).  Conti nued access fo llow
-up will begin the day  after the 
patient and the invest igator agree to discont inueolaratum ab m onotherapy  and last approximately 
30±7 days (see Figur e JGDR .2).  Follow -up procedures will be performed as shown in the 
Continued Access Schedule of Act ivities (TableJGDR .4).
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 60
LY3012207Abbreviations:  dox = doxorubicin; ifos = ifosfamide; olara = olaratumab.
Figur e JGDR .2. Continued access diagram.
Patients who are in short -term follow-up when the continued access period begins will cont inue 
in short -term follow
-up unt il the 30-day short -term fo llow
-up visit is co mpleted.  Long -term 
follow-up does not apply.
Patients who are in long -term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.

I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 61
LY30122078.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Patients will  be discont inued fro m study  treatm ent under the following circumstances :
the patient is enro lled in any other clinical trial involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
the pati ent becomes pregnant during the study
the pati ent is significant ly noncom pliant wi th study  procedures and/or 
treatm ent
the pati ent demonstrates disease progression
the pati ent has unacceptable toxicit y
the pati ent, f or any  reason, requi res treatm ent wi th another therapeuti c agent 
that has been demo nstrated to be effect ive for treatment of the study  
indicat ion.  Discont inuat ion from study  treatm entwill occur pri or to 
introducti on of  the new agent
the pati ent undergoes surgical tumor resection
the invest igator decides that the patient should be discontinued fr om study  
treatm ent
the pati ent requests to be discont inued fro m study  treatm ent
the pati ent’s designee (for exa mple, legal guardian or caregiver) reque sts that 
the pati ent be di scont inued fro mstudy  treatm ent
Patients who are di scont inued from study  treatm ent will have follow-up procedures performed as 
shown in the Schedule of Act ivities(Secti on2).
8.1.1. Discontinuation of Inadvertently Enrolled Patients
If Lilly or the invest igator ident ifies a patient who did not meet enrollment criteria and was 
inadvertent ly enrolled, a di scussio n must occur between the Lilly  CRP and the invest igator to 
determine if the pat ient may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly  CRP to allow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thoutstudy  treatm ent.
8.2. Discontinuation from the Study
Patients will  be discont inued fro m the study  under the following ci rcumstances:
participat ion in the study needs to be stopped for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions and good clinical 
practi ce (GCP)
the pati ent requests to be discont inued fro mthe study
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 62
LY3012207Patients who discont inue fromthe study  early will  have end -of-study  procedures perform ed as 
shown in the Schedule of Act ivities(Secti on2).
8.3. Lost to Follow -Up
A pat ient will be considered lost to fo llow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Study  site personnel are expected to m ake 
diligent attempts to contact patients who fail to return for a scheduled visit or who the site is 
otherwi se unab le to fo llow-up.
Study  site personnel , or an independent third party , will attem pt to collect the survival status for 
all enrolled patients who are lost to fo llow
-up, includi ng enrolled pat ients who do not receive 
study  treatm ent, within legal and ethical boundaries.  Public sources may  be searched for 
survival status inform ation.  If the patient ’s survival status i s determined, the survival status will 
be docum ented, and the patient will not be considered lost to fo llow-up.
Lilly personnel will not be invo lved in any attempts to collect survival status inform ation.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 63
LY30122079.Study  Assessments and Procedures
Secti on 2provides the Schedule o f Activities for this study .
Appendix 3 provi des a list of laboratory tests that wi ll be perform ed for this study .
Appendix 4 provi des the schedule for collect ionofsamplesin this study.
Unless otherwise stated in the fo llowing subsections, all samples co llected for specified 
laboratory  tests will be destroyed within 60 days a fter receipt of confirmed test results.  Certain 
samples may  be retained for a l onger peri od, if necessary , to com ply wi th applicable laws, 
regul ations, or laboratory  certificat ion standards.
9.1. Efficacy Assessments
9.1.1. Secondary Efficacy Assessments
Tumor assessments will be performed for each patient at the times shown in the Schedule of 
Activities(Secti on2).
Com puted tom ography  (CT) scans, i ncluding spiral CT, are the preferred method sof 
measurement (CT scan thickness reco mmended to be 5 mm); however, magnet ic resonance 
imaging is also acceptable in certain situat ions, such as when body  scans are indicated or if there 
is a concern about rad iation exposure associated with CT.   Intravenous and oral contrast is
requi red unless medically  contraindicated.
The CT portion of a positron emission tomography (PET) -CT scan may be used as a method of 
response assessment if the site can document that the CT is of identical diagnostic qualit y to a 
diagnosti c CT (wi th IVand oral contrast). A PET scan alone or as part of a PET -CT may be 
perform ed for addi tional analyses but cannot be used to assess response according to RECIST 
Versi on 1.1(Eisenhauer et al . 2009) .
The m ethod of tum or assessment used at baseline must be used consistently throughout the 
study .  Radi ological imaging of the chest , abdom en and pelvis and other areas , as clinically 
indicated ,is required.
See Secti on 10.3.1 for definit ionsof the efficacy endpo ints.
9.1.2. Appropriateness of Assessments
The m easures used to assess safet y and efficacy in this study  are c onsistent wi th those used in 
most convent ional onco logy trials.
9.2. Adverse Events
The invest igator will use NCI-CTCAE Versio n 4.0 (NCI 2009) to assign AE terms and severit y 
grades.
Invest igators are responsible for:
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 64
LY3012207monitoring the safet y of patients in this study  and for al erting Lilly or its designee to any  
event that seems unusual, even if this event may be considered an unanticipated benefit 
to the patient
the appropriate medical care of patients during the study
docum enting their review of each laboratory  safet y report
following, through an appropriate health care option, AEs that are serious or otherwise 
medically important, considered related to study  treatm ent or the study , or that caused 
the pati ent to discont inue study  treatm entbefore complet ing the study.  The patient 
shoul d be f ollowed until the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  Frequency of follow -up evaluat ion is left to the 
discreti on of  the in vestigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient’s pre exist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addi tion, study  site personnel  will record via eCRF any 
change in the preexist ing condit ions and any new condit ions as AEs.   Investiga tors shoul d record 
their assessment of the potential relatedness of each AE to study  procedure or study  treatm ent via 
eCRF.
The invest igator will interpret and docum ent whether or not an AE hasa reasonable possibilit y 
of being related to study  treatm ent o r a study  procedure, taking into account the disease, 
concomitant treatments ,or pathologies. A “reasonable possibilit y” means that there is a cause 
and effect relat ionship between the study  treatm ent and/or study  procedure and the AE.
Planned surgeries a nd nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
Study  site personnel  must report any  dose m odificati ons or treatm ent discont inuat ions that result 
from AEs to Lillyor its designee via eCRF, cl arifying, if possible, the circumstances leading to 
the dose m odificat ion or di scont inuat ion of treatment.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the f ollowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life
-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  the invest igator for any other reason:  importan t medical events 
that may  not resul t in death, be life -threatening, or require hospitalization ;may be 
considered serious, based upon appropriate medical judgment.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 65
LY3012207Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received study  treatm ent.  However, if an SAE occurs after 
signing the ICF, but prior to receiving study  treatment, i t needs to be reported ONLY if it is 
considered reasonably  possibly  related to study  procedure.
Study site personnel  must notify Lilly or its designee of any SAE within 24 hours of investigator 
aware ness of the event via a Lilly -approved m ethod.  If alerts are i ssued via telephone, they are 
to be immediately followed wit h official notification on study -specific SAE forms.   This 24 -hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE information.
Pregnancy (during maternal or paternal exposure to study  treatm ent)does not meet the definit ion 
of an AE but shoul d be reported.  However, to fulfill regulatory  requi rements ,any pregnancy 
shoul d be reported following the SAE process to collect data on the outcome for both mother and 
fetus.
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures , occurring 
during the safet y follow-up visit (Visit 801; approximately 30 days after complet ion of study  
therapy )must be reported to Lilly or its designee.   Invest igators are not obligated to actively seek 
AEs or SAEs in patients beyo nd Visit 801.  Howev er, if the invest igator learns of any SAE, 
including a death, at any  time after a pati ent has been discharged fro m the study , and he/she 
considers the event reasonably possibly related to the study  treatm ent or study  partici pation, the 
investigator must pr omptly notify Lilly.
Planned hospi talizat ions or procedures for preexisting condit ions that were recorded in the 
patient’s medical history  at the time of enrollment should not be considered SAEs.  
Hospitalization or prolongat ion of hospitalizat ion without a precipitat ing clinical AE (for 
example, for the administration of study  treatm ent or other protocol -requi red procedure) shoul d 
not be considered SAEs.
Serious adverse events, including death, caused by disease progression should not be reported 
unless th e investigator deems them to be possibly  related to study  treatm ent.
9.2.2. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as rel ated to study  treatm ent or study  procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs.  Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of SUSARs that are consistent with glo bal regulat ions and associated 
detailed guidances.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 66
LY30122079.2.3. Adverse Events of Special Interest
Adverse events of spec ial interest (AESI) are events that have been ident ified as safet y signals 
during preclinical or early  clinical tri als or based on class effects of similar drugs. These events 
will be monitored prospectively in the clinical developmental program. Each ev ent is defined by  
a careful assessment and grouping of individual related Medical Dict ionary for Regulatory  
Activities(MedDRA )preferred terms.
The fo llowing events will be considered as AESI for the combinat ion of olaratumab and 
doxorubi cin, ifo sfamide and mesna :
infusi on-related reacti ons
cardiac arrhy thmias and cardiac dysfunct ion
encephalopathy
renal toxicit y
Refer to Section 7.8.1 for treatment considerations relat ive to the occurrence of olaratumab IRRs.  
Refer to Section 7.4for treatm ent consi derat ions relat ive to dose delays, modifications and 
discontinuat ions from  doxorubicin , incl uding AEs of concern or AESI.
9.2.4. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em with the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
Refer to the olaratum ab IB for informat ion on the treatm ent of olaratumab overdose .  Refer to 
the doxorubicin, ifosfamide and mesna product labels for informat ionon overdose with these 
agents.
9.4. Safety
9.4.1. Other Safety Measures
For each patient, ECGs, vital signs, laboratory tests, or other tests shoul d be co llected as shown 
inthe Schedule of Activities (Secti on2). 
Any clinically  significa nt findings that result in a diagnosis and that occur after the patient 
receives the first dose of study  treatm entshoul d be reported to Lilly or its designee as an AE via 
eCRF.
9.4.2. Safety Monitoring
Lilly willperiodically  revie w evolving aggregate safet y data wi thin the study  by appropri ate 
methods.   In addit ion to the formal DLT period that occurs during Cycle 1, safet y data from  later 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 67
LY3012207cycles that areavailable at the time of the DLT assessment may  be used in the decision to move 
to the next cohort, or in the determinat ion of the recommended Phase 2 dose.
Clinical and laboratory  monitoring should be init iated by  the invest igator in the fo llowing 
circumstances:
1.The patient exper iences elevation o f serum  ALT 10 × ULN 
2. A patient wit hout liver tumors or liver metastatis experiences elevated ALT 5 × ULN 
and elevated total bilirubin 2 × ULN
3.A pat ient with liver tum or or liver m etastatis experiences elevated ALT 8 × ULN and 
elevated total  bilirubin 2 × ULN
4.The patient is discont inued fro m treatm ent due to a hepat ic event or abnormalit y of liver 
tests
5.The patient experiences a hepat ic adverse event considered to be an SAE
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.To ensure patient safety and comply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP regarding collect ion of specific reco mmended 
clinical informat ion and follow-up laboratory  tests (see Appendix 5 ).
9.5. Pharmacokinetics
At the visit s and timesspecified in the Pharm acokinet ic, Immunogenicit y and Biomarker 
Research Sampling Schedule (Appendix 4 ), venous blood sam ples will  be collected for all 
patients enrolled in the study .  These samples will be used to dete rmine the serum  concentrati ons 
of olaratum aband the pl asma concentrations o fdoxorubicin and ifo sfamide .
A maximum of 5 additional samples (in addit ion to those shown in Appendix 4 )may be 
collected at additional t ime points during the study if warranted and agreed upon between the 
investigator and Lilly.
Instructi ons for the collect ion and handling of blood samples will be prov ided by Lilly .  It is 
preferred that the blood samples be obtained fro m a peripheral location.  Blood sam ples can be 
collected via central access devices, but a sample drawn for PK fro m any t ype of central catheter 
cannot be diluted or it will not be viabl e for analysis.  If mult iple samples are obtained centrally, 
the PK sample should be the last specimen drawn to reduce the potential for a diluted or 
improperly drawn sample.  The actual date and time (24- hour clock time) of each sampling will 
be recorded.
These samples will be analyzed at 1or more laboratori es designated by Lilly .  Serum  
concentrations of olaratumab will be assayed using a validated enzyme -linked immunosorbent 
assay method .Doxorubicin and ifos famide concentrati ons in plasma will be anal yzed using 
individual validated methods based on liquid chromatography  with tandem  mass spectrom etry.
The PK samples will be stored at a facilit y designated by Lilly .  The rem aining serum  and 
plasma f rom the samples collected for PK may be pooled and used for exploratory  drug 
metabo lism work and other expl oratory  PK/pharmacodynamic (PD) work as deem ed appropri ate.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 68
LY3012207Bioanaly tical samples collected to m easure ol aratumab concentrati ons will be retained for a 
maximum o f 1 year following th e last pati ent visi t for the study .
9.6. Genetics
9.6.1. Whole Blood Samples for Pharmacogenetic Research
A whole blood sample will  be collected for pharmacogenet ic analysis as specified in Appendix 
4,where local regulat ions allow.
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to study  treatm ent
and to inv estigate geneti c variants though t to pl ay a rol e in sarco ma. Assessment of variable 
response may include evaluat ion of AEs or differences in efficacy.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the study  site personnel.  Sam ples will  be retained for a 
maximum o f 15 years after the last patient visit for the study , or for a shorter period if local 
regul ations and/or ethical review boards ( ERBs )/institutional review boards ( IRBs )impose 
shorter time limit s, at a facilit y selected by  Lilly .  This retention period enables use of new 
techno logies, response to questions fro mregul atory  agencies and invest igation of variable 
response that may not be observed unt il later in the development of study  drug(s) or after study  
drug(s) become (s
)commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing techno logies include whole geno me and exo me 
sequencing, geno me-wide associ ation studies, multiplex assays, candidate gene studies and 
epigenet ic analyses .  Regardl ess of the tech nology utilized, data generated will be used only for 
the specific research scope described in this sect ion.
9.7. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ) and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurement of bio molecul es including deoxy ribonucleic acid, 
ribonucleic acid, proteins, lipids and other cellular elements.  Requi red sam ples f or biomarker 
research to be collected from all pat ients in this study  are the fo llowing:
blood (plasma) (see Secti on 9.7.1 )
tumor tissue (see Sectio n 9.7.2 )
Optional samples for bi omarker research that should be collected from pat ients in the study  
where possible are the fo llowing:
newly obtained tumorspecimens co llected during or after the treatment peri od 
or at disease progressi on if medically feasible (see Secti on 9.7.2 )
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 69
LY3012207Samples for bi omarker research will be co llected as specified in Appendix 4 , where l ocal 
regul ations allow.
It is possible that bi omarker data for patients in the study  have al ready been generated from 
samples that were collected and analyzed prior to enrollment in this tria l.  This m ay include data 
generated fro m genet ic analyses.  If available, these data may be requested fro m medical records 
for use in the research described below.
9.7.1. Samples for Non pharmacogenetic Biomarker Research
Blood samples for nonpharmacogenetic bio marker research will be co llected as specified in 
Appendix 4 where local regulat ions allow.
Samples will  be examined for bio markers related to , but not lim ited to drug targets, di sease 
process, immune cells/immune and tumor microenvironment funct ioning wit hin the disease state 
and cancer -related condit ions, pathway s associ ated wi th cancer and study  drugs , vari able 
response to study drugs , the m echanism  of action of study drugs and/or for research -related 
methods, or validating diagnostic tools or assays.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the study  site personnel.
Samples will be retained for a maximum o f 15 years after the last patient visit for the study , or 
for a shorter peri od if local regulations and/or ERBs/IRBs impose shorter time limits, at a facilit y 
selected by  Lilly.   This retention period enables use of new techno logies, response to questions 
from regulatory  agencies and invest igation of variable response that may  not be observed unt il 
later in the development of study  drug(s) or after study  drug(s) becom e(s)commercially  
available.
9.7.2. Tissue Samples for Biomarker Resea rch 
Tumor tissue will  be examined for bio markers related to, but not lim ited to drug targets, disease 
process, immune cells/immune and tumor microenvironment funct ioning wit hin the disease state 
and cancer -related condit ions, pathway s associ ated wi th canc er and study  drugs , vari able 
response to study  drugs, the mechanism  of action of study  drugs and/or for research -related 
methods, or validating diagnostic tools or assays.
Collect ion of the fo llowing tum or tissue sample is required for all pat ients in orde r to participate 
in this study unless restri cted by  local regulat ions:
To m eet study  eligibilit y criteria, and therefore mandatory  for study participati on, 
patients m ust have sufficient available material from an archived formalin -fixed 
paraffin -embedded t umor tissue.  If such t issue is not available, a newly  obtained core 
or excisio nal biopsy  of a tum or lesion must be perform ed.  Pati ents f or whom  it is 
inadvisable to undergo a new biopsy  in the opinio n of the invest igator (for example, 
due to technically challenging tumor locat ion) may be enro lled, after prior discussio n 
with the Lilly CRP.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 70
LY3012207Collect ion of the fo llowing tum or tissue sample (s)is optional for all pat ients participat ing in this 
study :
Newly obtained tumorspecimens collected during or after the treatm entperiod .If 
theseadditional samples are requested, theywill be used to further invest igate 
biomarkers that may explain treatm ent response and resistance mechanisms.  A tum or 
tissue sample will be requested from patients who undergo surgical t umor resecti on 
subsequent to study  treatm ent.
Details for the handling and shipping of the tumor tissue will be provided by  the sponsor in a 
separate document. If addit ional tumor biopsies are collected as part of clinical care, they should 
be submitted, along with patho logy reports, for further analysis.  The ti ssue samples will be 
obtained using appropriate method. Tumor tissue should be submitted as a newly acquired 
excisio nal or core needle (minimum 18 gauge) bio psy in formalin. Cytological or fine -needle 
aspiration specimens and decalcified bone are not acceptable.  Previously obtained 
formalin-fixed paraffin -embedded tum or tissue shoul d be provi ded as a block or unstained slides.   
Due diligence should occur to ensure that tum or sample (not a normal adjacent or a tumor 
margin sample) is provided.  The p athol ogyreport may also be requested to accompany the 
archival t issue sample . The report must be coded with the patient number. Personal ident ifiers, 
including the patient’s name and init ials, must be removed fro m the inst itutional pathol ogy report 
prior to submissio n. Lilly has a right to retain a portion of the submitted tissue and archival 
blocks will be returned to the study  site. Slides and tissue samples collected on -study will not be 
returned . 
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if local regulations and/or ERBs/IRBs impose shorter time limits, at a facilit y 
selected by  Lilly.   This retentio n peri od enables use of new techno logies, response to questions 
from regulatory  agencies and invest igation of variable response that may  not be observed unt il 
later in the development of study  drug(s) or after study drug(s) beco me(s)commercially  
available .
Techno logies are expected to improve during the 15 -year storage period and therefore cannot be 
specifically named.  However, exist ing techno logies, including mutati on profiling, copy  number 
variabilit y, gene expressio n, multiplex assa ys and/or immunohistochemistry may be perform ed 
on these tissue samples to assess potential associat ions with these bio markers and clinical 
outcom es.
9.8. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected as shown in Appendix 4 to 
determine antibody  producti on against olaratum ab.  Immu nogenicit y will be assessed using a 
validated assay designed to detect antidrug ant ibodies in the presence of olaratum ab.  Ant ibodies 
may be f urther characteri zed and/or evaluated for their abilit y to neutralize the activit y of 
olaratum ab.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 71
LY3012207Samples will  be retained for a m aximum  of 15 y ears after thelast pati ent visi t for the study , or 
for a shorter peri od if regulat ions and ERBs/IRBs impose sho rter time limit s, at a facilit y 
selected by  Lilly.  The durati on allows Lilly to respond to future regulatory  requests rel ated to 
olaratum ab.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 72
LY301220710.Statistical Considerations
10.1. Sample Size Determination
The primary  object ive is to determine whether olaratum abcan be safely added to the 
doxorubi cin, ifo sfamide and mesna regimen in patients with advanced or metastatic STS. 
Secti on 5.1outlines the study  design. Atotal of approximately  45to 60 patients will be enrolled; 
at least 15 patients will be treated inthe olaratum ab 15 -mg/kg phase .
A tradit ional 3 + 3 study  desig n is not appropriate for this trial b ecause of the relat ively high rate 
of DLT -level toxicit yassoci ated with the backbone doxorubicin, ifosfamide and mesna regimen 
(Judson et al. 2014) .  Instead, a total of approximately 15 patients will be enro lled at th e first 
dose l evel of ol aratum ab (and incrementally evaluated after 6, 9 and 15 patients have received 1 
cycle of  therapy ) to all ow sufficient patient numbers to judge init ial tol erabilit y of o laratumab in 
combinat ion with doxorubi cin, ifosfamide and mesna .
Before enrolling the full 15 patients at a given dose level, the study  design requires that a n initial
group of 6 willbe enrolled and evaluated for DLTs. If6 ormorepatents with DLT sare 
observed in the first 6 patients , enrollment at the current dose level willbe stopped and 
appropriate dose de -escalat ion (or tri al halt) will occur .Similarly, if 6 or more patients wi th
DLTs are observed in the first 9 patients ,enrollment at the current dose level will be stopped and
appropriate dose de -escalat ion(or tri al halt)will occur.
Assuming that the true DLT rate of olaratumab plus doxorubicin , ifosfamide and mesna is 
unacceptably  high at 70%, thisdesign will allow a 73% power to de -escalate the dose to a n 
appropriate lowerdose level. That is, when the true DLT rate is 70%, the probabilit y of 
observing 6or moreDLT patients out of 9 patients is 0.73. Alternat ively , assuming that the true 
DLT rate of olaratumab plus doxorubicin ,ifosfamide and mesna is as low as 30%, then the 
probabilit y of observing 6 or more DLT pa tients out of 9 patients is only  0.03 (false-positive rate 
when the true DLT rate is 30% ).  
Assuming the true DLT rate of olaratumab plus doxorubicin, ifo sfamide and mesna is 
unacceptably  high at 70%, the curre nt design will allow an 87% power to de- escalate the dose to 
an appropriate lower dose level.  That is, when the true DLT rate is 70%, the probabilit y of 
observing 9or moreDLT patients out of 15 patients is 0.87. Alternatively , assuming the true 
DLT rat e of olaratumab plus doxorubicin, ifosfamide and mesna is as low as 30%, then the 
probabilit y of observing 9 or more DLT patients out of 15 patients is only 0.02 (false-positive 
rate when the true DLT rate is 30% ).  
Although the study  sample size i slimit ed, th e overall design allo ws sat isfactory  power and
false-positive rate.
10.2. Populations for Analyses
Safety population: All enrolled pat ients who receive any  quant ity of study  treatm ent,regardless 
of their eligibili ty for the study , will  be included in the safety analysis. Safet yevaluat ion will be 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 73
LY3012207perform ed based on the actual init ial therapy a patient has received. Efficacy analysis will be 
perform ed on the safet y populati on unless otherwise specified.
DLT -evaluable population: The DLT -evaluable popul ation will include all enrolled patients 
who com plete Cy cle 1 or di scontinue due to a DLT prior to complet ing Cycle 1 treatm ent.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y ofLilly or its desi gnee .
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, wi ll be described 
in the statist ical analysis plan (SAP)and the clinical study  report.  Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
The interpretation of the study  resul ts will be the responsibilit y of Lilly CRP, pharmacokineticist 
and statist ician. The CRP and statistician will also be responsible for the appropriate conduct of 
an internal review for both the final study  report and a ny study -related material to be authorized 
by Lilly  for publicat ion.
10.3.1. Efficacy Analyses
Efficacy analysis will be performed to invest igate ant itumor activit y within each phase .The 
investigator -assessed object iveresponse rate ( complete response [ CR]+ partial response [ PR]) 
and disease control rate (DCR =CR+PR+stable disease ) and the 90% exact confidence interval 
(CI)will be tabulated for each phase . The Kaplan -Meier m ethod ( Kaplan and Meier 1958) will 
be used to estimate the median wi th 90% CI for PFS, OS and durati on of  response . Addit ional 
analyses may be performed as necessary .Thedetails will be outlined in the SAP.
10.3.2. Safety Analyses
All patients who receive at least 1 dose of any study therapy will be evaluated for safet y and 
toxicity.
Treatm ent-emergent a dverse events will be summarized by MedDRA System Organ 
Class/preferred term , classified fro m verbat im terms. The incidence and percentage of 
patients wi th at least 1 occurrence of a preferred term will be included, according to the 
most sev ere NCI- CTCAE Version 4.0 grade. Causalit y (relat ionship to study  drug), 
action taken, and outcom e will be summarized separately . Durati on of  AE will  be 
determined and included in the list ings.
Study  drug exposure will be summarized for each arm with fo llowing vari ables: number 
of infusio n
s, number of cycles, duration of therapy, cumulat ive dose, dose intensit y,and 
relative dose intensit y.
Laboratory  resul ts will be classified according to NCI -CTCAE Version 4.0. Incidence of 
laboratory  abnorm alities wi ll be summarized .
Hospitalizations due to AEs, transfusio ns and vital signs will be summarized.
I5B - MC- JGDR(a )Phase  1  Onco logyP ro toco l Page  74
LY3012207 DLT sw i l l  b e  s umm a r i z e d  b y ph a s ei n  t h e  p a t i e n ts  who  a r e  ev a lu ab l e  fo r  DLT  
a s s e s sm e n t s  a n d  l i s t e d  b y  p a t i e n t.  ECG ,  ECHO /MUGA  a n d  imm u n o g e n i c i t y  d a t aw i l l  
a l s o  b e  s umm a r i z e d .  A d d i ti o n a l  an a ly s e s  m ay  b e  p e r fo rm e d  a s  n e c e s s a r y .  T h e  d e t a i l s  
w i l l  b e  o u t l i n e d  i n  t h e  SAP .
10 .3 .3 .O the r  Ana lyses
10 .3 .3 .1 . Pa t ien t  D ispos i t ion
A  d e t a i l e d  d e s c r i p t i o n  of  p a t i en t  d i spo s i t i on  w i l l  b e  p rov i d e d ,  i n c l u d i n g  a  summ a ry  o f  th e  
n um b e r  a n dp e r c e n t a g e  o f  p a t i e n t s  w h o  e n t e r e d  i n t o  t h e  s t u d y ,  en ro l l ed  in  th e  s tudy  and  t r e a t ed  
a s  w e l l  a s  th e  n um b e r  a n d  p e r c e n t a g e  o f  p a t i e n t s  c om p l e ti n g  t h e  s t u d y ,  a s  d e f i n e d  i n  t h e  SAP ,  o r  
d i s c o n t i n u i n g  ( o v e r a l l  a n d  b y  r e a s o n  f o r  d i s c o n t i n u a t i o n ) .   A  s umm a r y  o f  a l l  im p o r t a n t  p r o t o c o l  
d e v i a ti o n s  w i l l  b e  p r o v i d e d .
10 .3 .3 .2 . Pa t ien t  Cha rac te r is t ics
A  summ a ryo f  b a s e l i n e  p a ti e n t a n d  d i s e a s e  ch a r a c t e r i s t i c s ,  h i s t o r i c a l  d i a g n o s e s ,  p r e e x i s t i n g  
cond i t i o n sand  p r i o r  th e r ap i e s  w i l l  b e  r epo r t ed u s i ng  d e s c r i p ti v e  s t a t i s t i c s .  
O th e r  p a t i e n t  c h a r a c t e r i s ti c s  w i l l  b e  s umm a r i z e d  a s  d e em e d  a p p r o p r i a t e .
10 .3 .3 .3 . Concom i tan t  The rapy
A  summ a ryo f  p r i o r  a n d  c o n c om i t a n t  m e d i c a t i o n sw i l l  b e  r epo r t ed .
10 .3 .3 .4 . Pos t- s tudyT rea tmen tDiscon t inua t ion  The rapy
T h e  n um b e r s  a n d  p e r c e n t a g e s  o f  p a t i e n t s  r e c e i v i n g  p o s t -s tudyt r e a tm e n td i s c o n ti n u a t i o n  
a n t i c a n c e r  t h e r a p i e s  w i l l  b e  p r o v i d e d  b y  t y pe  o f  th e r apy  ( su rg e ry ,  r ad i o th e r apy  o r  sy s t em i c  
th e r apy ) ,  and  by  d rug  c l a s s  and /o r  n am e ,  and  ov e r a l l .
10 .3 .3 .5 . T rea tmen t  Comp l iance
T h e  n um b e r  o f  c y c l e s  r e c e i v e d,d o s e  om i s s i on s ,  d o s e  r e d u c t i o n s ,  d o s e  d e l a y s  a n d  d o s e  i n t e n s i ty  
w i l l  b e  s umm a r i z e d  f o r  a l l  t r e a t e d  p a t i e n t s  b ye a ch  p h a s e .
S tudy t r e a tm e n t  w i l l  b e  a dm i n i s t e r e d  a t  t h e  i n v e s t i g a t i v es i t e ,  th e r e fo r e  t r e a tm en t  com p l i an c e  i s  
a s s u r e d .
10 .3 .4 .Pha rmacok ine t ic  Ana lyses
U n l e s s  s t a t e d  o t h e rw i s e ,  th e  L i l l y  p h a rm a c o k i n e ti c i s t  w i l l  b e  r e s p o n s i b l e  f o rth e  PK  a n d  PK /PD  
a n a l y s e s .
P h a rm a c o k i n e ti c  p a r am e t e r  e s t im a t e s  f o r  o l a r a t um a bw i l l  b e  c a l c u l a t e d  u s i n gs t a n d a r d  
n o n c om p a r tm en ta l  m e t h o d s  o f  a n a l y s i s .   Th e  p r im a ry p a r am e t e r s  f o r  a n a l y s i s  w i l l  b e  m a x im um  
c o n c e n t r a t i o n  a n d  a r e a  u n d e r  t h e  c o n c e n t r a t i o n - t im e  c u r v e  (AUC [0 - t l a s t ] ,  AUC[0 - ∞])  o f
o l a r a tum a b .   O th e r  non com p a r tm en t a l  p a r am e t e r s ,  s u c h  a s  h a l f - l i f e ,  a p p a r e n t  c l e a r a n c e  a n d  
a p p a r e n t  v o l um e  o f  d i s t r i b u ti o n  m ay  b e  r epo r t ed .   
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 75
LY3012207Addi tional analyses such as populati on PKanalyses may also be conducted if deemed 
appropriate.   Other validated PKsoftware programs (for example, NONMEM) may  be used if 
appropriate and approved by  Global Pharmacokineti c management.  The versio n of any  software 
used for the analysis will be documented and the program will meet the Lilly requirements of 
software validat ion.
Plasma doxorubicin and ifo sfamide concentrati ons at different time points will be summarized 
by descript ive statist ics.
10.3.5. Biomarker Ana lyses
Biomarker assay  resul ts will be listed and summarized for all pat ients qualif ying for the 
transl ational research portion of the study . Other exploratory  analyses may  also be undertaken to 
investigate the correlat ions and/or associations between mark er status/l evel and drug disposit ion, 
target engagement, PD, mechanism o f action, variabilit y of patient response (including safety ) 
and clinical outcome s.These assessments may include bio marker signatures consisting o f 
marker status/levels o f multiple b iomarkers.  F or biomarkers that are serially measured, change 
from baseline to a subsequent time point may also be used as a potenti al explanatory  variable in 
correl ative assessments involving other trial data endpo ints and as a dependent variable in PD
analyses .
10.3.6. Immunogenicity Analyses
Incidence of treatment -emergent ant i-olaratum ab ant ibodies will be tabulated.  The potential 
impact of immunogenicit y on ol aratum ab exposure will be evaluated in the populat ion PK 
modeling exercises where immunogenicit y will be evaluated as a covariate.  In addit ion, 
graphical assessments will be conducted, as appropriate, to compare drug exposure between 
treatm ent-emergent antidrug ant ibody  (ADA) -negative and treatment -emergent -ADA -positive 
patients at correspondent visits, or before and after treatm ent-emergent -ADA development for 
patients who developed treatm ent-emergent -ADA.
In the event of an IRR, the immunogenicit y and olaratum ab serum  concentrati ons will  be 
tabul ated.
10.3.7. Subgroup Analyses
Subgroup analyses will be perfo rmed as deemed appropriate.
10.3.8. Interim Analyses
Since this is a safet y study , data will  be reviewed on at least a cohort-by-cohort basis during the 
study . The purpose of these safet yreviews i s to eval uate the safet y data at each phase to 
determine if the current safety  profile supports continual enrollment based on the study  design . 
The invest igators and the Lilly study team will make the determinat ion regarding thepatient 
enrollmentbased upon their review of the safet y and tolerabilit y data as described in this 
protocol .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 76
LY301220711.References
[ACS] American Cancer Societ y. Sarcoma: adult soft tissue cancer. 2014. Available at: 
http://www.cancer.org/acs/groups/cid/documents/webcontent/003138 -pdf.pdf .Accessed 
February  20, 2017.
Andrae J, Gallini R, Betsho ltz C. Role of platelet -derived growth factors in physio logy and 
medicine. Genes Dev . 2008;22(10):1276-1312.
[ASHP] American Societ y of Heal thSystem  Pharmacists. ASHP guidelines on handling 
hazardous drugs. Am J Health Syst Pharm . 2006;63:1172 -1193.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16:31 -41.
D’Angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy : past approaches 
and future direct ions. Sarcoma . 2014;2014:391967.
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST gu ideline (versio n 1.1). 
Eur J Cancer . 2009;45(2) 228 -247.
Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, Ezzat A, 
Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, EORTC Soft Tissue 
Bone Sarcoma Group and the N ational Cancer Institute of Canada Clinical Trials 
Group/Canadian Sarco ma Group. A randomised phase II study on neo -adjuvant chemotherapy  
for ‘high -risk’ adul t soft-tissue sarco ma. Eur J Cancer . 2001;37(9):1096–1103.
Grobmyer SR, Maki RG, Demetri GD, Mazum dar M, Ri edel E, Brennan MF, Singer S. 
Neo-adjuvant chemotherapy for primary high -grade extremit y soft tissue sarco ma. Ann Oncol . 
2004;15(11):1667 –1672.
Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol . 2009;471:3 –29.
Judson I, Verweij J, Gelderblo m H, Hartm ann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky  J, 
Whelan J, Hohenberger P, Krarup- Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, 
Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT. Adriamycin alone versus 
intensified adriamycin plus ifo sfamide for first -line treatment of advanced or metastatic 
soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol . 2014;15(4):415 -323.
Kaplan EL, Meier P. Nonparametric estimat ion of inco mplete observat ions. J Amer Stat Assoc . 
1958;53:457 -481.
LiA, Xi a X, Yeh J, Kua H, Liu H, Mishina Y, Hao A, LiB. PDGF -AA pro motes osteogenic 
different iation and migrat ion of mesenchymal stem cell by down -regul ating PDGFRα and 
derepressing BMP -Smad1/5/8 signaling. PLoS One. 2014;9(12):e113785.
Linch M, Miah A, Thway  K, Judson IR, Benson C. Sy stemic treatm ent of soft -tissue sarco ma -
gold standard and novel therapies. Nat Rev Clin Oncol. 2014;11:187 -
202.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 77
LY3012207Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty  B. Targeting the plate let derived growth factor 
receptor α with a neutralizing human mo noclonal  antibody  inhibits the growth of tumor 
xenografts: implicat ions as a potential therapeut ic target. Mol Cancer Ther . 
2005;4(3):369 -379.
Maurel J, López-Pousa A, de l as Pe ñasR, Fra J, Martín J, Cruz J, Casado A, Poveda A , 
Martínez -TruferoJ, BalañáC, Gómez MA,Cubedo R, Gallego O, Rubi o-ViqueiraB, Rubi ó J, 
Andr és R, Sevilla I, de la Cruz JJ, del  Muro XG, Buesa JM. Efficacy  of sequent ial high- dose 
adriamycin andifosfamide compared with standard -dose adriamycin in patients with advanced 
soft tissue sarcom a: a
n open-label 
rando mized phase II study of the Spanish Group for 
Research on Sarcomas . J Clin Oncol . 2009; 27:1893-1898.
[NCCN] National Co mprehensive Cancer Network Guidelines .
Myeloid growth factors. Version
2.2014 .Available at: http://williams.medicine.wisc.edu/myelo id_growth.pdf. Accessed 
February  20, 2017.
[NCI] Nati onal Cancer Institute. Cancer Therapy Evaluat ion Program , Comm on Termino logy 
Criteria for Adverse Events, Versi on 4.0 ,DCTD, NCI, NIH, DHHS. Publish date: 
29May 2009.
NgF, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, 
Rao MS, Tanavde V. PDGF, TGF -beta, and FGF signaling is important for different iation and 
growth of mesenchyma l stem  cells (MSCs): transcri ptional profiling can ident ify markers and 
signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and 
osteogeni c lineages. Blood . 2008;112(2):295 -307.
[NIOSH ]NIOSH a lert: prevent ing occupational exposure to antineoplast ic and other hazardous 
drugs in healt hcare settings. 2004. US Department of Health and Human Services, Public 
Health Service, Centers for Disease Control and Prevent ion, Nati onal Inst itute for 
Occupational Safet y and Healt h
.DHHS ( NIOSH) Publicat ion No. 2004- 165.
Oken MM, Creech RH , Torm ey DC, Horton J , 
Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the Eastern Cooperative Oncology Group .Am J Clin Oncol . 
1982;5:649 -655.
[OSHA ] OSHA Technical Manual, TED 1 -0.15A, Section VI: Chapter 2. Controlling 
occupational exposure to hazardous drugs. 1999. Available at: 
http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html . Access edJanuary  13, 2017.
Pisters PWT, Weiss M, Maki R, Raut CP. Cancer management; so ft tissue sarc omas; rol e of 
adjuvant chem otherapy . Cancer Network web site.01 June 2016. Available at: 
http://www.cancernetwork.com/cancer -management/soft -tissue -sarcom as/page/0/5. Accessed 
February  
09, 2017.
Polovich M, White JM, Kelleher LO, eds. Chemotherapy and biot herapy guidelines and 
recommendat ions for practi ce. 4thed.Pittsburgh, PA: Oncology  Nursing Society ; 2014 .
Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rat ionale for the development 
of IMC -3G3, a fully human immunoglobulin G subclass 1 monoclonal ant ibody  targeting the 
platelet-derived growth factor receptor alpha. Cancer . 2010;116(4 Suppl ):1018 -1026.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 78
LY3012207Sharma S, Taky ar S, Manson SC, Powell S, Penel N. Efficacy and safet y of pharm acological  
intervent ions in second -or later-line treatment of patients with advanced so ft tissue sarco ma: a 
systemic review. BMC Cancer . 2013;13:385.
Smith TJ, Khatcheress ian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, 
Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg 
L, Som erfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. Update 
of recommendat ions fo r the use of white blood cell growth factors: an evidence -based clinical 
practi ce guideline. J Clin Oncol . 2006;24:3187-3205.
Soft tissue sarco ma statist ics page. Cancer Research UK web site. Available at: 
http://www.cancerresearchuk.org/health -professional/cancer -statist ics/statist ics-by-cancer -
type/so ft-tissue -sarcoma#heading- Zero. Accessed February  20, 2017 .
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias D, Adkins D, Agulnik M, Cooney  MM, 
Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A , Croni er DM, Il aria R, 
Conti  I, Cosaert J, Schwartz GK. Olaratumab and doxorubi cinversus doxorubi cinalone f or 
treatm ent of so ft-tissue sarco ma: an open -label phase 1b and rando mised phase 2 trial. Lancet . 
2016; 388(10043):488-497.
Worden FP, Taylor JM, B iermann JS, Sondak VK, Leu KM, Chugh R, McGinn CJ, 
Zalupski MM, Baker LH. Rando mized phase II evaluat ion of 6 g/m 2of ifosfamide plus 
adriamycin and granulocy te col ony-stimulat ing factor (G -CSF) compared with 12 g/m 2of 
ifosfamide plus adriamycin and G -CSF in the treatment of poor -prognosis so ft tissue sarco ma.
J Clin Oncol . 2005; 23:105 -112.
I5B - MC- JGDR(a )Phase  1  Onco logyP ro toco l Page  79
LY3012207Append ix  1 .Abb rev ia t ions  and  De f in i t ions
Te rm De f in i t ion
ADA a n t i d r u g  a n t i b o d y
AEa d v e r s e  e v e n t :   a n y  u n t ow a r d  m e d i c a l  o c c u r r e n c e  i n  a  p a t i e n t  o r  c l i n i c a l  i n v e s t i g a t i o n  
p a t i e n t  a dm i n i s t e r e d  a  p h a rm a c e u t i c a l  p r o d u c t  a n d  t h a t  d o e s  n o t  n e c e s s a r i l y  h a v e  a  
c a u s a l  r e l a t i o n s h i p  w i t h  t h i s  t r e a tm e n t .   A n  a d v e r s e  e v e n t  c a n  t h e r e f o r e  b e  a n y  
u n f a v o r a b l e  a n d  u n i n t e n d e d  s i g n  ( i n c l u d i n g  a n  a b n o rm a l  l a b o r a t o r y  f i n d i n g ) ,  s ym p t om ,  
o r d i s e a s e  t em p o r a l l y  a s s o c i a t e d  w i t h  t h e  u s e  o f  a  m e d i c i n a l  ( i n v e s t i g a t i o n a l )  p r o d u c t ,  
w he th e r  o r  n o t  r e l a t e d  t o  t h e  m e d i c i n a l  ( i n v e s t i g a t i o n a l )  p r o d u c t .
AES Ia d v e r s e  e v e n t s  o f  s p e c i a l  i n t e r e s t
ALTa l a n i n e  am i n o t r a n s f e r a s e
ANCa b s o l u t e  n e u t r o p h i l  c o u n t
ASCOAm e r i c a n  S o c i e t y  o f  C l i n i c a l  O n c o l o g y
ASTa s p a r t a t e  am i n o t r a n s f e r a s e
AUC[0 - t las t ]a r e a  u n d e r  t h e  c o n c e n t r a t i o n  v e r s u s  t im e  c u r v e  f r om  t im e  z e r o  t o  t im e  t ,  w h e r e  t  i s  t h e  
l a s t  t im e  p o i n t  w i t h  a  m e a s u r a b l e  c o n c e n t r a t i o n
AUC[0 -∞ ∞]a r e a  u n d e r  t h e  f i r s t  m om e n t  c u r v e  f r om  z e r o  t o  i n f i n i t y
b l ind ing /mask ingA  p r o c e d u r e  i n  w h i c h  o n e  o r  m o r e  p a r t i e s  t o  t h e  t r i a l  a r e  k e p t  u n aw a r e  o f  t h e  t r e a tm e n t  
a s s i g nm e n t .   U n l e s s  o t h e rw i s e  s p e c i f i e d ,  b l i n d i n g  w i l l  r em a i n  i n  e f f e c t  u n t i l  f i n a l  
d a t a b a s e  l o c k .
A  s ing l e- b l i n d  s t u d y  i s  o n e  i n  w h i c h  t h e  i n v e s t i g a t o r  a n d / o r  h i s  s t a f f  a r e  aw a r e  o f  t h e  
t r e a tm e n t  b u t  t h e  p a t i e n t  i s  n o t ,  o r  v i c e  v e r s a ,  o r  w h e n  t h e  s p o n s o r  i s  aw a r e  o f  t h e  
t r e a tm e n t  b u t  t h e  i n v e s t i g a t o r  a n d / h i s  s t a f f  a n d  t h e  p a t i e n t  a r e  n o t .   
A  d o u b l e- b l i n d  s t u d y  i s  o n e  i n  w h i c h  n e i t h e r  t h e  p a t i e n t  n o r  a n y  o f  t h e  i n v e s t i g a t o r  o r  
s p o n s o r  s t a f f  w h o  a r e  i n v o l v e d  i n  t h e  t r e a tm e n t  o r  c l i n i c a l  e v a l u a t i o n  o f  t h e  p a t i e n t s  a r e  
aw a r e  o f  t h e  t r e a tm e n t  r e c e i v e d .
C I c o n f i d e n c e  i n t e r v a l
Cm in1 t r o u g hs e r um  l e v e l  a t  t h e  e n d  o f  t h e  f i r s t  c y c l e  o f  t r e a tm e n t
CNS c e n t r a l  n e r v o u s  s y s t em
co l lec t ion  da tabase Ac om p u t e r  d a t a b a s e  w h e r e  c l i n i c a l  t r i a l  d a t a  a r e  e n t e r e d  a n d  v a l i d a t e d .
CR c om p l e t e  r e s p o n s e
CRP c l i n i c a l  r e s e a r c h  p h y s i c i a n :   I n d i v i d u a l  r e s p o n s i b l e  f o r  t h e  m e d i c a l  c o n d u c t  o f  t h e  s t u d y .   
R e s p o n s i b i l i t i e s  o f  t h e  CRP  m a y  b e  p e r f o rm e d  b y  a  p h y s i c i a n ,c l i n i c a l  r e s e a r c h  s c i e n t i s t
(CRS ) ,  g l o b a l  s a f e t y  p h y s i c i a n ,  o r  o t h e r  m e d i c a l  o f f i c e r .
CT c om p u t e d  t om o g r a p h y
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 80
LY3012207DLT dose-limiting toxi city
ECG electrocardiogram
ECHOechocardiogram
eCRFelectronic case report form
effective method of 
contraceptionmale condom with spermicide, female condom with spermicide, diaphragm with 
spermicide, cervical sponge, or cervical cap with spermicide.
Also see the definition of highly effective method of contraception.
EORTC European Organisation for Research and Treatment of Cancer
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board: A board or committee (instit utional, 
regio nal, or national) composed of medical and nonmedical members whose 
responsibility is to verify that the safety, welfare and human rights of the patients 
participating in a clinical study are protected.
GCP good clinical practice
G-CSF granu locyte -colon y
-stimulating factor
highly effective 
method of 
contraceptioncombined o ral contraceptive pill and mini -
pill, NuvaRing ®, implantable contraceptives, 
injectable contraceptives (such as Depo -Provera ®), intrauterine device (such as 
Mirena ®and Pa raGard®), contraceptive patch for women <90 kg (<198 pounds), total 
abstinence, or vasectomy.
Also see the definition of effective method of contraception.
HR hazard ratio
IB Investigator’s Brochure
ICF informed consent form
ICH International Council forHarmonisation
INR internatio nal no rmalized ratio
interim analysis An interim analysis is an analysis of clinical trial data conducted before the final 
reporting database is created/locked.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
market ed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 81
LY3012207IRR infusion -related reaction
IV intravenous /intravenous ly
IWRS interactive web response system
LVEF left ventricular ejec tion fraction
MedDRA Medical Dictionary for Regulatory Activities
MUGA multiple -gated acquisition
NCCN Natio nal Comprehensive Cancer Network
NCI-CTCAE Natio nal Cancer Institute -Common Terminology Criteria for Adverse Events
OS overall survival
PD pharmacodynamics( s)
PDGFR platelet -derived growth factor receptor
PDGFR α platelet -derived growth factor receptor alpha
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic (s)
PR partial response
QTc corrected QT interval
QTcF Fridericia’s QT corrected interval
RECIST Response Evaluation Criteria in Solid Tumors
reporting database A point -in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
re-screen To screen a patient who was previously declared a screen failure for the same study .
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
screen failure patient who does not meet one or more criteria required for participation in a trial
STS soft tissue sarcoma
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 82
LY3012207SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event :  an untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment .
ULN upper limit of normal
US United States
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 83
LY3012207Appendix 2. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the patient understands the potential risks and benefits of participat ing in 
the study
ensuring that informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any study procedures and prior to the administration of study  treatm ent
answering any quest ions the pati ent m ay have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the patient’s willingness to 
continue his or her participat ion in the trial.
Ethical Review
Docum entati on of  ERB/IRB approval of the protocol and the ICF must be provided to Lilly
before the study  may begin at the invest igative site(s).  Lilly or its representatives must approve 
the ICF, including any changes made by  the E RBs/IRBs, before it is used at the invest igative 
site(s).   All ICFs must be compliant with the International C ouncil  forHarm onisat ion (ICH)
guideline on GCP.
The study  site’s ERBs/IRBs sho uld be provi ded with the following :
the current IB and updates duri ng the course of the study
the ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and Counc il for Internati onal Organizat ions of Medical Sciences 
International Ethical guidelines
applicable ICH GCP guidelines
applicable laws and regulations.
Some obligat ions of Lilly may be assigned to a third-party  organizat ion.
Investigator Information
Licensed physicians specializing in onco logy will participate as invest igators in this clinical trial.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 84
LY3012207Protocol Signatures
Lilly ’srespons ible medical officer will approve the protocol, confirming that, to the best of his 
or her knowledge, the protocol accu rately  describes the planned design and conduct of the study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The clinical st udy report coordinat ing invest igator will sign the final clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study . 
The invest igator with the mostenrolled pat ients will serve as the clinical study  report 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  Lilly to serve as the clinical study  report coordinat ing invest igator .
Lilly ’sresponsible medical officer and statist ician will approve the final clinical study report for 
this study , confi rming that, to the best of his or her knowledge, the report accurately describes 
the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete and reliable data, Lilly or its representatives will do the following:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators. This sessio n 
will give instruction on the protocol, the completion of the CRFs and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone and/or fax
revie w and eval uate CRF data and use standard computer edits to detect errors in data 
collect ion
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source doc uments at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original  source data.  Thi s might include laboratory  
tests, medical records and clinical notes.  If requested, the invest igator will provide Lilly ,
applicable regulatory  agencies, and applicable ERBs/IRBs with direct access to ori ginal  source 
docum ents.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 85
LY3012207Data Capture System
An electron ic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  the si te into Lilly -provi ded el ectroni c data capture system.
Case report form data will be encoded and stored in a clinical trial database .  Data managed by a 
central  vendor, such as laboratory  test data or ECG data, will be stored electronically in the 
central  vendor’s database system.  Data will subsequent ly be transferred from the central vendor 
to the Lilly data warehouse .
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee, the invest igator, or the 
ERB/IRB of the study  site judges i t necessary for medical, safet y, regul atory , or other reasons
consistent with applicable laws, regulat ions and GCP.
Discontinuation of the Study
The study  will be di scontinued ifLilly or i ts desi gnee judges itnecessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions and GCP.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 86
LY3012207Appendix 3. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology -local and central laboratory a
Leukocytes (WBC) Erythrocy tes (RBC)
Neutrophils b Hemoglobin (HGB)
Lymphocy tes Hematocrit (HCT)
Monocytes Mean corpuscular volume (MCV)
Eosinophils Mean corpuscular hemoglobin concentration (MCHC)
Basophils Platelets (PLT)
Coagulation -local laboratory
Activated partial thromboplastin time (aPTT) or partial thro mboplastin time (PTT)
International normalized ratio (INR) or prothrombin time (PT) 
Clinical Chemistry -local and central laboratorya
Serum Concentrations of:
Alanine aminotransferase (ALT) Cholesterol
Albumin Creatinine
Alkaline phosphatase Glucose ,random
Aspartate aminotransferase (AST) Magnesium
Bilirubin, direct Phospho rous
Bilirubin, total Potassium
Blood urea nitrogen (BUN) or blood urea Sodium
Calcium Uric acid
Urinalysis -local laborat ory
Blood Protein
Glucose Specific gravity
Ketones Urine leukocyte esterase
pH
Pregnancy Test (for female patient s of childbearing potential ) -local laboratory
Serum pregnancy test (screening)
Serum or Urine pregnancy test (on study)
Confirmation of Menopaus e(for female patients of menopausal age) –local laboratory
Follicle -stimulating hormone (FSH) c
Abbreviation:  CRF =case report form . 
aTreatment decisions will be based on local laboratory results.
bNeutrophils reported using automated differential hematology instruments include both segmented and band 
forms. When a manual differential is needed to report the neutrophils, the segmented and band forms should be 
added together and recorded on the CRF, unless the CRF specif ically  provides an entry field for bands.
cTo be performed at screening only when needed to confirm post -menopausal status ; applicable for women who
have experienced spontaneous amenorrhea for 6 to 12 months. 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 87
LY3012207Appendix 4. Pharmacokinetic, Biomarker, 
Pharm acogenetics and Immunogenicity  Sampling 
Schedules
It is essent ial that the exact infusio n start and stop times (actual clock readings) are recorded.  
The exact time of co llection of each venous blood sample will be based on the clock used to 
record infusio n times.  It is essent ial that the PKblood sam ples not be drawn from the same site 
as the drug infusio n.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 88
LY3012207Pharmacokinetic, Biomarker, Pharmacogenetic and Immunogenicity Sampling Schedule
Cycle Day Dosing Sampling Time aPK Sampling Biomarker Sampling
PGx IGe,fOlara PK b,f Dox PK c,lIfos 
PKd,lPlasma Tumor Tissue g
Baseline - X (mandatory) g
11≤60 min pre -olara XhX XiX
Olara (1 hr)
≤5 min post -olara X
Obs (1 hr)
60±10 min post -olara X
Dox ( <1 hr)j
≤5 min post -dox Xj
Ifos (3 hr)
≤5 min post -ifos X X
2Dox (<1 hr)
Ifos (3 hr)
≤5 min post -ifos X X
3Dox (<1 hr)j
≤5 min post -dox Xj
Ifos (3 hr)
≤5 min post -ifos X
4Ifos (3 hr)
≤5 min post -ifos X X
8≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
Obs (1 hr)
60±10 min post -olara X
4±0.5 hr post -olara X
10 48±3 hr post -olara X 
15 Anytime X
21≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
8≤60 min pre -olara Xh
Olara (1 hr)
≤5 min post -olara X
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 89
LY301220731≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
Dox (<1 hr)i
≤5 min post -dox X Xj
Ifos (3 hr)
≤5 min post -ifos X X
2Dox (<1 hr)
Ifos (3 hr)
≤5 min post -ifos XkX
3Dox (<1 hr)i
≤5 min post -dox Xj
Ifos (3 hr)
≤5 min post -ifos X
4Ifos (3 hr)
≤5 min post -ifos XkX
8≤60 min pre -olara Xh
Olara (1 hr)
≤5 min post -olara X
60±10 min post -olara X
4±0.5 hr post -olara X
10 48±3 hr post -olara X 
15 Anytime X
4 1 ≤60 min pre -olara Xh
5 and then 
every 
other 
cycle1 ≤60 min pre -olara XhX
Visit 801 Anytime XX X (optional ; for 
patients who 
undergo surgical 
tumor resection 
subsequent to study 
treatment )X
Abbreviation s:  C = cycle; D = day; dox = doxorubicin; hr = hour; ifos = ifosfamide; IG= immunogenicity; min = minute; IRR = infusion -related reaction; obs = 
observation; olara = olaratumab; PGx = pharmacogenetics; PK = pharmacokinetic s.
aPost-infusion is defined as after the completion of the infusion.
bSamples of approximately 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in serum.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 90
LY3012207cSamples of approximately 2mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of ifosfamide in plasma.
dSamples of approximately 3mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of doxorubicin in plasma.
eFor the immunogenicity assay, approximately 5mL of whole blood will be drawn into a serum separator tube without anticoagulant to generate serum 
samples.
fIf a patient experiences an IRR to olaratumab, blood samples for immunogenicity and PK analysis will be taken at the followin g time points:  (1) as soon as 
possible after the onset of the IR R, (2) at the resolution of the IRR and (3) 30 days (±3 days) after the IRR.
gPatients must have sufficient available material from an archived formalin -fixed paraffin -embedded tumor tissue. If such tissue is not available, a newly 
obtained core or excis ional biopsy of a tumor lesion must be performed. 
hPretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab inf usion and must be taken prior to 
administering any premedication.
iIt is high ly recommended to draw the PGx sample prior to the first dose of study  drug (C1D1); however, it can be collected at a later time p oint,if necessary.
jIf doxorubicin is administered as a 24 hour infusion, the doxorubicin PK sample should be collected at the same time as the ifosfamide PK sample (that is, 
approximately 3 to 4 hours after the start of the doxorubicin infusion).
kFor patients whohave discontinued dox orubicin/ifosfamide early , these samples may be omitted if there is no other reason for the patient to visit the clinic.
lShould a patient discontinue doxorubicin or ifosfamide, all subsequent PK samples for the corresponding chemotherapeutic agen t can be omitted.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 91
LY3012207Appendix 5. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin (HGB)
Hematocrit (HCT) Hepatic Coagulation a
Erythrocy tes (RBC) Prothrombin time (PT)
Leukocytes (WBC) Prothrombin time, INR
Neutrophils b
Lymphocy tes Hepatic Serologies a,c
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets (PLT) Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase (ALT) Recommended Autoimmune Serology a
Aspartate aminotransferase (AST) Anti- nuclear antibody
Gamma -glutamyl transferase (GGT) Anti-smooth muscle antibody
Creatine phosphokinase (CPK) Anti- actin antibody
Abbreviations:  CRF =case report form; IgG =immunoglobulin G; IgM =immunoglobulin M; INR =international 
normalized ratio .
aAssay ed by Lilly -designated laboratory.
bNeutrophils reported using automated differential hematology instruments include both segmented and band 
forms. Whenever a manual differential is needed to report the neutrophils, the segmented and band forms should 
be added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
cReflex/confirmati on dependent on regulatory requirements and/or testing availability.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 92
LY3012207Appendix 6. Creatinine Clearance Formula
Note:   This formula is to be used for calculat ing creatinine clearance (CrCl) fro m local 
laboratory results only.
For serum creatinine concentration in 
mg/dL:
CrCl =
(mL/min) (140 – agea) (wt) 0.85 (if female) , or1.0 (if male)
72serum creatinine (mg/dL )
For serum creatinine concentration in mol/L:
CrCl   =
(mL/min)(140 – agea) (wt) 0.85 (if female) , or1.0 (if male)
0.81serum creatinine (mol/L )
aAge in y ears, weight (wt) in kilograms.
Source:  Cockcroft and Gault 1976.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 93
LY3012207Appendix 7. Fridericia’s QTCorrection Formula
Fridericia’s QTCorrection Formula
Formula QTcF=QT/(RR)1/3
Abbreviations:  QT = ECG interval measured from the onset of the QRS complex to the offset of the T wave ; QTcF
= QT interval corrected for heart rate using Fridericia’s formula ;RR = time between corresponding points on 2 
consecutive R waves on ECG .
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 94
LY3012207Appendix 8. Protocol A mendment I5B-MC-JGDR(a )
Summary  A Phase 1b Study  of Olaratumab, 
Doxorubicin and Ifosfamide in the Treatment of 
Patients with A dvanced or Metastatic Soft Tissue 
Sarcoma
Overview
Protocol  I5B-MC-JGDR, A Phase 1b Study  of Olaratum ab, Doxorubicin and Ifosfamide in the 
Treatment of Pa tients wi th Advanced or Metastatic Soft Tissue Sarcoma has been amended.  The 
new protocol is indicated by  Amendment (a) and will be used to conduct the study  in place o f 
any preceding version o f the protocol.
The overall changes and rationale for the chan ges made to thi s protocol  are as fo llows:
The Schedule o f Activities was amended to remove visits and/or procedures not 
intended for pati ents receiving o laratumab monotherapy after complet ing6 cycles 
of olaratum ab pl us doxorubi cinand ifosfamide or otherwi se having discont inued 
doxorubi cin and ifo sfamide. Changes are as follows:
On-Study  Treatm entSchedule of Act ivities
-Olaratum ab m onotherapy section added for Cy cle 7 and bey ond
-Footnote was added to schedule to explain o laratumab monotherapy schedu le 
for Cycle 7 and bey ond
-Vital sign assessments were reduced to just Day  1
-Radiologic imaging and measurement of palpable or visible lesio ns procedure 
note was m odified, deleting the 12 -week timing for patients receiving 
olaratum ab as m onotherapy  following discont inuatio n of co mbination therapy 
-For ECGs, l anguage was added for t iming of ECGs in Cycle 7 and beyo nd, 
which will be performed Day  1 of Cycle 7 and approximately  6 months and 
12 m onths after disc ontinuat ion of of doxorubicin and ifo sfamide treatment.
-For pati ents receiving olaratumab as mo notherapy  following discont inuat ion 
of combinat ion therapy , echocardi ograms will be perform edapproximately 6 
months (±14days) and 12 months (±14days) after discont inuat ion of 
doxorubi cin and ifo sfamide treatment
-For uri nalysis, patients will be m onitored for evidence o f micro -and/or 
macroscopic hematuria and treat edaccordi ng to institutional standards.  F or 
patients receiving olaratumab mo notherapy  Cycle 7 and beyo nd, urinalysis is 
not performed.
Post-Treatment Follow -Up Schedule of Act ivities
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 95
LY3012207-ECGs were added during short -and long -term follow up.  All patients should 
have a 12 -lead ECG performed at short- term follow-up.  Patients should also 
have a 12 -lead ECG performed approximately 6 months (±7 day s) and 12 
months (±7 days) after the end of t reatment with doxorubicin and ifo sfamide.  
-For echo and MUGA, clarifying language was added to make clear the after 
the end of treatment with doxorubicin and ifo sfamide, specificially.
Secti on 6.1 Inclusion Criteria
-Clarifying language was added to inclus ion criterion [7] explicit ly stating that 
adjuvant or neo -adjuvant treatment will not be counted as a prior line of 
therapy
-Inclusio n criterion [12] was m odified to del ete general  language and add 
treatm ent-specific duration requirements related to male co ntraception
-Female pregnancy  testing and contracepti on language in [13] was modified , 
increasing the prior -to-treatm ent pregnancy testing window to 7 days, and 
making the duration of contraception requirements treatment specific -at least 
3 months f ollowing the l ast dose of ol aratum ab and 6 m onths fo llowing the 
last dose of doxorubicin or ifosfamide .  
Secti on 6.2 Exclusion Criteria
-Addit ional language was added to [23] regarding patients’ history  of prior 
malignancies as fo llows:
onon-metastatic prostate cancer, or 
oother primary  nonhematol ogic malignancies treated with curat ive intent, 
no known active disease, and no treatment administered during the last 3 
years prior to enrollment, that the invest igator and Lilly Medical 
representative agree will not af fect interpretation of study  resul ts or woul d 
be unsuitable for participat ion in the study  
-In Section 7.1, Table JGDR.6, for clarity, footnote “b” was added to the 
ifosfamide rows in the Total D osecolumn (that i s, 10b g/m2 ifosfamide )
-Clarifying edits re lated to premedicat ion were added in Section 7.1.1
-In Section 7.2.1 clarifying language was added for delays for Cycle 2 and 
beyo nd
-Clarifying language was added in Section 7.2.2.1 to explain DLTs in relati on 
to further enro llment and pat ients.  A note was added making it clear that IRR 
are not considered DLTs.
-A footnote was added to Table JGDR.7 to clarify threshho lds pati ents 
experiencing DLTs and further patient enrollment.
-In Section 7.4, textwas added to make clear the secti on is referring to patient s 
being treating wit h olaratum ab pl us doxorubi cin and ifosfamide.   Addit ional 
text was inserted to state monitoring for hematuri a.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 96
LY3012207-In Section 7.4.1, text was inserted to further detail guidance around dose 
delays.  If Day  8 treatm ent is delayed >7 days, tr eatm ent m ay be resumed with 
planned Day 1 treatm ent of the next cy cle. Dosing delay bey ond 14 days m ay 
be permissible if AEs are not considered to be primarily related to olaratumab 
and the invest igator deems cont inuat ion of study  treatm ent to have clinica l 
benefit for the patient.   Dose del ays do to unforeseen circumstances or 
scheduling issues are also addressed.
-In Section 7.4.2, clarifying text was added to address discont inuat ions.
-Secti on 7.4.3 was m odified rel ated to guidance for dose modificat ion –
referring the reader to specific subsect ions, and addressing potential for 
variat ions from guidelines wi th respect to l ocal standard of care and labels.
- In Section 7.4.3.1, text related to number of and specifics o f olaratum ab dose 
modificati ons.
-Secti on 7.4.3.1.1 was edited, indicat ingthat the guidelines for dose 
modificati ons due to hematol ogic toxi cities are outlined in Table JGDR.8 and 
shoul d be used when olaratumab is given in combinat ion with doxorubicin 
and ifo sfamide.
-Clarifying text was added to Section 7.4.3.2 explaining that doxorubicin dose 
modificati ons will fo llow guidelines outlined in the protocol, and that 
adjustm ents m ay be made based on local standard of care and label .
-Secti on 7.4.3.3 was edi ted to expl ain that dose m odificat ions will f ollow 
guidelines outlined in the protocol, and that adjustments may  be m ade based 
on local standard of care and label.
-Secti on 7.8.6 was added to provide detailed guidance regarding other 
concomitant therapies during Study  JGDR.
-Minor cl arifying text was a dded to Section 9.1.1 regarding secondary efficacy 
assessment .
-Serum  pregnancy test was added as an option to urine pregnancy  test in 
Appendix 3 for on -study  pregnancy  testing.
-Footnotes were added to the the sampling table in Appendix 4.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 97
LY3012207Revised Protoc ol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
2.Schedule of Activities
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 98
LY3012207Table JGDR. 2. On-Study Treatment Schedule of A ctivities
Day within Cycle
ProcedureEvery Cycle Cycles 1 -6 
(olaratumab + doxorubicin 
+ ifosfamide;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy
a(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Physical 
examinationX X X Perform prior to infusion of study drug(s) on Day 1 .
Includes weight and BSA.
For patients receiving olaratumab as monotherapy following discontinuation of combination 
therapy , perform on D1 of every cycle.
Vital signs X X X X X X X Vital signs include temperature, blood pressure, pulse rate, respiration rate.  
Concomitant 
medicationX X Concomitant medications will be recorded continuously throughout the treatment period.
AE collection X X Collect continuously throughout the treatment period; CTCAE Version 4.0.
ECOG performance 
statusX X
Radiologic imaging 
and measurement of 
palpable or visible 
lesionsX
q 6 weeksX Perform according to RECIST 1.1, by the same method used at baseline, q 6weeks ( -7 day s) 
from the start of treatment until radiographic disease progression, death, or study completion, 
whichever occurs first.
Perform as scheduled, even if study treatment is delayed or omitted.
For patients receiving olaratumab as monotherapy following discontinuation o f combination 
therapy , perform ever y 12 weeks ( -7days).
ECG X
C1
-
C6X Perform local 12 -lead ECG on Day 1 of Cycle 1 through Cycle 6.
Perform local 12 -lead ECG on Day 1 of Cycle 7 and approximately 6 months (±14 days) and 
12months (±14 days) after discontinuation of doxorubicin and ifosfamide treatment
Echocardiogram 
and/o r MUGA scanX
C4 and C6X Perform at the end of C4 and C6; perform additional evaluations in the setting of cardiac 
symptoms and/or at the discretion of the investigator.
For patients receiving olaratumab as monotherapy following discontinuation of combination 
therapy , perform approximately 6 months (±14 days) and 12 months (±14 days) after 
discontinuation of doxorubicin and ifosfamide treatment.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 99
LY3012207Day within Cycle
ProcedureEvery Cycle Cycles 1 -6 
(olaratumab + doxorubicin 
+ ifosfamide;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy
a(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Hematology X X X X X 3 days prior to administration of study treatment on D1 and ≤1 day prior to administration of 
study treatment on D8, unless more frequent assessment is clinically indicated. Day 15 labs may be 
drawn within ±1 day of Day 15.  See Appendix 3 .  To be performe d locally for patient management 
and centrally for analysis purposes.
Coagulation X X 3 days prior to administration of study treatment on D1, unless more frequent assessment is 
clinically indicated.  For patients receiving olaratumab as monotherapy following combination 
therapy  discontinuatio n, perform o n D1 of ever y other cycle.  See Appe ndix 3 .  To be performed 
locally.
Clinical chemistry X X X X 3 days prior to administration of study treatment on D1 and ≤1 day prior to administration of 
study treatment on D8, unless more frequent assessment is clinically indicated. Day 15 labs may be 
drawn within ±1 day of Day 15.  See Appendix 3 .  To be performe d locally for patient management 
and centrally for analysis purposes.
Urinaly sis X X X X Monitor patients for evidence of micro -and/o r macroscopic hematuria and treat according to 
institutional standards.   Prior to administration of study treatment on each treatment day. 
Patients must have ≤10 RBCs per high -power field present in urinalysis in order to proceed with 
ifosfamide dosing.  For patients receiving olaratumab as monotherapy following discontinuatio n of 
combinatio n therapy , perform on D1 of ever y other cy cle.  See Appendix 3 .  To be performed 
locally.
Urine pregnancy  
Pregnancy testX X Applies only to women of childbearing potential
Where required by local law or regulation, perform once every 21 days ( -7 days) prior to 
administration of study treatment. 
To be performed locally
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 100
LY3012207Day within Cycle
ProcedureEvery Cycle Cycles 1 -6 
(olaratumab + doxorubicin 
+ ifosfamide;
(Cycle = 21 days)Cycles 7-N
Olaratumab 
Monotherapy
a(Cycle = 21 
days ) Instructions
1 2 3 4 8 151 8
Administer 
olaratumabX X X X Administer IV over 60 (±5) min.  Administer until a maximum of 6 cycles is complete, or until PD, 
unacceptable toxicity, death, or other withdrawal criteria are met.  Patients who discontinue 
doxorubicin, ifosfamide and mesna treatment without evidence of disease progression will receive 
olaratumab as monotherapy until there is evidence of disease progression, death, intolerable 
toxicity, or other withdrawal criteria are met.  Patients who undergo surgical tumor resection 
following study treatment are not e ligible to receive olaratumab as monotherapy.  See section 7.1.1
for olaratumab premedication requirements.  See section 7.8.1 for olaratumab IRR monitoring 
period requirements.
Administer 
doxorubicin X X X Administer IV over less than 60 (±5) min or as a continuous IV infusion (according to institutional 
guidelines) after completion of olaratumab infusion and any required observation period.  
Administer until a maximum of 6 cycles is complete, or until PD, u nacceptable toxicity, death, or 
other withdrawal criteria are met. See Section 7.1.2 for details of dexrazoxane administration.
Administer 
ifosfamideX X X X
*Administer IV over 3 hours (±15 min) after completion of doxorubicin administration.   Administer 
until a maximum of 6 cycles is complete, or until PD, unacceptable toxicity, death, or other 
withdrawal criteria are met. 
*Patients treated in cohorts with ifosfamide dose reduction will have the Day 4 dose omitted (that 
is, ifosfamide will b e administered at a dose of 2.5 g/m2on D1, D2 and D3).
Administer mesna X X X X See Section 7.1.3 for details of mesna administration.
G-CSF X The use of G -CSFs is required.  Administer according to ASCO and NCCN guidelines.  In general, 
G-CSF products like filgrastim or pegfilgrastim should be administered approximately 24 hours 
after the completion of cytotoxic chemotherapy (for example, on Day 5 for patients in full- dose 
ifosfamide cohorts or Day 4 for patients in reduced -dose ifosfamide coho rts).
Sample collection For all sample collection, see Appendix 4 .
Pharmacodynamics 
Pharmacokinetics
Immunogenicity
Pharmacogenetics
Other biomarkers
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 101
LY3012207Abbreviations:  AE = adverse event; ASCO = American Society of Clinical Oncology; BSA =body surface area; C = cycle; CTCAE =Common Terminology 
Criteria for Adverse Events (NCI 2009); D = day; ECG =electrocardiogram; ECOG =Eastern Cooperative Oncology Group (Oken et al. 1982); G -CSF = 
granulocyt e-colon y stimulating factor; IRR =infusion -related reaction; IV = intravenously; LVEF = left ventricular ejection fraction; min = minutes; MUGA 
= multiple -gated acquisition; NCCN = National Comprehensive Cancer Network; PD = progressive disease; q = every ; RBC = red blood cell; RECIST 
1.1=Response Criteria in Solid Tumors Version 1.1 (Eisenhauer et al. 2009).
aOlaratumab monotherapy schedule applies to patients whohave completed 6 cycles of olaratumab plus doxorubicin and ifosfamide and are continuing 
treatment with olaratumab monotherapy or have discontinued doxorubicin plus ifosfamide and are continuing with olaratumab mon otherapy.  Note: if a 
patient discontinues doxorubicin plus ifosfamide treatment prior to completing 6 cycles and is continuing tr eatment with olaratumab monotherapy, perform 
procedures according to the olaratumab monotherapy schedule beginning the next cycle after the patient discontinues doxorubic in/ifosfamide.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 102
LY3012207Table JGDR. 3. Post -Treatment Follow -Up Schedule of A ctivities
ProcedureShort -Term 
Follow -Up aLong -Term 
Follow -Up Instructions
Visit 801 802–8XX
Physical examination X Including weight and vital signs (temperature, blood pressure, pulse rate, 
respiration rate)
Concomitant medication X
AE collection X CTCAE Version 4.0 . 
ECOG performance status X
Radiologic imaging and measurement of 
palpable or visible lesionsX X* *For patients whose disease has not progressed:
Perfor m q 6weeks × 2, then q 3 mo until:
the patient has objective disease progression according to 
RECIST 1.1 or
thestudy’s primary /final analy sis
Perform using the same method used at baseline and throughout the study.
For patients who have had objective disease progression:
Radiologic tests and measurement of palpable or visible lesions are no 
longer required;  these patients should be followed up for OS and 
collection of post -study treatment anticancer therapy information 
collection approxim ately every 90days (14days)until death or study 
completion as indicated below .
Collection of survival information X Perform q 2 mo (±7 days ) for the first 2 years after discontinuation from 
study treatment and q 6 mo (±14 days) thereafter until death or study 
completion .  If an in-person visit is not possible, confirm survival by 
contacting the patient directly via phone.
Collection of post -study  treatment anticancer 
therapy  informationX X Perform q 2 mo (±7 days) for the first 2 years after discontinuation from 
study treatment and q 6 mo (±14 days) thereafter until death or study 
completion.
ECG X X All patients should have a 12- lead ECG performed at short -term 
follow -up.
Patients should also have a 12- lead ECG performed approximately 6 
months (±7 days) and 12 months (±7 days) after the end of treatment 
with doxorubicin and ifosfamide.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 103
LY3012207ProcedureShort -Term 
Follow -Up aLong -Term 
Follow -Up Instructions
Visit 801 802–8XX
Echocardiogram and/or MUGA scan X Perform at 6 months (±7 days) and 12 months (±7 days) after the end of 
study treatment with doxorubicin and ifosfamide .  
Echocardiograms/MUGA scans may be discontinued if the patient begins 
another anticancer therapy.  Perform additional evaluations in the setting 
of cardiac symptoms and/or at the discretion of the investigator.
Hematology X See Appendix 3 .  To be performed locally for patient management and 
centrally  for analy sis purposes.
Coagulation X See Appendix 3 .  To be performed locally.
Clinical chemistry X See Appendix 3 .  To be performed locally for patient management and 
centrally  for analy sis purposes.
Urinaly sis X See Appendix 3 .  To be performed locally.
Sample collection
For all sample collection, see Appendix 4 .Pharmacodynamics
Pharmacokinetics
Immunogenicity
Pharmacogenetics
Other biomarkers
Abbreviations:  AE =adverse event; CTCAE =Common Terminology Criteria for Adverse Events (NCI 2009); ECOG =Eastern Cooperative Oncology Group 
(Oken et al. 1982); mo = month; MUGA = multiple -gated acquisition; OS = overall survival; q =every; RECIST 1.1 =Response Criteria in Solid Tumors 
Version 1.1 (Eisenhauer et al. 2009).
aShort -term follow -up begins the day after the patient and the investigator agree that the patient will no longer continue study treatment and l asts 
approximately 30 days (±7 days).  No follow -up procedures will be performed for a patient w ho withdraws informed consent unless he or she has explicitly 
provided permission and consent.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 104
LY30122073.2.1 Rationale for Amendment (a)
The ori ginal  Study  JGDR protocol , versi on dated 14 March 2017, was amended to remove visits 
and/or procedures not intended for patients receiving olaratumab mo notherapy  only after 
completing 6 cycles of olaratumab plus doxorubicin and ifosfamide (or discont inued doxorubicin 
and ifo sfamide before).  In particular, visits and procedures specifically  used to adminis ter and 
monitor for toxicit y from the doxorubi cin and ifo sfamide co mbinat ionhave been remo ved for 
patients receiving olaratumab mo notherapy .
The timing of ECHO/MUGA scans after discont inuation of doxorubicin plus ifo sfamide 
treatm ent was cl arified and ECG evaluat ions were added at the same frequency to ensure 
complete evaluat ion of any  potenti al cardi otoxic effects following treatment with doxo rubicin 
plus ifo sfamide.  
The wording pertaining to required contraceptive use fo llowing study  treatm ent has been 
clarified to align with label requi rement f or doxorubicin.
In addit ion, some minor editorial changes have been made throughout the protocol t o improve 
clarity and pract icalit y of the protocol  and secure alignment with the intended study  design.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 105
LY30122075.Study Design
5.1 Overall Design
Study  JGDR is a m ulticenter, nonrandomized, open -label, ….
Olaratumab 15- mg/kg Dose Level:   The first phase of the stu dy (Dose -Finding Phase) will 
evaluate the safet y and tol erabili ty of adding o laratumab to the regimen of doxorubicin 
(75mg/m2plus given as IV infusions of 25 mg/m2on Day s 1 to 3), ifosfamide (10 g/m2given as 
IV infusio ns of 2.5 g/m2on Day s 1 to 4) and mesna according to a 21- day cycle.  Fifteen pat ients 
will be init ially enro lled and treated with a 15 -mg/kg dose of olaratumab (on Day s 1 and 8 of a 
21-day cycle) in combinat ion with doxorubi cin, ifo sfamide and mesna and assessed for safet y 
after 1 cy cle of therapy .  The full  cohort of 15 patients will be enrolled if 5 or fewer patients wi th
DLTs are observed in the first 6 and 9 patients, respectively.  
Olaratumab 20- mg/kg Loading Dose Cycle Dose Level:   Following an evaluat ion of safet y in 
the full coho rt of 15 patients (and provided 8 or fewer of these pat ients have experienced DLTs), 
the study  will progress to evaluate a loading dose cycle of o laratumab (20 mg/kg IV on Days 1 
and 8 of Cycle 1 only , then 15 m g/kg on Day s 1 and 8 of subsequent cy cles) in combinat ion with 
doxorubi cin, ifo sfamide and mesna in a new cohort of 15 patients.  Section 5.5.1 details the 
rationale for the l oading dose.  The full cohort of 15 patients will be enrolled if 5 or fewer 
patients wi thDLTs are observed in the first 6 and 9 pati ents, respecti vely.  
Olaratumab 15- mg/kg Dose Level:  Ifosfamide Dose Reduction Option
If during enrollment into the olaratumab 15 -mg/kg dose level, DLTs are observed in 6 of the first 
6 pati ents, in ≥6 of the first 9 patients, or in ≥9 of the full cohort of 15 pati ents, the study  will 
proceed to explore a reduced ifosfamide dose (7.5 g/m2 total dose) in combinat ion with 
olaratum ab 15 m g/kg and the same doxorubicin dose in a new cohort of 15 patients.  If DLTs are 
observed in 6 of the first 6 patien ts, in ≥6 of  the first 9patients , or in ≥9 of the full cohort of 15 
patients at this reduced ifosfamide dose, the study  will halt and no f urther patients will be 
enrolled.  If 8 or fewer patients wi thDLTs are observed in this full cohort of 15 patients, the 
study  will progress to expl ore the ol aratum ab Loading Dose Cy cle as previously  described in 
combinat ion with the reduced ifosfamide dose (and same doxorubicin dose) as previously  
described.
Olaratumab 20- mg/kg Loading Dose Cycle Dose Level:  Ifosfamide Dose Reduction Option
If during enrollment into the olaratumab 20 -mg/kg Loading Dose Cycle dose level, DLTs are 
observed in 6 of the first 6 patients, in ≥6 of  the first 9 patients, or in ≥9 of the full cohort of 
15patients, no further patients will be e nrolled at this dose level and olaratumab 15 mg/kg will 
be declared the recommended dose for combinat ion with reduced -dose ifosfamide/mesna and 
doxorubi cin.  If 8 or fewer patients wi thDLTs are observed in this full cohort, the olaratumab 
20-mg/kg loading dose cy cle together wi th a reduced ifosfamide/mesna dose will be declared the 
recommended doses for combinat ion with doxorubicin.
.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 106
LY3012207Abbreviations:  D = day; DLT = patients experiencing a dose-limiting toxicity; Dox = doxorubicin; g = grams; Ifos = ifosfamide; kg 
= kilogram; m2= square meters; mg = milligrams; Olara = olaratumab; N = number; TBD = to be determined.
aPatients who discontinue combination study therapy without evidence of d isease progression will receive olaratumab as 
monotherapy until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met .
Figure JGDR. 1. Illustration of study design.

I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 107
LY30122076.Study Population
All patients m eeting the eligibilit y requirements will be considered for enrollment regardless of 
race, religio n, or gender.  The invest igator or the sponsor will not grant except ions to eligibilit y 
criteria.  Prospective approval o f protocol  deviati ons to r ecruit ment and enro llment criteria, also 
known as protocol waivers or exempt ions, is not permitted.
6.1.Inclusion Criteria
[7] Have received no prior lines of systemic therapy  (adjuvant or neo -adjuvant 
treatm ent will not be counted as a prior line) and ar e suitable to receive 
doxorubi cin, ifo sfamide and mesna.  All previous ant icancer treatments must 
have co mpleted ≥3 weeks (21 days) prior to the first dose of study  treatm ent.
[12] If male, m ust be sterile or agree to use an effective method of contraception or 
a highly effective method of contraception during the study and for at least :
12weeks following the last dose of study  treatm ent.
3 months f ollowing the l ast dose of ol aratum ab
6 months f ollowing the l ast dose of doxorubicin or ifosfamide
Refer to Appendix 1 for definit ions of effective method of contraception and 
highly effective method of contraception . 
[13]If female and o f child -bearing potential, must:
a.  have a negative serum pregnancy test at the time of enro llment,
a.have a negat ive urine serum pregnancy  test wi thin 24 hours 7 days prior 
to the first dose of study  treatm ent, and
b.agree to use a highly effective method of contraception during the 
study  and f or 3 months fo llowing the l ast dose of study  treatm entat 
least 3 m onths fo llowing the last dose of olaratumab and 6 months 
following the last dose of doxorubicin or ifosfamide .
Refer to Appendix 1 for the definit ions of highly effective method of 
contraception andeffective method of contraception .
6.2. Exclusion Criteria
[23]Have a histo ry of another primary  malignancy , with the excepti on of :
a.curatively  treated non -melano matous skin cancer
b.curatively  treated cervi cal carcino ma in situ
c.non-metastatic prostate cancer, or 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 108
LY3012207d.other primary  nonhematol ogic malignancies treated with curat ive 
intent, no known active disease, and no treatment administered 
during the last 3 y ears pri or to enrollment, that the investigator 
and Lilly  Medical representative agree will not affect 
interpretati on of  study  resul ts or woul d be unsui table for 
participat ion in the study .
7.1. Treatment A dministered (Dosing Schedule)
Table JGDR.6 shows the treatment regimens.  On days where mult iple study  drugs are to be 
administered, the drugs should be administered in the order shown in Table JGDR.6.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 109
LY3012207Table JGDR. 6. Treatments A dministered (Dosing Schedule)
Phase and 
Dose Cohort
Drug Name and DoseDay of 21 -day 
(±3 days) cycleTotal 
dose Route and duration of 
administration NotesDose-Finding Phase
Olara 15 mg/kgOlaratumab 15 mg/kg a D1 and D8 IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements and Section 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min 
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1 and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4 b 10bg/m 2IV over 3 hours (±15 min) Administer after dox on D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4 b According to institutional practiceOlara Loading Dose CycleOlaratumab 20 mg/kg Cycle 1
Olaratumab 15 mg/kg Cycles 2 to 6 aD1 and D8
D1 and D8IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements and Section 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1 and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4 b 10bg/m 2IV over 3 hours (±15 min) Administer after dox on D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4 b According to institutional practiceDose Confirmation Phase
Recommended Olara DoseOlaratumab dose determined from 
Dose -Finding Phase aD1 and D8 IV over 60 (±5) min
Infusion rate should not exceed 25 
mg/minSee Section 7.1.1 for premedication 
requirements and Section 7.8.1 for 
IRR monitoring period requirements
Doxorubicin 25 mg/m 2per day a D1, D2, D3 75 mg/m 2IV over less than 60 min
or 
continuous IV infusion (according to 
institutional practice)Administer after olara on D1 and 
after any required observation period
Ifosfamide 2.5 g/m 2per day a D1, D2, D3, D4 b 10bg/m 2IV over 3 hours (±15 min) Administer after dox on D1, D2, D3
Mesna dose ≥60% of ifos dose a D1, D2, D3, D4 b According to institutional practice
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 110
LY3012207Abbreviations:  C = cycle; CRP = clinical research physician; D = day; DLT = dose -limiting toxicity; dox = doxorubicin; g = grams; ifos = ifosfamide; IRR= 
infusion -related reaction; IV = intravenous; kg = kilogram; m2= square meters; mg = milligrams; min = minutes; olara = olaratumab.
aAll patients will receive study therapy (olaratumab + doxorubicin/ifosfamide/mesna) for a maximum of 6 cycles, or until a discontinuation crite rion is met.  
Patients who discontinue doxorubicin, ifosfamide and mesna treatment without evidence of disease progression will re ceive olaratumab as monotherapy until 
there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
bIf DLT rules (see Section 7.2.2.1) are exceeded in the olaratumab 15 -mg/kg cohort, a reduced dose of ifosfamide (7.5 g/m2 total dose) will be explored.  This 
reduced dose will be communicated by the Lilly CRP and will be accomplished by omitting the Day 4 dose (that is, ifosfamide w ill be administered at a dose 
of 2.5 g/m2 on D1, D2 and D3).  The Day 4 dose of mesna will be correspondingly omitted.  A Loading Dose Cycle of olaratumab (20 mg/kg on Days 1 and 8 
of C1, then 15 mg/kg on Days 1 and 8 of subsequent cycles) may also be explored in combination with the reduced dose of ifosfamide.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 111
LY30122077.1.1. Olaratumab Premedications and Required Monitoring
The infusio n rate of olaratumab should not exceed 25 mg/min.  Infusio n durations longer than 
60min are permitted in specific circumstances (that is, for patients with higher body  weight for 
whom the upper limit of infusio n rate is limited or in the setting of prior olaratumab Grade 1 or 2 
infusio n-related reacti on [IRR]); the infusio n duratio n must always be accurately recorded.
All patients will receive the fo llowing (or equivalent) premedicat ionsPremedicate pati ents prior 
to administration of o laratumab as bel ow:  
onOnDays 1 and 8 of Cycle 1:  Mandatory administration of a histamine H1 
antagonist (for example, diphenhydramine) and dexamethasone IV 30 to 60 minprior to 
the start of the olaratumab infusio n.
For subsequent cy cles, premedication all patients will  be premedicated with a histamine 
H1 antagonist (for example, di phenhydramine) IV 30 to 60 min is recommended prior to 
each dose of olaratumab.
Addit ional premedication(s) may  be provi ded at the invest igator’s discretion.  Premedicat ion 
must be provided in the setting of a prior Grade 1 or 2 olaratumab IRR, as detailed in 
Secti on7.8.1 .  All premedicat ions administered must be adequately documented in the electronic 
case report form (eCRF).
Patients are requi red to be m onitored f or 1 hour after the ol aratum ab infusio n in Cycles 1 and 2 
for signs or symptoms of IRRs; see Section 7.8.1 for full descript ion of required o laratumab 
monitoring peri od in Cycles 1 and 2.  Patients should complete the required monitoring period 
prior to the start of the doxorubicin administration.
7.2.1. Selection and Timing of Doses
A cycle is defined as an interval of 21 days .  In Cycl e 2 and bey ond, (up to 3 days ’delay of a 
cycle(that is, Day  1) or Day  8 will be permitted due to holidays, weekends, bad weather, or other 
unforeseen circumstances and will not count as a protocol deviat ion). In except ional cases, 
longer delays may be allowed in later cy cles f ollowing consultat ion with Lilly  medical  
representative.
7.2.2. Dose -Finding Phase
7.2.2.1. Dose -Limiting Toxicity Determination
Because of the relatively  high rate o f  DLT -level toxicity with the backbone doxorubicin, 
ifosfamide and mesna regimen (Judson et al. 2014) and the generally  acceptable toxici ty profile 
of the 15 -mg/kg dose of olaratumab (Days 1 and 8 every 21 days) in combinat ion with other 
chemotherapeut ic agents including doxorubicin, approximately  15 pati ents will be enrolled at the 
first dose l evel of ol aratum ab (provided safet y data confirms the required number of pat ients 
without DLTs have been met for each DLT threshold as described in Table JGDR.7 and
evaluated after 6, 9 and 15 patients have received 1 cy cle of therapy ) to all ow sufficient pati ent 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 112
LY3012207numbers to judge init ial tol erabilit y of o laratumab in combinat ion with doxorubi cin, ifo sfamide 
and mesna.
In the Dose -Finding Phase, DLT assessment will be perform ed.  A DLT i s defined as events such 
as the fo llowing, graded according to the NCI -CTCAE Versio n 4.0, when it occurs within 
Cycle 1 and is considered to be related to study  treatm ent by  the invest igator in conjunct ion with 
the sponsor:
1. Grade 3 o r 4 febrile neutropenia, or sepsis ., or
2. Grade 4 neutropenia last ing 7 days or longer .
3. Grade 4 thrombocy topeni a, or Grade 3 thrombocy topeni a com plicated by  hemorrhage.
4. Nonhematologic Grade ≥3 toxi city, except for toxi cities (such as nausea, vo miting, 
transi ent el ectroly te abnorm alities, or diarrhea) that can be controlled with optimal 
medical management within 48 hours or clinically non -significant l aboratory  
abnorm alities.
A dose -limiting equivalent toxicit y is an AE that meets the DLT criteria as defined above and 
occurs in any  cycle other than Cycle 1 .  In addit ion to the DLT assessment period in Cycle 1, 
available safet y data bey ond Cycle 1 m ay also be taken into consideration prior to a decisio n to 
advance to the next dose level or the determin ation of the Confirmat ion Phase dose.
Note: Infusio n-related reacti ons will  not be considered as DLTs, as they  occur independent of 
dose l evel.
Table JGDR.7 shows the DLT thresho lds that will be used to determine study  progressi on.  
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 113
LY3012207Table JGDR. 7. Dose -Limiting Toxicity Thresholds for Study JGDR
Dose Level Regimen If… Thenb…
Olara 15 mg/kg
(Starting Dose 
Level)Olara 15 mg/kg D1, D8
Ifos10 g/m 2D1 to D4 a
Dox 75 mg/m 2D1 to D36 DLTs in first 6 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients).
≤5 DLTs in first 6 patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6 DLTs in first 9 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients).
≥9 DLTs in full 15 patients Proceed to Olara 15 mg/kg with Ifos Reduction Dose Level (new cohort of 
approximately 15 patients).
≤8 DLTs in full 15 patients Proceed to Olara 20- mg/kg Loading Dose Cycle Dose Level.
Olara 15 mg/kg 
with Ifos 
ReductionOlara 15 mg/kg D1, D8
Ifos7.5 g/m 2D1 to D3 a
Dox 75 mg/m 2D1 to D36 DLTs in first 6 patients Halt study .  No further patients enrolled.
≤5 DLTs in first 6 patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6 DLTs in first 9 patients Halt study .  No further patients enrolled.
≥9 DLTs in full 15 patients Halt study .  No further patients enrolled.
≤8 DLTs in full 15 patients Proceed to Olara 20- mg/kg Loading Dose Cycle Dose Level with Ifos 
Reduction.
Olara 20 -mg/kg 
Loading Dose 
CycleOlara 20 mg/kg D1, D8 
of C1; then 15 mg/kg D1, 
D8 of C2 to C6 
Ifos10 g/m 2D1 to D4 a
Dox 75 mg/m 2D1 to D36 DLTs in first 6 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≤5 DLTs in first 6 patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6 DLTs in first 9 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≥9 DLTs in full 15 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg as recommended dose.
≤8 DLTs in full 15 patients Proceed to Recommended Dosing Regimen cohort with Olara 20 -mg/kg 
Loading Dose Cycle as recommended dose.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 114
LY3012207Dose Level Regimen If… Thenb… 
Olara 20 -mg/kg 
Loading Dose 
Cycle with Ifos 
ReductionOlara 20 mg/kg D1, D8 
of C1; then 15 mg/kg D1, 
D8 of C2 to C6 
Ifos7.5 g/m 2D1 to D3 a
Dox 75 mg/m 2D1 to D36 DLTs in first 6 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg with Ifos reduction as recommended 
dose.
≤5 DLTs in first 6 patients Enroll 3 additional patients and evaluate DLTs in this group of first 9 
patients.
≤5 DLTs in first 9 patients Enroll full cohort of 15 patients.
≥6 DLTs in first 9 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg and Ifos 7.5 g/m 2as recommended 
doses.
≥9 DLTs in full 15 patients Discontinue enrollment into cohort.  Proceed to Recommended Dosing 
Regimen cohort with Olara 15 mg/kg and Ifos 7.5 g/m 2as recommended 
doses.
≤8 DLTs in full 15 patients Proceed to Recommended Dosing Regimen cohort with Olara 20 mg/kg 
Loading Dose Cycle and Ifos 7.5 g/m 2as recommended doses.
Recommended 
Dosing RegimenOlara dose TBD
Ifosdose TBD
Dox 75 mg/m 2D1 to D3Enroll 15 patients and treat with Recommended Dosing Regimen.
Abbreviations:  D = day; DLT = patients experiencing a dose-limiting toxicity; dox = doxorubicin; g = grams; Ifos = ifosfamide; kg = kilogram; m2= square 
meters; mg = milligrams; Olara = olaratumab; TBD = to be determined.
aWith concomitant mesna administration.
bIf a sufficient number of patients successfully complete the DLT period at a given dose level (ensuring the DLT threshold will not be exceeded), further 
enrollment may proceed as described in Table JGDR.7, upon agreement of the Sponsor and Investigators.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 115
LY30122077.4. Dosage Delays, Discontinuations and Modifications
To begin dosing at Cycle 2 and each cycle( Day 1) thereafter (for cy cles in which olaratumab is 
administered with doxorubicin and ifo sfamide) , the fo llowing cri teria must be f ulfilled (see 
Table JGDR.9 for hem atological parameters for dosing o laratumab on Day 8) :
ANC ≥1.5 × 10 3cells/µL ( ≥1500 cells/µL; ≥1.5 × 10 9/L)
Platelets ≥100 × 10 3cells/µL ( ≥100,000 cells/µL; ≥100 × 10 9cells/L)
Hem oglobin ≥8.0 g/dL.  Note:  For study  inclusio n, hem oglobin ≥9.0 g/dL
Total  bilirubin bel ow ULN.  In pati ents wi th Gilbert’s syndrome, total bilirubin should be 
3 mg/dL
Serum  creatinine ≤1.5 times ULN.  If creatinine is above ULN, the patient’s creat inine 
clearance is ≥60 m L/min (refer to Appendix 6 for the Cockcroft -Gault formula for 
creatinine clearance)
AST and ALT ≤3 ×ULN, or ≤5 ×ULN if the transaminase elevat ion is due to liver 
metastases
Nonhematologic toxicit y must be less than Grade ≤2 or must have returned to baseline, 
unless the toxicit y is deemed not clinically s ignificant by  the invest igator or is a 
laboratory  abnorm ality that is m anageable by  institutional standards (for exam ple, l ow 
serum  potassi um, m agnesium , or phosphate).
In addit ion, patients shoul d be m onitored f or evi dence of  micro-and/or macroscopic hem aturia 
and treated according to inst itutional standards. the following criteria must be fulfilled on each 
day of ifosfamide dosing (D1, D2, D3 and D4 of each cycle):
≤10 red blood cells per high- power field present in urinalysis.
7.4.1. Delays
In general, dose delays of 1 study  drug (ol aratum ab, doxorubi cin, or ifosfamide/mesna ) due to 
toxicities outlined in Section 7.4.3 will not necessitate delays o f the other study  drugs.  However, 
close considerat ion must be made by the inve stigator to administer all study treatments per the 
schedule outlined in Sect ion7.1.
Treatment may be delayed for up to 14 days to allo w a patient sufficient time for recovery  from 
study  drug -related toxici ty.  If Day  8 treat ment is delayed >7 days, treatm ent may  be resumed 
with planned Day  1 treatm ent of  the next cy cle.
Dosing delay bey ond 14 day s may be permissible if AEs are not considered to be primarily  
related to ol aratum ab and the invest igator deems continuat ion of stu dy treatm ent to have clinical 
benefit for the patient. This decisio n has to be documented and be jo intly made by  the 
investigator and the Lilly team. 
In the event of unforeseen circumstances or scheduling issues that require adjust ments to the 
schedule, appropriate adjustments or delays to the schedule may be made fo llowing discussio n 
between the invest igator and the s ponsor and written approval by the Lilly medical 
representative.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 116
LY30122077.4.2. Discontinuations
The need to permanently discont inue doxorubicin and/or ifosfamide due to drug -related toxi city 
shoul d be done according to local standard of care and labels.  Criteria for olaratumab 
discontinuat ion are discussed in the olaratumab dose modificat ion sect ion (7.4.3.1 ) and in the 
olaratum ab infusio n-relate d reaction section (7.8.1) The need to permanently discontinue 
doxorubi cin, ifo sfamide and mesna due to drug -related toxicit y will resul t in the perm anent 
discontinuat ion of all study  drugs in the doxorubicin, ifosfamide and mesna regimen.
Patients whose disease has not progressed at the time of doxorubicin, ifosfamide and mesna 
discontinuat ion will  receive ol aratumab as monotherapy until there i s evidence of disease 
progression, death, intolerable toxicit y, or other withdrawal criteria are met ( Section 8 ).  These 
patients will  cont inue study  assessments as outlined in Table JGDR.2 .  Pati ents who undergo 
surgi cal tum or resecti on following study  treatm ent are not eligible to receive o laratumab as 
monotherapy .
Patients who exhibit disease progression at the time of doxorubicin, ifosfamide and mesna 
discontinuat ion will  receive post -treatm ent follow-up assessments as outlined in Table JGDR.3 .
7.4.3. Dose Modifications
Any pat ient who requires a dose reduction for drug -related toxicit y will cont inue to receive the 
reduced dose for the remainder of the study .
General guidelines for dose modificat ions are provided below.  Sections 7.4.3.2 and 7.4.3.3 
outline guidelines for dose modificat ions of doxorubicin and ifosfamide, respectively; variat ions 
from these guideline smay be allowed according to local standard of care and labels.  
7.4.3.1. Olaratumab Dose Modifications
A one-time reduct ion in the dose of olaratumab will be permitted if the doses of doxorubicin and 
ifosfamide have been previously reduced once for toxi city, and the same or similar toxicit y has 
recurred despite reduction of doxorubicin, ifosfamide and mesna, and the toxicit y is deemed 
potenti ally related to the addi tion of  olaratum ab in combinat ion with doxorubi cin, ifosfamide and 
mesna.  In this scenario, an olaratumab dose reductio n shoul d occur in conjunct ion with a 
second reduct ionin the doxorubicin and ifo sfamide doses according to the guidance outlined in 
Secti ons7.4.3.2 and 7.4.3.3 .
A second reduct ion in the olaratumab dose will not be per mittedduring treatment with 
combinat ion therapy  of olaratum ab pl us doxorubi cin and ifosfamide.
Patients who have not progressed on study  will receive ol aratumab as monotherapy following 
discontinuat ion of the co mbination therapy unt il there is evidence of disease progression, death, 
intolerable toxi city, or other wi thdrawal cri teria are m et.  Pati ents receiving olaratumab as 
monotherapy  will have assessments performed as per Table JGDR.2.
Patients who have a dose reduction of olaratumab during the combinat ion therapy  porti on and 
then proceeding to receive olaratumab mo notherapy after discont inuat ion of doxorubicin and 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 117
LY3012207ifosfamide combinat ion may have thei r dose of olaratum ab re -escalated to the original dose level 
at the investigator ’s discret ion.
7.4.3.1.1. Hematologic Toxicity
Table JGDR.8 shows ol aratumab dose modificat ions that should be made for hematologic 
toxicities judged as potentially related to olaratumab in co mbinat ion with doxorubicin, 
ifosfamide and mesna, and that have recurred or failed to improve/reso lve despite 1 reduction in 
doxorubi cin and ifo sfamide doses.  These guidelines should be used for olaratumab dosing, when 
given in co mbinat ion with doxorubi cin and ifosfamide.
Table JGDR. 8. General Guidelines for Olaratumab Dose Modification due t o 
Hematologic Toxicities
Toxicity Required Dose Modification
Neutropenia
  ANC Grades 1 -3 No dose modification required
  ANC <500 cells/ µL (Grade ≥4) No treatment administered; treatment cycle delayed
  At re -treatment:
  If ≥Grade 3 neutropenic fever/infection 
has occurred and 1 reduction in 
doxorubicin, ifosfamide and mesna doses 
has already occurredWithhold dose until ANC is ≥1500 cells/µL; 
15-mg/kg Dose Level:  Reduce dose to 12 mg/kg
20-mg/kg Loading Dose Cycle Le vel:  Reduce dose to 
15mg/kg
  If Grade 4 neutropenia lasting ≥1week 
has occurred and 1 reduction in 
doxorubicin, ifosfamide and mesna doses 
has already occurredWithhold dose until ANC is ≥1500 cells/µL; 
15-mg/kg Dose Level:  Reduce dose to 12 mg/kg
20-mg/kg Loading Dose Cycle Level:  Reduce dose to 
15mg/kg
  Grade 4 ANC without fever/infection 
lasting ≤1weekAdminister next olaratumab at full dose, at investigator’s discretion
After 1 reduction of olaratumab and 2 
reductions of doxorubicin, ifosfamide 
and mesna, recurrence of either:
  1) ≥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting ≥1 weekDiscontinue combination therapy (olaratumab + 
doxorubicin/ifosfamide/mesna).  Patients w ho have not progressed 
will receive olaratumab as monotherapy until there is evidence of 
disease progression, death, intolerable toxicity, or other withdrawal 
criteria are met.
Abbreviation:  ANC = absolute neutrophil count.
Omitt ing the Day 8 dose of olaratumab based on ANC and platelet c ounts judged as potentially 
related to ol aratum ab in co mbinat ion with doxorubicin, ifo sfamide ,and mesna is permissible as 
shown in Table JGDR.9.
7.4.3.2. Doxorubicin Dose Modifications
Dose m odificat ions of doxorubicin will fo llow the guidelines outlined below and may  be 
adjusted according to local standard of care and label. Two reducti ons in doxorubicin dose will be 
permitted during the study  according to the guidance outlined in Sect ions 7.4.3.5 and 7.4.3.6.   If 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 118
LY3012207a third dose reduction is necessary , the patient will be discontinued from the combinat ion therapy  
(olaratumab + doxorubicin/ifosfamide/mesna) and will be fo llowed as outlined in Section 7.4.2 .
7.4.3.2.1. Hematologic Toxicity
Doxorubi cin will not be administered after the init ial dose if the patient’s ANC is <1500 cells/µL 
or if the platelet coun t is <100,000 cells/µL.  When necessary , the next treatm ent cycle should be 
delayed unt il the ANC is ≥1500 cells/µL and the platelet count is ≥100,000 cells/µL and any 
nonhematologic toxicit ies have resolved.  For patients who experience ≥Grade 3 neutropenic 
fever or infect ion or Grade 4 neutropenia without fever last ing more than 1 week, doxorubicin 
shoul d be reduced to 75% of the starting dose (that is, t o approximately 60 mg/m2).  If a pati ent 
experiences a second incidence of neutropenic fever/infection or has another episode of Grade 4 
neutropeni a last ing >1 week, then a second dose reduction to 45 mg/m2shoul d occur will be 
necessary .
7.4.3.3. Ifosfami de Toxicities and Dose Modifications
Dose m odificat ions of ifo sfamide will fo llow the guidelines outlined below and may  be adjusted 
according to local standard of care and label. Two reductions in ifo sfamide dose for toxi city will 
be permitted during the study .  If a thi rd dose reducti on is necessary , the pati ent will be 
discontinued fro m the combinat ion therapy  (olaratum ab + doxorubi cin/ifo sfamide/mesna) and 
followed as outlined i n Sect ion 7.4.2 .
General guidelines for ifosfamide dose modification are shown in Table JGDR.12.  Dose 
modificati ons of  ifosfamide due to hepatic impairment are shown in Table JGDR.13.
7.4.3.3.2 . Ifosfamide -Assoc iated Urotoxic Effects
The incidence of urotoxi c effects without an uroprotector can be up to 40% and is dose 
dependent ; coadministration of mesna and adequate hydration are mandatory  in this study .  
Patients m ay present wi th hematuri a, symptom atic cystit is, or bladder fibrosis.  Past or 
concomitant radiation of the bladder or busulfan treatment may increase the risk of hemorrhagic 
cystitis.  Several methods of treatment for established hematuria have been described:  bladder 
irrigation with water or norm al saline, intra vesical inst illation of astringents (alum, silver nitrate), 
systemic administration of ant ifibrino lytics (amino caproi c acid, tranexamic acid), cy stoscopy  to 
evacuate the bladder of clots, continuous bladder irrigat ion and intravesical prostaglandins.  For 
severe or refractory  hematuri a, intravesical formalin, pheno l, or prostaglandin has been used wit h 
or wi thout surgical intervent ion (electrocautery , cryosurgery , diversi on of urine flow, 
hypogastric artery  ligat ion, or cy stectomy).  Ifosfamide should be di scont inued or dose 
reducedDiscont inuat ion or dose reduction of ifo sfamide shoul d follow local standard of care and 
label for patients wi thmacroscopic hematuria.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 119
LY30122077.4.3.3.3. Ifosfamide -Assoc iated Proximal Tubular Damage
Glomerular, proximal, or distal tubular impairment may  all occur, often in combinat ion and m ay 
progress even after ifosfamide has been discontinued.  Proximal tubular damage often presents as 
Fanconi syndro me with low serum bicarbonate, pr oteinuria, glucosuria, aminoaciduria and 
hypochloremic metabolic acidosis.  Risk factors for the development of nephrotoxicit y include 
preexist ing renal impairment, concurrent use of nephrotoxic drugs, reduced renal reserve 
(unilateral nephrectomy), hydron ephrosis and total cumulative dose.  Renal impairment may 
increase the risk of myelo suppression and possibly, cardiotoxicit y.  Mesna does not appear to be 
protective against the proximal tubular abnormalit ies induced by  ifosfamide.  Dose m odificati ons 
guidelines of ifosfamide due to renal impairment are shown in Table JGDR.14.
7.7. Treatment Compliance
The study  medicat ion will be administered only at the invest igational sites by  the authorized 
study  site personnel.  As a result, treatment compliance is ens ured.
7.8.6. Other Concomitant Therapies
No other chemotherapy , radi otherapy , immunotherapy , cancer -related horm one therapy , or 
experimental drugs will be permitted while the patients are on this study .  An except ion will be 
made for: 
prostate cancer pati ents continuing GnRH agonist therapy or breast cancer patients 
continuing anti -estrogen therapy  (for example, an arom atase inhibitor) as long as those 
therapi es have been installed for at least 3 months and are known to have been well 
tolerated
bisphosphon ate osteocl ast inhibi tors (f or exam ple, zol edronic acid or pamidronate) for 
treatm ent of bone m etastases will be permitted while pat ients are on study  treatm ent. The 
osteocl ast inhibitor denosumab is also allowed.  Denosumab is a monoclonal ant ibody  
and i s associ ated wi th a risk of hypersensit ivity reacti ons. Therefore, denosumab should 
not be administered within 3 days of o laratumab administration.
palliat ive local treatm ent (f or exam ple, radi otherapy o f ≤14 calendar days) in Cycles 2 
and bey ond following discussi ons between the investigators and the sponsor (for 
example, for pain control of a so litary [non -skull ] skel etal metastasi s) and wri tten 
approval  by the sponsor, as long as the patient has not developed another reason for study  
discontinuat ion.
9.1. Efficacy Assessments
9.1.1. Secondary Efficacy Assessments
Tumor assessments will …
The m ethod of tum or assessment used at baseline must be used consistently throughout the 
study .  Radi ological scan imaging of the chest thorax, abdo men and pelvis and o ther areas, as 
clinically indicated, is required.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 120
LY3012207See Secti on 10.3.1 for definit ions of the efficacy endpo ints.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 121
LY301220710. Statistical Considerations
10.1. Sample Size Determination
The primary  object ive is to …
Before enrolling the full 15 patients at a given dose l evel, the study  design requi res that an init ial 
group of 6 will be enrolled and evaluated for DLTs.  If 6 or more patents with DLTs are 
observed in the first 6 patients, enrollment at the current dose level will be stopped and 
appropriate dose de -escalation (or tri al halt) will occur.  Similarly , if 6 or m orepatients wi th 
DLTs are observed in the first 9 patients, enrollment at the current dose level will be stopped and 
appropriate dose de -escalat ion (or tri al halt) will occur.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 122
LY3012207Appendix 3. Clinical Laboratory Tests
Clinical Laboratory Tests
Hematology -local and central laboratory a
Leukocytes (WBC) Erythrocy tes (RBC)
Neutrophils b Hemoglobin (HGB)
Lymphocy tes Hematocrit (HCT)
Monocytes Mean corpuscular volume (MCV)
Eosinophils Mean corpuscular hemoglobin concentration (MCHC)
Basophils Platelets (PLT)
Coagulation -local laboratory
Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT)
International normalized ratio (INR) or prothrombin time (PT) 
Clinical Chemistry -local and central laboratorya
Serum Concentrations of:
Alanine aminotransferase (ALT) Cholesterol
Albumin Creatinine
Alkaline phosphatase Glucose, random
Aspartate aminotransferase (AST) Magnesium
Bilirubin, direct Phospho rous
Bilirubin, total Potassium
Blood urea nitrogen (BUN) or blood urea Sodium
Calcium Uric acid
Urinalysis -local laboratory
Blood Protein
Glucose Specific gravity
Ketones Urine leukocyte esterase
pH
Pregnancy Test (for female patients of childbearing potential) -local laboratory
Serum pregnancy test (screening)
Serum or Urine pregnancy test (on study)
Confirmation of Menopause (for female patients of menopausal age) –local laboratory
Follicle -stimulating hormone (FSH) c
Abbreviation:  CRF =case report form. 
aTreatment decisions will be based on local laboratory results.
bNeutrophils reported using automated differential hematology instruments include both segmented and band 
forms.  When a manual differential is needed to report the neutrophils, the segmented and band forms should be 
added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
cTo be performed at screening only when needed to confirm post -menopausal status; applicable for women who 
have experienced spontaneous amenorrhea for 6 to 12 months. 
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 123
LY3012207Appendix 4. Pharmacokinetic, Biomarker, Pharmacogenetics and 
Immunogenicity Sampling Sc hedules
It is essent ial that the exact infusio n start and stop times (actual clock readings) are recorded.  
The exact time of co llection of each venous blood sample will be based on the clock used to 
record infusio n times.  It is essent ial that the PK bloo d samples not be drawn fro m the same site 
as the drug infusio n.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 124
LY3012207Pharmacokinetic, Biomarker, Pharmacogenetic and Immunogenicity Sampling Schedule
Cycle Day Dosing Sampling Time aPK Sampling Biomarker Sampling
PGx IGe,fOlara PK b,f Dox PK c,lIfos 
PKd,lPlasma Tumor Tissue g
Baseline - X (mandatory) g
11≤60 min pre -olara XhX XiX
Olara (1 hr)
≤5 min post -olara X
Obs (1 hr)
60±10 min post -olara X
Dox (<1 hr)j
≤5 min post-dox Xj
Ifos (3 hr)
≤5 min post -ifos X X
2Dox (<1 hr)
Ifos (3 hr)
≤5 min post -ifos X X
3Dox (<1 hr)j
≤5 min post -dox Xj
Ifos (3 hr)
≤5 min post -ifos X
4Ifos (3 hr)
≤5 min post -ifos X X
8≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
Obs (1 hr)
60±10 min post -olara X
4±0.5 hr post -olara X
10 48±3 hr post -olara X 
15 Anytime X
21≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
8≤60 min pre -olara Xh
Olara (1 hr)
≤5 min post -olara X
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 125
LY301220731≤60 min pre -olara XhX X
Olara (1 hr)
≤5 min post -olara X
Dox (<1 hr)i
≤5 min post -dox X Xj
Ifos (3 hr)
≤5 min post -ifos X X
2Dox (<1 hr)
Ifos (3 hr)
≤5 min post -ifos XkX
3Dox (<1 hr)i
≤5 min post -dox Xj
Ifos (3 hr)
≤5 min post -ifos X
4Ifos (3 hr)
≤5 min post -ifos XkX
8≤60 min pre -olara Xh
Olara (1 hr)
≤5 min post -olara X
60±10 min post -olara X
4±0.5 hr post -olara X
10 48±3 hr post -olara X 
15 Anytime X
4 1 ≤60 min pre -olara Xh
5 and then 
every 
other 
cycle1 ≤60 min pre -olara XhX
Visit 801 Anytime XX X (optional; for 
patients who 
undergo surgical 
tumor resection 
subsequent to study 
treatment)X
Abbreviations:  C = cycle; D = day; dox = doxorubicin; hr = hour; ifos = ifosfamide; IG = immunogenicity; min = minute; IRR = infusion -related reaction; obs = 
observation; olara = olaratumab; PGx = pharmacogenetics; PK = pharmacokinetics.
aPost-infusion is defined as after the completion of the i nfusion.
bSamples of approximately 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in serum.
I5B-MC-JGDR (a)Phase 1 Oncology Protocol Page 126
LY3012207cSamples of approximately 2 mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of ifosfa mide in plasma.
dSamples of approximately 3 mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of doxorubic in in plasma.
eFor the immunogenicity assay, approximately 5 mL of whole blood will be drawn into a serum separa tor tube without anticoagulant to generate serum 
samples.
fIf a patient experiences an IRR to olaratumab, blood samples for immunogenicity and PK analysis will be taken at the followin g time points:  (1) as soon as 
possible after the onset of the IRR, (2) at the resolution of the IRR and (3) 30 days (±3 days) after the IRR.
gPatients must have sufficient available material from an archived formalin -fixed paraffin -embedded tumor tissue.  If such tissue is not available, a newly 
obtained core or excisional biopsy of a tumor lesion must be performed. 
hPretreatment olaratumab PK samples may be collected up to 60 minutes prior to the olaratumab infusion and must be prior to ad ministering any 
premedication. Pretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab infusion and must be 
taken prior to administering any premedication.
iIt is highly recommended to draw the PGx sample prior to the first dose of study drug (C1D1); however, it can be coll ected at a later time point, if necessary. 
jIf doxorubicin is administered as a 24 hour infusion, the doxorubicin PK sample should be collected at the same time as the i fosfamide PK sample (that is, 
approximately 3 to 4 hours after the start of the doxor ubicin infusion).
kFor patients whohave discontinued doxorub icin/ifosfamide early, these samples may be omitted if there is no other reason for the patient to visit the clinic.
lShould a patient discontinue doxorubicin or ifosfamide, all subsequent PK samples for the corresponding chemotherapeutic agent can be omitted.
Leo Document ID = 162b3c09-f0fb-440a-956f-85d421fbbebd
Approver: 
Approval Date & Time: 26-Jun-2018 09:46:55 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 26-Jun-2018 09:46:55 GMT
Signature meaning: Approved
PPD
PPD